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AIM OF STUDY To assess the relationships between age, respiratory symptoms,
airways calibre and nonspecific bronchial responsiveness in a population sample
including large numbers of elderly adults.
METHODS Caucasian adults aged >45 years were selected from lists of GPs in
Central Manchester using random number tables, and sent a respiratory symptoms
questionnaire (exclusions: housebound, confused). A random sample of those failing
to respond after 2 reminders was contacted by 'phone or home visit. Those not
excluded from bronchial challenge (exclusions: ischaemic heart disease, oral
steroids, beta-blocker or anticholinergic medication) were invited to attend for
spirometry, bronchial challenge (using methacholine and Newcastle dosimeter
method), and venous blood sampling.
RESULTS 783 questionnaires were sent to eligible subjects; 508 returned the full
questionnaire and 215 an abbreviated version (overall response rate 92.3%). 395
subjects were invited to attend; 247 did so, of whom 246 performed spirometry and
208 completed bronchial challenge. Questionnaire responders were representative
of study population; attenders were slightly younger. Prevalence of smoking was
high (29.2% current smokers, 37.3% ex-smokers). Asthma was reported by 7.3%,
bronchitis by 15.4%; a further 7.3% reported both diagnoses. 53.8% of subjects
reported one or more respiratory symptoms. Chronic airflow obstruction (defined
as FEVj/FVC<60% for age <65 years; for age >65 lower limit of FEVj/FVC
was calculated from reference ranges (Enright et al. 1993) was present in 26.4% of
the population; bronchial hyper-responsiveness (PD20< 100/xg) was found in 26.0%.
Comparison with values calculated from reference ranges suggested that FEVj in
non-smoking Manchester adults was lower than predicted. Only 55.4% of those with
chronic airflow obstruction reported a diagnosis of asthma or bronchitis, and only
35.4% were using appropriate inhaled medications. There was no difference in the
prevalence of reported symptoms, diagnoses, or chronic airflow obstruction between
adults aged <65 or >65 years. Multiple regression analysis with bronchial
responsiveness (log dose-response slope) as the dependent variable showed an
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independent negative relationship with FEVU and positive relationships with age and
total IgE level.
CONCLUSIONS Respiratory morbidity is common in this middle-aged and elderly
inner-city population, but is frequently undiagnosed and untreated. There is a
positive relationship between bronchial responsiveness and age. Atopy is associated
with bronchial responsiveness even in older adults.
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DEFINITIONS AND ABBREVIATIONS
The terminology of obstructive airways disease is controversial. The considerable
difficulty in distinguishing clinically between asthma and smoking-related airways
obstruction (particularly in older adults) has led to the use of non-committal
terminology (chronic nonspecific lung disease, chronic obstructive bronchitis etc),
rather than terms such as asthma and chronic bronchitis, for which standardised
definitions are available. ("Chronic obstructive pulmonary disease" is about to be
clearly defined, with the publication of new guidelines on its management). In the
interests of clarity, the terminology used throughout this thesis is defined below.
ASTHMA: a disease characterised by increased responsiveness of the airways to
various stimuli, and manifested by bronchoconstriction which varies spontaneously
or secondary to therapy (American College of Chest Physicians. - American Thoracic
Society Joint Committee on Pulmonary Nomenclature. 1975);
CHRONIC BRONCHITIS: a syndrome of mucus hypersecretion, associated with
chronic cough productive of sputum daily for 3 consecutive months in at least 3
consecutive years (Medical Research Council 1960);
CHRONIC AIRFLOW OBSTRUCTION: a persistent obstructive ventilatory
impairment detected by spirometry.
The following abbreviations are use throughout this thesis:
PEFR - peak flow rate
FEV! - forced expiratory flow in 1 second
FEF50 - forced expiratory flow rate at 50% from vital capacity
FVC - forced vital capacity
GP - general practitioner
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Chapter 1: INTRODUCTION AND LITERATURE REVIEW
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A) NONSPECIFIC BRONCHIAL RESPONSIVENESS IN ASTHMA AND
CHRONIC BRONCHITIS
Nonspecific bronchial responsiveness represents the tendency of the airways to
constrict in response to an inhaled stimulus, which may be a physical or chemical
agent (for example cold air, histamine, methacholine). The term "nonspecific" refers
to the fact that such agents produce bronchoconstriction in all individuals (including
those with normal airways) if inhaled in sufficient doses. This differs from bronchial
responsiveness to specific allergens, which is dependent on prior exposure and
sensitisation.
i) Increased bronchial responsiveness in asthma
It has been known for over 50 years that the inhalation of histamine produces
bronchoconstriction in asthmatics (Curry 1946). More recently, studies have shown
that increased sensitivity to the broncho-constrictor effect of inhaled histamine or
cholinergic agents is almost universal in individuals with current symptomatic
asthma (Cockcroft et al. 1977; Townley,RG et al. 1979). Asthmatic subjects show
three main differences from normal subjects in their response to inhaled histamine
or methacholine. Firstly, they develop bronchoconstriction at a lower dose of
inhaled agent than normal subjects (increased sensitivity). Secondly, if dose-response
curves are plotted, the slope of the curve is steeper for asthmatic subjects than for
normals (increased reactivity) (Orehek et al. 1977). Thirdly, whereas in normal
subjects inhalation of increasing doses of histamine/methacholine will eventually fail
to produce further bronchoconstriction (producing a "plateau" on the dose-response
curve), in many asthmatics there is no evidence of such a plateau, and
bronchoconstriction is limited only by the side-effects of the provoking agent
(Woolcock et al. 1984). This altered response to inhaled histamine in asthmatic
subjects has been variably referred to as both "bronchial hyper-reactivity",
"bronchial hyper-responsiveness" and "increased nonspecific bronchial
responsiveness"; to avoid confusion, the latter two terms will be used throughout
this thesis to represent both increased sensitivity and reactivity to inhaled histamine
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or methacholine.
Measurement of bronchial responsiveness has been used in both clinical and
epidemiological studies of asthma. Such studies have shown that increased bronchial
responsiveness is not specific to asthma, but is also found in a spectrum of other
disorders, including atopic rhinitis, chronic bronchitis, cystic fibrosis, and
pulmonary oedema. Indeed, in a study of a young population, Cockcroft et al found
that 4%-5% of non-atopic, non-asthmatic "normal" individuals also had bronchial
hyper-responsiveness (Cockcroft et al. 1985). Consequently, the positive predictive
value of increased bronchial responsiveness for a diagnosis of asthma is relatively
low: while almost all subjects with current asthma will have increased bronchial
responsiveness, only approximately 40% of subjects with increased bronchial
responsiveness have definite asthma (Cockcroft et al. 1985; Cockcroft 1988).
Epidemiological surveys show that bronchial responsiveness is continuously
distributed throughout the young population, with asthmatic subjects representing a
subgroup within the hyper-responsive end of the distribution (Cockcroft and et al.
1983; Cockcroft et al. 1983; Nieminen 1992). However, it has not been possible to
identify a cut-off point which convincingly separates asthmatic from non-asthmatic
subjects because of the considerable degree of overlap between them. Despite this,
a quantitative relationship has been demonstrated between level of bronchial
responsiveness and symptom severity, treatment requirements and diurnal peak flow
variability in patients with asthma (Juniper et al. 1981; Murray,AB et al. 1981;
Brand et al. 1991). Furthermore, changes in bronchial responsiveness were
associated with changes in symptom frequency and medication use in a community
population survey (Britton et al. 1988a).
ii) Increased bronchial responsiveness in chronic bronchitis
Increased bronchial responsiveness is found in approximately 50% of subjects with
chronic bronchitis (Yan et al. 1985; Engel et al. 1989). However, comparisons of
bronchial hyper-responsiveness in patients with chronic bronchitis and asthma have
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identified important differences between the two diseases. Firstly, the mean level of
bronchial responsiveness in patients with chronic bronchitis is usually less than that
of patients with current symptomatic asthma, and is approximately equivalent to
levels seen in mild asthma or atopic rhinitis (Yan et al. 1985; Engel et al. 1989;
Woolcock et al. 1991; Nieminen 1992). Nevertheless, there is considerable overlap,
and level of bronchial responsiveness alone does not reliably differentiate between
asthma and chronic bronchitis (Yan et al. 1985; Enarson et al. 1987; Cerveri et al.
1988; Engel et al. 1989; Woolcock et al. 1991; Nieminen 1992).
There are also qualitative differences between bronchial hyper-responsiveness in
asthma and chronic bronchitis. The slope of the dose-response curve produced when
histamine or methacholine is inhaled by a subject with chronic bronchitis is usually
intermediate between the steep slope of an asthmatic dose-response curve, and the
more gradual incline of a normal curve (Woolcock et al. 1991). There may also be
differences in the shape of the curve: in chronic bronchitis (as in normals) a plateau
is usually reached when maximal bronchoconstriction has occurred - this plateau is
not seen in the dose-response curve of subjects with symptomatic asthma (DuToit
et al. 1986; Woolcock et al. 1991).
Furthermore, the level of bronchial responsiveness in subjects with both chronic
bronchitis and emphysema is strongly associated with the degree of baseline airflow
obstruction present (measured as FEV, or FEVj/FVC); this relationship is weaker
in subjects with asthma and normal baseline airways calibre (Yan et al. 1985;
Mullen et al. 1986; Verma et al. 1988; Woolcock et al. 1991; Ulrik 1993). This
observation has led to the suggestion that increased bronchial responsiveness in
subjects with chronic airflow obstruction is merely secondary to the decreased
airways calibre, rather than the result of a specific disease process (Ramsdale and
Hargreave 1990).
Some other differences between bronchial hyper-responsiveness in asthma and
chronic bronchitis tend to support this theory. Firstly, the level of bronchial
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responsiveness in subjects with chronic bronchitis and chronic airflow obstruction
does not show the strong link with measures of disease severity (eg peak flow
variability, treatment requirements) that is seen in asthma (James et al. 1988; Brand
et al. 1991). Secondly, asthmatic subjects with increased bronchial responsiveness
will respond with pronounced bronchoconstriction to a wide variety of inhaled
stimuli, including cold air hyperventilation, sulphur dioxide, and propranolol,
whereas subjects with chronic bronchitis often fail to respond to these other agents
(Ramsdale et al. 1984, 1985b; DuToit et al. 1986; Ramsdale and Hargreave 1990;
Woolcock et al. 1991).
However, other characteristics of bronchial hyper-responsiveness in chronic
bronchitis suggest that it is not merely the result of decreased airways calibre.
Increased bronchial responsiveness may be present in smokers with normal baseline
FEV,, but is not invariable in smokers with chronic airflow obstruction (Taylor et
al. 1985b; Yan et al. 1985). Moreover, pre-treatment with bronchodilators may
reduce bronchial responsiveness in subjects with chronic airflow obstruction, without
significantly increasing baseline FEV, (Yan et al. 1985); pre-treatment with
salbutamol and ipratropium had different effects on bronchial responsiveness despite
producing the same degree of bronchodilatation (Britton et al. 1988c). In one study
of the effect of prior bronchoconstriction on bronchial responsiveness in normal
subjects, histamine challenge was performed following inhalation of either nebulised
saline or methacholine (Chung and Snashall 1984). Although inhalation of
methacholine increased airways resistance before the start of the histamine
challenge, the level of bronchial responsiveness was not affected, suggesting that the
result of the histamine challenge was not merely a direct reflection of the pre-
challenge airways calibre.
Longitudinal studies monitoring airways calibre and bronchial responsiveness over
time have failed to clarify this area. A 4 year study of 27 smokers and 16 ex-
smokers found that smokers with increased bronchial responsiveness had an
accelerated decline in FEV, (Taylor et al. 1985b). However, this decline in FEV,
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was accompanied by a further increase in bronchial responsiveness, raising the
possibility that the bronchial hyper-responsiveness was the result of, rather than the
cause of, the low FEVi (Lim et al. 1988). In contrast, Postma et al studied 81 non-
allergic current or ex-smokers with chronic airflow obstruction for 2-21 years, and
found that the faster rate of FEV! decline in those with bronchial hyper-
responsiveness was independent of baseline airways calibre (Postma et al. 1986).
Longitudinal studies of subjects without chronic bronchitis likewise give conflicting
results. A survey of 2280 healthy men (excluding those with asthma, chronic
bronchitis or respiratory symptoms) found an initial correlation between airways
calibre and bronchial responsiveness, but subsequent changes in bronchial
responsiveness were not related to either baseline or annual change in FEV!
(Sparrow et al. 1994). However, in 35 asthmatics studied over 6 months, 35% of
between-subject variation and 45% of within-subject variation in bronchial
responsiveness could be attributed to differences in pre-challenge FEVi (Dirksen et
al. 1992).
Studies suggesting that increased bronchial responsiveness predisposes to accelerated
rate of decline in airways calibre have been taken as supporting evidence for the
"Dutch hypothesis". This was developed in the 1960s after a cross-sectional
population survey in Holland found that FEVi had a stronger relationship with
measures of atopy than with smoking. The hypothesis proposed that underlying
"host factors" determined which smokers would develop chronic airflow obstruction,
and atopy and bronchial hyper-responsiveness were suggested as the host factors
involved (Orie et al. 1961; van der Lende et al. 1969). Despite some supportive
evidence for the Dutch hypothesis, other longitudinal population surveys have
produced contradictory results (Burrows et al. 1987).
In summary, it is clear that although bronchial responsiveness is increased in a
proportion of subjects with chronic bronchitis, there are both similarities and
differences between the bronchial hyper-responsiveness seen in chronic bronchitis
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and asthma. This suggests that the mechanisms producing the increase in bronchial
responsiveness may differ between the two disease processes. As yet it is still
unclear whether bronchial hyper-responsiveness in chronic bronchitis is the cause
of, or the consequence of, decreasing airways calibre (Dosman et al. 1990).
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B) METHODS OF MEASUREMENT OF NONSPECIFIC BRONCHIAL
RESPONSIVENESS
Nonspecific bronchial responsiveness is measured by monitoring airways calibre
whilst giving measured doses of inhaled stimulus under controlled conditions.
Unfortunately, several versions of this "bronchial challenge" technique are available,
differing in the challenge agent inhaled, the method of administration of this agent,
the method of measurement of airways calibre, and in the parameter used to express
the challenge result. In an attempt to standardise these various methods, the
European Respiratory Society has published an official statement of
recommendations for measurements of bronchial responsiveness (Sterk et al. 1993).
Some of the techniques currently in use will be briefly discussed below.
i) Choice of challenge agent
Pharmacological agents such as histamine or methacholine are more often used than
physical agents for the measurement of bronchial responsiveness. Both histamine
and methacholine stimulate contraction of bronchial smooth muscle, but do so by
different mechanisms. Histamine acts on HI receptors, and may also stimulate
cholinergic pathways producing vagally mediated effects; methacholine stimulates
muscarinic postganglionic parasympathetic receptors producing bronchial wall
smooth muscle contraction (Pratter and Irwin 1984). Despite these different actions,
the results of bronchial challenge with the two agents are similar (Juniper et al.
1978, 1981; Hargreave et al. 1981). However, they are not interchangeable: in one
comparison using identical protocols in stable asthmatic subjects, bronchial
responsiveness measured with histamine was 3.5 times higher than with
methacholine (Connolly et al. 1988a). Whilst methacholine is accepted to have a
cumulative bronchoconstrictive effect when administered in sequential increasing
doses, there is disagreement whether histamine has a cumulative or non-cumulative
action (Juniper et al. 1978; Connolly et al. 1988a). As methacholine has fewer
adverse effects, it is the agent of choice for large studies of bronchial
responsiveness.
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ii) Method of administration of challenge agent.
Both histamine and methacholine are prepared as solutions, and so must be
nebulised for inhaled administration. Recommendations for the preparation and
storage of solutions of histamine and methacholine for bronchial challenge have been
made by the European Respiratory Society (Sterk et al. 1993).
To allow administration of accurate doses of nebulised agent, nebuliser output must
be standardised. Various different types of nebuliser are commercially available,
having different outputs and producing particles of differing sizes. In a comparative
study using three different nebuliser types in identical bronchial challenge protocols,
nebulisers of different models and different nebulisers of the same model produced
different outputs and particle sizes (Ryan et al. 1981a). Nebuliser output varied with
flow rate, and bronchial challenge result was significantly altered by changes in
nebuliser output but not by particle size.
Accurate calibration of nebuliser output is thus essential to ensure precision in the
dose of challenge agent being administered. Traditionally, output has been assessed
by nebuliser weight loss during a period of nebulisation. However, this assumes that
all solution lost from the nebuliser is the result of nebulisation, whereas in fact there
is also significant loss of solvent by evaporation (Cockcroft et al. 1989).
Consequently, nebuliser calibration by weight loss will over-estimate aerosol output.
Direct measurement of nebuliser output using a solute tracer and aerosol impaction
can also be performed (Dennis et al. 1990). Using this method, it has been
confirmed that continuous nebulisation causes cooling of the reservoir solution in the
nebuliser, and increases the concentration of solute due to evaporation of solvent.
Weight loss during nebulisation, but not output of solute, increases substantially with
the temperature of the reservoir solution, as a result of increased evaporation.
However, both weight loss and solute output are dependent on flow rate. Thus flow
rate should be standardised for all bronchial challenges, which should be carried out
at a constant ambient temperature. Nebuliser reservoir solutions should be replaced
regularly to minimise the effects of decreasing temperature and increasing
concentration (Sterk et al. 1993).
Once the nebuliser has been adequately calibrated, there are three different methods
of administering the nebulised challenge agent to the subject: the tidal breathing
method, the dosimeter method, and the Yan method. In the tidal breathing method,
the nebuliser is calibrated to give a known output of challenge agent per minute, and
the subject inhales sequential doubling concentrations of nebulised challenge agent
by normal tidal breathing. Each concentration of challenge agent is inhaled for 2
minutes, with 5 minutes break between successive concentrations (Cockcroft et al.
1977; Hargreave et al. 1981). Spirometry is performed before the test and following
each 2 minute inhalation period; the test ends when lung function has fallen by 20%.
The dosimeter method for bronchial challenge allows estimation of the dose, rather
than the concentration, of challenge agent producing a particular change in lung
function. The dosimeter itself is an electronic timing device which operates the
nebuliser for the precise periods of time necessary to administer a particular dose
of challenge agent (Hendrick et al. 1986). The nebuliser is only operated during
inspiration, with the start of nebulisation being triggered either by a flow sensor, or
by the test operator. Nebulisers are calibrated so that output per second is known,
and then the time period of nebulisation required to produce a 10/xl output of
solution per actuation is calculated for each nebuliser and programmed into the
dosimeter. Sequential doubling doses of nebulised challenge agent are given at 5
minute intervals; each dose is inhaled during 5 inspiratory capacity breaths, each
lasting 5 seconds, with no delay between breaths. Spirometry is performed at the
start of the test, and then immediately before administration of the next dose. As
with the tidal breathing method, the test ends when spirometry results fall by 20%.
The Yan method has been widely used in epidemiological studies as it uses a
portable hand-held nebuliser and does not need a fixed air supply (Yan et al. 1983).
The nebuliser is operated by squeezing, and is triggered at the start of two 3-second
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inhalations, each of which is followed by breath-holding for 3 seconds. The different
doses of challenge agent are given by varying both the number of breaths taken and
the concentration of the solution of challenge agent.
The dosimeter method has several theoretical advantages over the tidal breathing and
Yan methods. Firstly, the activation of the nebuliser only during inspiration prevents
wastage of nebulised challenge agent during expiration. Secondly, the use of
controlled 5-second inhalations, standardised for all subjects, reduces variation in
particle deposition throughout the lung caused by variation in breathing patterns
(Ryan et al. 1981a; Bennett and Smaldone 1987). Thirdly, accurate control of
nebuliser timing should allow more precise determination of the dose of challenge
agent administered.
In fact, comparisons between tidal breathing, dosimeter, and Yan methods have in
general shown similar results with all 3 methods. Ryan et al found that a tidal
breathing method and a dosimeter method gave similar measurements of bronchial
responsiveness, and were equally reproducible (Ryan et al. 1981b). Britton et al
compared the tidal breathing and Yan methods with a method using an ultrasonic
nebuliser; reproducibility was similar for all 3 methods, but tidal breathing gave
readings 1.75-2.3 doubling concentrations lower than the other two methods (Britton
et al. 1986). Knox et al compared Yan and dosimeter methods, and found that the
Yan method gave slightly lower measurements of bronchial responsiveness than the
dosimeter; reproducibility was similar for both techniques, and improved with the
experience of the subject (Knox et al. 1991). Beach et al compared dosimeter and
tidal breathing methods and found better reproducibility of recordings with the
dosimeter (Beach et al. 1993). However, examination of the results showed that the
different reproducibilities of the two methods were the result of the different
methods of measuring lung function, rather than the differing methods of delivery
of the challenge agent.
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iii) Measurement of airways calibre during bronchial challenge
The parameter most frequently used as a measure of airways calibre during
bronchial challenge is FEV,. Measurement of FEV, is simple to perform, does not
require complex or expensive equipment, and is reproducible. Peak flow is also
simple to perform, but tends to be less reproducible than FEV^! (Connolly et al.
1988b). Other measures are more sensitive to small changes in airways calibre than
FEV!, but require the use of complex equipment (eg airways resistance), or are less
reproducible (eg FEF50, FEF35) (Dehaut et al. 1983).
The timing and number of spirometric measurements during bronchial challenge also
varies between different challenge protocols. Dosimeter techniques commonly use
the mean of a fixed number (3-6) of repeated FEV[ manoeuvres performed
immediately before each subsequent dose of challenge agent (Hendrick et al. 1986).
In contrast, the tidal volume technique described by Cockcroft et al uses the lower
of two FEVi measurements performed 0.5 and 1 minute following each inhalation
(Cockcroft et al. 1977).
Using the mean of several recordings will reduce the effect of variable technique
and so improve accuracy (Ullah et al. 1983). This was demonstrated by a
comparison between dosimeter and tidal breathing methods, which found that the
superior reproducibility of the dosimeter technique resulted from the use of the mean
of 6 readings of FEVi rather than the lowest of two (Beach et al. 1993). However,
the use of multiple FEV, manoeuvres may itself cause bronchodilatation (as the
result of repeated maximal inspiration), which could in theory alter results (Orehek
et al. 1981). Furthermore, there is a risk of producing fatigue, which can adversely
affect performance (Tager et al. 1976). In theory, this might be a particular problem
in elderly subjects; in practise, a dosimeter technique using the mean of three
measurements of FEV, prior to each inhaled dose of challenge agent was well
tolerated and reproducible in subjects over 65 years (Connolly et al. 1988b).
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iv) Expression of results
The results of bronchial challenge are usually expressed as either the dose
(dosimeter technique) or concentration (tidal breathing technique) of challenge agent
producing a 20% fall in baseline lung function. This parameter is termed the
provoking dose or concentration of challenge agent (PD20 or PC20). However, if the
decrease in lung function during bronchial challenge is <20%, these parameters
cannot be calculated, thus data is censored at lower levels of bronchial
responsiveness. This is a particular problem in cross-sectional population surveys,
where the majority of subjects tested are not asthmatic, and has led to a search for
other parameters which can be calculated even if there is little change in lung
function during bronchial challenge.
Alternative parameters proposed have included the area under the dose-response
curve, and methods involving extrapolation of the curve beyond the final dose of
challenge agent given. These methods increase the number of subjects for whom the
bronchial challenge result can be quantified, but require relatively complex
calculations (Chinn et al. 1987; Hopp et al. 1987). A more simple method is to
summarise each dose-response curve by calculating the slope of a line extending
from the origin to the last data point obtained (the "dose-response slope", DRS)
(O'Connor et al. 1987). In one population survey of bronchial responsiveness, PD20
could only be calculated for 8% of the sample, and extrapolation of PD20 using a
curve-fitting method produced a result in only half of the remaining cases; in
contrast, the dose-response slope could be calculated for all subjects, and was highly
reproducible (Abramson et al. 1990).
Some authors have expressed reservations about the sensitivity and reproducibility
of the dose-response slope, particularly in subjects with low levels of bronchial
responsiveness (Cockcroft and Berscheid 1983; Bruschi et al. 1989; Higgins et al.
1989a; Seppala 1991; Trigg and Davies 1991). However, several published
epidemiological surveys have now used both dose-response slope and PD20 as
measures of bronchial responsiveness: the fact that dose-response slope can be easily
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calculated for all subjects studied make it the parameter of choice for cross-sectional
surveys of bronchial responsiveness (Peat et al. 1991, 1992b; Rijken et al. 1993a;
Sparrow et al. 1994; Trigg et al. 1994).
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C) PATHOPHYSIOLOGY OF INCREASED NONSPECIFIC BRONCHIAL
RESPONSIVENESS
Whilst many factors have been shown to influence bronchial responsiveness, the
relative contributions of these in asthma and chronic bronchitis is unclear. It is also
possible that different mechanisms are involved in these different disease processes.
There is evidence that both genetic and environmental factors are involved in the
pathogenesis of asthma (Burney 1992; Paoletti et al. 1992). The genetic component
may be linked to an inherited atopic tendency (Peat et al. 1992c), or to
polymorphism of the beta-adrenoceptor (Hall et al. 1995). The environmental
triggers involved have not been fully identified, but may include viral infections
(Empey et al. 1976), respiratory infections in infancy, and/or environmental
pollutants (Burney 1992; Paoletti et al. 1992). The most important environmental
trigger for chronic bronchitis is cigarette smoke exposure, but the factors
determining whether or not an individual smoker will develop chronic airflow
obstruction are not clear.
Three mechanisms identified as possible causes of bronchial hyper-responsiveness
in asthma and chronic bronchitis are abnormalities of bronchial smooth muscle,
inflammation of the bronchial wall epithelium, and altered autonomic control of
airway calibre. These are discussed below.
i) Abnormality of bronchial smooth muscle
Biopsy and post-mortem specimens of lung tissue from patients with asthma or
chronic bronchitis show evidence of smooth muscle hypertrophy (Hogg 1990). This
could in theory increase bronchial responsiveness by exaggerating the effect of a
contractile stimulus (Moreno et al. 1986; James et al. 1989), and by reducing the
elastic recoil of the airways. However, it is difficult to envisage this as the cause of
the rapid fluctuations in airways calibre seen in asthma.
Alternatively, the sensitivity of bronchial smooth muscle to contractile stimuli could
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be increased in asthma (Black 1991). However, several studies have failed to show
a correlation between in vivo bronchial responsiveness to histamine or methacholine
and in vitro sensitivity of isolated airway preparations to the same agonists (Holgate
et al. 1987; Hogg 1990; Black 1991). This does not support the existence of an
intrinsic smooth muscle abnormality in asthma.
There is some evidence that the sensitivity of bronchial smooth muscle to contractile
stimuli may be influenced by inflammatory mediators (eg mast cell-derived
prostaglandins and thromboxane) (Jongejan et al. 1990). Thus it is possible that
abnormal smooth muscle contraction in asthma could result not from a primary
muscle abnormality, but from the effects of bronchial wall inflammation.
ii) Inflammation of bronchial wall
It is now widely accepted that inflammation is involved in the pathophysiology of
both chronic bronchitis and asthma, although the inflammatory cells and mediators
involved may differ between the two disease processes (Jeffery 1991; Barnes and
Lee 1992). Endobronchial biopsies from asthmatic subjects have shown an infiltrate
of chronic inflammatory cells, and pathological specimens from subjects dying of
acute asthma show evidence of acute inflammation (Chung 1986; Beasley et al.
1989; Hogg 1990). The level of immune activity of infiltrating inflammatory cells
is reflected in the level of HLA-DR expression: this has been shown to correlate
with the level of bronchial responsiveness to histamine (Poulter et al. 1990).
Several of the stimuli increasing bronchial responsiveness in asthma (eg inhaled
allergens and viral infections) cause inflammation of the bronchial epithelium
(Djukanovic et al. 1990). The increased bronchial responsiveness caused by inhaled
ozone has been shown to correlate with the intensity of inflammatory response
(Holgate et al. 1987). Bronchial wall inflammation results in the release of mast cell
mediators (Chung 1986; Townley,RJ and Hopp 1987); measured levels of some of
these correlate with bronchial responsiveness in asthmatic patients (Djukanovic et
al. 1990).
Mast cell-derived mediators are capable of producing many of the abnormalities seen
in pathological specimens from patients with asthma (Chung 1986; Holgate et al.
1987; Townley,RJ and Hopp 1987). Lymphokines released from inflammatory cells
may also alter beta-adrenoceptor function, and so may be responsible for some of
the abnormalities in the beta-adrenergic system seen in subjects with asthma (see
below) (Nijkamp and Henricks 1990). Thus, the increased bronchial responsiveness
seen in asthma could be explained by interactions between inflammatory cells,
mediators and bronchial smooth muscle and its neural control (Chung 1986).
Bronchial wall inflammation could also contribute to bronchial responsiveness by
increasing the thickness of the bronchial wall. A study of postmortem lung
specimens taken from patients with asthma confirmed increased thickness of
membranous and cartilaginous airway mucosa and submucosa (James et al. 1989).
As a result, less smooth muscle shortening was required to occlude the lumen,
although baseline airways resistance was only slightly increased. However, the
authors commented that the geometric consequences of altered airways structure
could not entirely explain the marked airways hyper-responsiveness seen in asthma.
Chronic bronchitis is characterised by mucus hypersecretion and enlargement of
submucosal glands; this may also be associated with inflammation of bronchiolar
walls (Jeffery 1991). In smokers undergoing surgery for bronchogenic carcinoma,
pre-operative bronchial responsiveness was related to the degree of bronchiolar
inflammation in the resected lung (Mullen et al. 1986). Differences have been found
between the inflammatory infiltrates in the airways of asthmatic and chronic
bronchitic subjects (Laitinen and Laitinen 1991).
iii) Altered autonomic control
Autonomic nerves have effects on airway smooth muscle, bronchial vessels and
mucous glands, and thus could contribute to airway narrowing in both asthma and
chronic bronchitis (Barnes 1987; De Jongste et al. 1991). Both sympathetic and
parasympathetic nervous systems innervate the lung, and there is also evidence that
a third "non-adrenergic non-cholinergic" (NANC) system may be involved (Barnes
1984). An imbalance between the effects of the cholinergic and sympathetic nervous
systems was suggested as a cause of asthma as long ago as 1921 (Alexander and
Paddock 1921); the possible contributions of the different nervous systems to
increased bronchial responsiveness in asthma and chronic bronchitis will be
discussed below.
a) Parasympathetic (cholinergic) nervous system
There is direct innervation of the walls of the major bronchi by cholinergic nerves
originating in the vagus and synapsing in ganglia within the bronchial wall. Inhaled
cholinergic antagonists (eg ipratropium) cause bronchodilatation in normal
individuals, indicating a degree of resting cholinergic bronchoconstrictor tone.
Activation of these cholinergic nerves (by reflex mechanisms or stimulation of
afferent bronchial wall irritant receptors) produces bronchoconstriction; this is
thought to be one of the mechanisms by which histamine alters bronchial calibre.
Although cholinergic agonists produce exaggerated pupillary responses in asthmatic
and atopic subjects compared with normals, there is no direct evidence that
cholinergic tone is increased in asthma (Barnes 1986). The fact that anticholinergic
agents produce relatively more bronchodilatation in chronic bronchitis than in
asthma implies a more important role for increased cholinergic tone in the
pathophysiology of chronic bronchitis (van Schayck et al. 1991). Possible
mechanisms of such enhanced cholinergic activity could include potentiation by
inflammatory mediators, defects in pre- or post-junctional receptor function, or
increased end-organ responsiveness to acetylcholine (Barnes 1986; De Jongste et al.
1991). Alternatively, airways inflammation could increase reflex vagal activity by
exposing sensory nerve endings to nonspecific irritants.
b) Sympathetic (adrenergic) nervous system
Although there is no direct sympathetic innervation of the bronchi, both alpha and
beta-adrenoceptors are found in the lungs. These receptors may bind circulating
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endogenous catecholamines: control of beta-adrenoceptor density and binding
affinity by circulating catecholamine levels has been demonstrated in normal
volunteers (FraserJ et al. 1981; Feldman et al. 1983). There is evidence of
defective catecholamine release in some asthmatics: post-exercise catecholamine
levels are lower in subjects with exercise-induced asthma, and catecholamine levels
do not increase even in acute severe asthma (Barnes 1987).
The majority of evidence suggests that beta rather than alpha-adrenoceptors are
involved in the pathogenesis of asthma. Alpha-adrenoceptors are sparse in the lung,
although may be increased in chronic bronchitis. Some studies have shown increased
alpha-receptor responsiveness in asthma, and receptor stimulation can under some
conditions cause contraction of airways smooth muscle and submucosal gland
secretion (Barnes 1986). Flowever, alpha-receptor blockers do not alter lung
function or bronchial responsiveness in asthmatics (Barnes 1986, 1987).
Beta-adrenoceptors are widespread throughout small and large airways smooth
muscle, epithelial cells, and submucosal mucus glands (Carstairs et al. 1985). Beta-
adrenoceptor agonists not only promote bronchial smooth muscle relaxation, but also
may increase mucociliary clearance (Pavia et al. 1980; Phipps et al. 1982), stabilise
mast cells (Peters et al. 1982) and reduce vascular permeability (Persson et al.
1982). Thus defective beta-adrenoceptor function might be expected to produce
several of the airways abnormalities seen in asthma.
The observation by Szentivanyi and colleagues that intraperitoneal administration of
Bordatella pertussis in animals induced both increased airways sensitivity to
histamine and decreased response to beta-adrenoceptor agonists revived the theory
of beta-adrenoceptor dysfunction as a cause of asthma (Szentivanyi 1968). Since
then, numerous in vitro and in vivo studies of beta-adrenoceptor density and activity
have been performed, some of which support this hypothesis. However, there is no
convincing evidence to suggest that altered beta-adrenoceptor activity is present in
patients with chronic bronchitis (De Jongste et al. 1991).
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The fact that beta adrenergic antagonists cause bronchoconstriction in asthmatic but
not normal subjects suggests that resting airways tone is maintained by sympathetic
drive in asthma (McNeill 1964). Furthermore, asthmatic subjects have diminished
pulse rate and metabolic responses to beta-agonists (Lockey et al. 1967; Grieco et
al. 1968; Middleton and Finke 1968; Bernstein et al. 1972). Moreover, monitoring
of blood pressure, pupillary responses and cutaneous blood flow showed evidence
of beta-adrenoceptor hyporeactivity and increased cholinergic and alpha-adrenergic
responses in patients with asthma and allergic rhinitis compared with controls
(Kaliner et al. 1982; Lemanske and Kaliner 1990).
Direct measurement of alpha- and beta-adrenoceptor number and function has been
possible following the identification of such receptors on human peripheral
leukocytes, and the demonstration of similarities between these and lung
adrenoceptors (Conolly and Greenacre 1977; Goldie et al. 1984). Using this model,
several authors have shown abnormalities of both receptor number (Brooks et al.
1979; Kariman 1980), and function (Parker and Smith 1973; Connolly et al. 1992b;
Nielson et al. 1992) in patients with asthma.
A major confounding factor in such research is the use of beta-agonist medications
by the majority of patients with asthma. The discovery of tachyphylaxis in response
to beta-agonist stimulation raised the possibility that the in vivo and in vitro beta-
adrenoceptor abnormalities demonstrated in asthmatics may be the result of beta-
agonist therapy (Morris 1980). In vitro, prolonged exposure to beta-agonists leads
to desensitization of mononuclear cell beta-adrenoceptors (Galant et al. 1978;
Conolly et al. 1979). Despite this, there is little evidence for a clinically significant
reduction in bronchodilator response following prolonged beta-agonist therapy in
vivo (Harvey and Tattersfield 1982; Schuster et al. 1991). It is possible that blood
mononuclear cell beta-adrenoceptors are more susceptible to agonist-induced down-
regulation than lung beta-adrenoceptors (Svedmyr et al. 1976; Tashkin et al. 1982).
The influence of beta-agonists can be overcome by studying patients who have never
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used this treatment. Beta-adrenergic hyporesponsiveness has been demonstrated in
vivo in untreated subjects with allergic rhinitis (Kaliner et al. 1982; Lemanske and
Kaliner 1990). More significantly, a study of mild asthmatics never treated with
beta-agonists found inverse relationships between bronchial responsiveness in vivo,
and in vitro measurements of mononuclear cell beta-adrenoceptor density, binding
affinity and functional response to beta agonist (Connolly et al. 1992b; Nielson et
al. 1992). However, the importance of intrinsic beta-adrenoceptor abnormalities in
the pathogenesis of asthma and other forms of airflow obstruction remains unclear.
Beta-adrenoceptor autoantibodies have been described in a small proportion of
patients with asthma or allergic rhinitis, as well as some normal individuals (Venter
and Fraser 1980; Fraser and Venter 1982). Moreover, decreased beta-adrenergic
sensitivity was demonstrated in autoantibody-positive individuals (Venter and Fraser
1985). In a population of 376 asthmatic children, beta-receptor autoantibodies were
found in 8.8% of severe asthmatics and 3.4% of mild asthmatics (Blecher 1984;
Fraser,CM and Venter 1984). Thus it is possible that in a small subset of patients
with asthma, the presence of auto-antibodies to beta-adrenoceptors mediates
autonomic dysfunction and contributes to the pathogenesis of the disease.
Some of the abnormalities of beta-adrenergic function described in asthma are
similar to changes occurring as part of the normal ageing process. In vivo, the heart
rate response to isoprenaline decreases progressively with age (Vestal et al. 1979;
Bertel et al. 1980; Fitzgerald et al. 1984), and plasma noradrenaline levels are
higher in older than younger subjects (Krall et al. 1981). In vitro, lymphocytes of
healthy elderly subjects have been shown to have similar beta-adrenoceptor density,
but reduced receptor response to agonists when compared with those of younger
subjects (Dillon et al. 1908; Abrass and Scarpace 1981, 1982; Doyle et al. 1981;
Krall et al. 1981; Heinsimer and Lefkowitz 1985). A study of non-asthmatic and
asthmatic young and elderly subjects confirmed normal mononuclear leucocyte beta-
adrenoceptor density, but reduced receptor binding affinity in elderly normal
subjects; binding affinity was further reduced in elderly asthmatics (Connolly et al.
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1994). In contrast, young asthmatic subjects had normal beta-adrenoceptor binding
affinity, but reduced density when compared with young normals. Bronchial
responsiveness was related to receptor affinity in all subject groups, but a
relationship between receptor density and bronchial responsiveness was seen only
in young asthmatic subjects.
If decreased beta-adrenergic function contributes to increased bronchial
responsiveness in asthma, then it might also be expected that the decrease in beta-
adrenergic function occurring as a part of normal ageing would lead to an increase
in bronchial responsiveness with age. Epidemiological evidence for and against a
change in the prevalence of bronchial hyper-responsiveness with age is discussed
below (page 55).
c) Non-adrenergic non-cholinergic system
There has been evidence for some time for the existence of a further inhibitory
neural pathway which does not respond to either adrenergic or cholinergic stimuli
(Boushey et al. 1980; Barnes 1984). Despite much research, the nature of the
neurotransmitter involved in these non-adrenergic non-cholinergic (NANC)
inhibitory nerves is unclear, although it is believed to be a neuropeptide (Barnes
1984).
Defective function of this system could in theory contribute to increased bronchial
responsiveness. However, there is as yet no firm evidence that this is the case:
further research into the nature of the neurotransmitters involved in the NANC
system, and into ways of influencing NANC activity is awaited.
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D) EPIDEMIOLOGY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC
AIRFLOW OBSTRUCTION, AND NONSPECIFIC BRONCHIAL
RESPONSIVENESS
i) Methods of estimating the prevalence of asthma, chronic bronchitis and
chronic airflow obstruction
Several epidemiological surveys have described the prevalence and associations of
asthma and chronic bronchitis in different populations; some of these are
summarised in tables 1.1-1.3. These results have been obtained over a time period
of at least 20 years; changes in smoking habits and environmental conditions over
the same time period complicate direct comparison between studies.
Unfortunately, there is no universally agreed definition of asthma, and no consensus
on which symptoms or investigations are essential to establish this diagnosis (Gross
1980). Consequently, different surveys have used different defining criteria, and the
results are not directly comparable. Furthermore, the relationship between asthma
and other parameters may be influenced by the definition of asthma. For example,
a study defining atopy as an essential feature of asthma is likely to find strong
relationships between asthma and measures of atopy (eg skin test results, total IgE
levels) (Tager et al. 1987).
Methods used to identify asthma in epidemiological surveys include questionnaires
to identify subjects reporting physician-diagnosed asthma or asthma-associated
symptoms; clinical examination of subjects by a physician; spirometric
measurements, with or without measurement of response to inhaled bronchodilators
("reversibility"); and measurement of bronchial responsiveness by bronchial
challenge. None of these methods can be regarded as a gold-standard test for the
detection of asthma (Samet 1987; Woolcock 1987). Similarly, studies of the
prevalence of chronic bronchitis have used questionnaires about respiratory
symptoms and smoking habits, and pulmonary function tests have been used to 1-























































































































































































































































































































































































































































































































































ii) Estimated prevalence of self-reported asthma and chronic bronchitis
Perhaps the simplest method of measuring the prevalence of a disease is to ask
subjects whether they have ever received this diagnosis. The accuracy of this
method depends not only on the subject's memory, but also on the diagnostic
methods and communication skills of their doctor. Despite this, several population
surveys of asthma have relied solely on this method of disease detection; it has been
used less commonly in studies of chronic bronchitis.
One obvious problem with the use of self-reported diagnoses of asthma or chronic
bronchitis is the similarity in symptoms associated with these two disorders, and the
lack of established diagnostic criteria with which to distinguish between them. This
can lead to patients receiving multiple diagnostic labels for the same respiratory
symptoms. For example, in the Tucson survey (table 1.2) approximately half of
subjects aged >65 years reporting asthma also reported chronic bronchitis and/or
emphysema (Dodge and Burrows 1980). Furthermore, when the symptoms and
pulmonary function of individuals reporting either asthma or chronic bronchitis (or
emphysema) have been compared, there has been considerable overlap between the
different diagnoses (Dodge et al. 1986). In one study, the particular diagnostic label
given seemed to be influenced more by social class and gender than by symptoms
or lung function (Littlejohns et al. 1989).
The accuracy of self-reported diagnoses has also been questioned by studies
comparing self-reported asthma and chronic bronchitis with diagnoses recorded in
medical records. A study of 14404 Americans found substantial under-reporting of
diagnoses, particularly by older individuals, with under-reporting being greater for
the diagnosis of chronic bronchitis than for asthma (McWhorter et al. 1989). The
opposite was found in a British study, where 8.7% of the study population reported
that they had at some time suffered from asthma, but only 4.9% had a diagnosis of
asthma recorded by their general practitioner (Trigg et al. 1990). In a preliminary
report of a study of adults aged >65 years, although 24.4% of subjects were
thought to have asthma on the basis of symptoms and spirometry, only 7% of these
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were aware that they might have asthma (Parameswaran et al. 1995).
Furthermore, studies including both the question "have you ever had asthma/chronic
bronchitis", as well as "have you ever been diagnosed as having asthma/chronic
bronchitis by a doctor", have identified a small proportion of subjects who answered
affirmatively to the first question but not the second (Lundback et al. 1991; Viegi
et al. 1994a). The significance of "self-diagnosed" asthma (ie not diagnosed by a
doctor) is unclear. In the Tucson study, subjects with an unconfirmed diagnosis of
asthma tended to be diagnosed as asthmatic by their physician during subsequent
years (Dodge et al. 1986). However, in Tecumseh only 53% of subjects reporting
"self-diagnosed" asthma were judged to have asthma by the study physician (Broder
et al. 1974). Thus relying on self-reported diagnoses of asthma or chronic bronchitis
may not be a reliable method of detecting these conditions in an adult population.
Table 1.4 summarises the results of studies measuring the prevalence of self-
reported asthma or chronic bronchitis: where available, the rate of physician-
diagnosed (rather than self-diagnosed) disease is stated. It can be seen that most
estimates for the cumulative prevalence of asthma lie between 5% and 10%. The
exception is the second study of the population of Busselton, Australia, which
reported the prevalence of physician-diagnosed asthma to be 16% (Peat et al.
1992a). This figure is significantly higher than that found in the same population 5
years earlier (Woolcock et al. 1987), suggesting an increase in the prevalence of
asthma over this time period. However, the prevalence of bronchial hyper-
responsiveness was similar in the two Busselton surveys, and longitudinal surveys
in other areas have suggested a much smaller increase in the prevalence of
diagnosed asthma (Viegi et al. 1994a). Thus increased awareness of asthma and
altered diagnostic practices may have contributed to the very high prevalence of
diagnosed asthma in the second Busselton survey (Peat et al. 1992a).
Three of the studies in Table 1.4 give separate figures for the prevalence of asthma



















































































































older subjects: physician-diagnosed asthma was reported by 6% of subjects aged 65-
66, but by only 4%-5% of those aged 35-36 and 50-51 (Lundback et al. 1991). In
contrast, two other studies report lower prevalence of self-reported asthma in older
age-groups: in Tucson, 7.8% of subjects aged 45-74 and 4.7% aged >75 reported
asthma (Lebowitz et al. 1975), and diagnosed asthma was also inversely correlated
with age in French subjects aged 22-45 years in the European Community
Respiratory Health survey (Neukirch et al. 1995). These prevalences of self-reported
asthma in older adults are all much lower than that described in the preliminary
report of a study of 2004 adults aged >65 years in Sunderland, UK (Parameswaran
et al. 1995). In this study, 24.4% of subjects satisfied criteria for a diagnosis of
asthma on the basis of a symptoms questionnaire and spirometry. Thus no clear
pattern of the effect of age on the prevalence of diagnosed asthma can be found
from these studies. Furthermore, differences between age groups in a cross-sectional
survey may be the result of changes in disease awareness and diagnostic practices
over time; actual changes in disease prevalence with age can only be assessed
accurately by a longitudinal study.
Comparisons between prevalence of asthma in different geographical regions are
hampered by the different methodology used by different authors. Three studies
have compared the prevalence of reported asthma using identical methodology in
different regions. Viegi et al compared a rural area of Italy (the Po River Delta)
with a more industrial area (Pisa), and also repeated the Po River Delta study after
the opening of a large industrial site (Viegi et al. 1991a, 1994a). The prevalence of
reported asthma was slightly higher in Pisa than in the first Po Delta study; in the
second Po Delta study, this difference was less apparent, suggesting that exposure
to environmental pollutants may have been a factor. Secondly, a report from the
European Community Respiratory Health Study has compared rates of reported
asthma in three French cities, and found significantly lower rates in a city in the
Alps (Grenoble) than in Paris. Again, environmental factors were suggested as a
cause for this difference (Neukirch et al. 1995). Finally, the second NHANES study
in America included a national sample of the population of the United States.
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Comparison of diagnoses reported by subjects living in urban and rural areas
showed higher prevalence of asthma in rural areas, while allergic rhinitis was
reported more commonly in urban areas (Turkeltaub and Gergen, 1991).
The effect of smoking on the prevalence of reported asthma has been assessed by
several of the studies summarised in Tables 1.1-1.3. Two studies found similar
rates of reported asthma in both smokers and non-smokers (Schachter et al. 1984;
Bakke et al. 1990). Furthermore, in one population the number of male smokers
aged >75 reporting asthma was unexpectedly low, raising the possibility of
increased mortality in aged male asthmatic smokers (Isoaho et al. 1994b). Evidence
for a link between smoking and asthma was reported in a study of twins, where a
diagnosis of asthma was found to be more common in those who were smokers
(Vesterinen et al. 1988). In the NHANES II study, all upper and lower respiratory
conditions were reported more often by smokers, except allergic rhinitis, which was
more frequent in non-smokers (Turkeltaub and Gergen, 1991).
In an attempt to characterise subjects reporting diagnosed asthma, some authors have
compared them with the rest of the population. In the Tucson study, a reported
diagnosis of asthma was associated with increased serum IgE, eosinophil counts,
positive skin tests, and reduced FEVj (Burrows et al. 1988). Several surveys have
shown increased frequency of respiratory symptoms (particularly wheeze and
nocturnal breathlessness) in subjects reporting asthma (Mortagy et al. 1986;
Lundback et al. 1991; Neukirch et al. 1995). Ethnic differences have also been
reported, with diagnosed asthma being more common in non-Hispanic than Hispanic
inhabitants of Bernallillo (Samet et al. 1982), and more common in Anglo-
Americans than Mexicans (Di Pede et al. 1991).
Few studies have measured the prevalence of chronic bronchitis based on physician
diagnosis, perhaps recognising the wide variation in diagnostic practice in this area
(Table 1.4). The reported prevalences vary from 1.3% to 7%; this is much lower
than the prevalence of chronic bronchitis estimated by other methods (see pages 42,
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45). Increasing age and cigarette consumption have been identified as risk factors
for a reported diagnosis of chronic bronchitis (Samet et al. 1982; Lundback et al.
1991; Turkeltaub and Gergen, 1991), although in the Tucson study the prevalence
of chronic bronchitis was similar for subjects aged younger and older than 75
(Lebowitz et al. 1975).
iii) Estimated prevalence of respiratory symptoms
Several questionnaires have been designed to assess the prevalence of symptoms
associated with asthma and chronic bronchitis (van der Lende and Orie 1972;
Mortagy et al. 1986; Burney and et al. 1989; Venables et al. 1993). Most of these
are adapted from respiratory symptoms questionnaires designed by the Medical
Research Council (MRC) (Medical Research Council 1960) or the American
Thoracic Society (ATS) (Ferris 1978). However, the symptoms associated with
asthma and chronic bronchitis (and indeed emphysema) are similar. The same
symptoms are also seen in other respiratory and cardiovascular diseases, and
questionnaire data alone may be insufficient to distinguish between these. Evaluation
of the sensitivity and specificity of symptoms questionnaires for the identification
of asthma or chronic bronchitis is thus important, but problematic in view of the
absence of a gold-standard test for the diagnosis of asthma or chronic bronchitis
(Toren et al. 1993). Most studies have compared the results of questionnaires with
those of bronchial challenge tests or physician examinations.
The results of epidemiological surveys which have estimated the population
prevalence of respiratory symptoms are summarised in Table 1.5. It can be seen that
the reported cumulative prevalence of the various symptoms vary widely between
populations, and in some populations are surprisingly high. Even higher figures are
obtained when the prevalence of any respiratory symptom is considered: 36.5% of
Italian men and 21.2% of women aged 18-64 reported one or more respiratory
symptoms (Viegi et al. 1991a), as did 41% of Swedes aged less than 67 years





































































































































































































1991; Horsley et al. 1991), 50% of Dutch adults aged 20-70 (Boezen et al. 1995)
and 38.4% of men and 36.5% of women aged 18-70 in Cracow, Poland
(Krzyzanowski and Lebowitz 1992).
Most surveys have shown an increase in the prevalence of symptoms with age
(Lebowitz et al. 1975; Burr et al. 1979; Mortagy et al. 1986; Rijken et al. 1987;
Bakke et al. 1991c; Lundback et al. 1991; Viegi et al. 1991a; Boezen et al. 1995),
with this relationship even extending above the age of 65 (Dow et al. 1991).
Smoking is also associated with a higher prevalence of respiratory symptoms (Milne
and Williamson 1972; Samet et al. 1982; Rijken et al. 1987; Bakke et al. 1991c; Di
Pede et al. 1991; Horsley et al. 1991; Lundback et al. 1991; Viegi et al. 1991a;
Krzyzanowski and Lebowitz 1992; Menezes et al. 1994). In the Normative Aging
Study, current smoking was the strongest predictor of new onset of wheezing over
3 years of follow-up; the risk of developing wheeze also increased with increasing
age (Sparrow et al. 1993). Thus, differences between the age range and smoking
habits of the various populations studied may explain some of the variation in
symptom prevalence.
Exposure to pollution has also been suggested as a factor contributing to the
variation in symptom prevalence between urban and rural areas. Several population
comparisons have suggested higher symptom prevalence in areas with environmental
pollution than in non-polluted areas (Viegi et al. 1991a), with this difference being
particularly prominent in non-smokers (Detels et al. 1981; Hodgkin et al. 1984).
However, this difference was not confirmed by the European Community
Respiratory Health Survey of French cities (Neukirch et al. 1995). Occupational
exposure to dusts or gases has also been associated with increased reporting of
respiratory symptoms in some populations (Hodgkin et al. 1984; Bakke et al. 1991c;
Viegi et al. 1991b). In a study of adults with asthma or chronic bronchitis,
frequency of respiratory symptoms increased with increasing levels of ambient air
pollution (Higgins et al. 1995). However, studies comparing the prevalences of
asthma and atopy in West and East Germany have found higher levels of both in the
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affluent West than in the industrial East (Magnussen et al. 1993).
There is some evidence that the reporting of respiratory symptoms is increasing.
The two cross-sectional studies of the Busselton population in 1981 and 1990 used
the same respiratory symptoms questionnaire: all symptoms were more common in
the second survey, particularly wheeze (reported by 17.5% of the population in
1981 and 28.8% in 1990) (Woolcock et al. 1987; Peat et al. 1992a). Barbee et al
have reported a much smaller increase in symptoms over 8 years of follow-up of a
subset of subjects taking part in the Tucson epidemiological survey: the prevalence
of allergic rhinitis increased by 11% in this cohort over 8 years of follow-up
(Barbee et al. 1991).
Several population-based surveys have found differences in the respiratory symptoms
reported by men and women. Men describe cough, sputum and wheeze more often
than women (Caird and Akhtar 1972; Milne and Williamson 1972; Lebowitz et al.
1975; Burr et al. 1979; Krzyzanowski et al. 1990; Bakke et al. 1991c; Viegi et al.
1991a; Isoaho et al. 1994a; Neukirch et al. 1995), whereas breathlessness is more
common in women than men (Milne and Williamson 1972; Lebowitz et al. 1975;
Krzyzanowski et al. 1990; Bakke et al. 1991c; Viegi et al. 1991a; Isoaho et al.
1994a).
Some authors have compared levels of pulmonary function and bronchial
responsiveness in symptomatic and asymptomatic subjects. Symptomatic subjects
tend to have lower spirometry results than asymptomatic subjects (Caird and Akhtar
1972; Burr et al. 1979; Krzyzanowski et al. 1990; Isoaho et al. 1994a; Lundback
et al. 1994), and in one population, mean FEVi progressively decreased with
increasing number of symptoms reported (Boezen et al. 1995). Symptomatic subjects
also have a higher prevalence of bronchial hyper-responsiveness than asymptomatic
subjects (Rijken et al. 1987; Trigg et al. 1990), with increased bronchial
responsiveness being more strongly associated with wheeze than cough or sputum
(Rijken et al. 1987, 1989; Trigg et al. 1990). Symptoms suggesting "bronchial
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irritability" (morning chest tightness for >1 hour, nocturnal breathlessness, and
breathlessness or wheeze triggered by exposure to inhaled irritants) were strongly
associated with increased bronchial responsiveness in a population sample of young
adults (Mortagy et al. 1986), but not in older adults (Horsley et al. 1991; Dow et
al. 1992b).
Comparison of Tables 1.4 and 1.5 shows that the prevalence of respiratory
symptoms is higher than the prevalence of diagnosed asthma or chronic bronchitis
in most populations. The significance of this is not clear. It may be that subjects
completing questionnaires report symptoms which are not of sufficient severity to
take them to their doctor. Alternatively, doctors may be failing to make appropriate
diagnoses in symptomatic patients, so underestimating the prevalence of respiratory
disease. In Tucson, many symptomatic subjects without a diagnosis of asthma or
chronic bronchitis went on to receive such a diagnosis in subsequent years (Dodge
and Burrows 1980). In contrast, studies including physician examination of all
subjects have found that only a small proportion of symptomatic subjects meet
diagnostic criteria for asthma or chronic bronchitis (Broder et al. 1974; Cerveri et
al. 1987; Lundback et al. 1993a; Murray,SA and Graham 1995). Thus it seems
likely that surveys relying on respiratory symptoms questionnaires alone will over¬
estimate the population prevalence of asthma.
Unlike asthma, the definition of chronic bronchitis is based purely on the presence
of a particular combination of symptoms (ie chronic cough and sputum production).
Consequently, it might be expected that the prevalence of these symptoms would be
similar to the prevalence of diagnosed chronic bronchitis. However, as Tables 1.4
and 1.5 show, cough and sputum production are reported far more commonly than
a diagnosis of chronic bronchitis. Under-reporting of diagnosed chronic bronchitis
by older smokers has been noted in the NHANESI health survey (McWhorter et al.
1989), and this may contribute to the discrepancy between the prevalence of
symptoms and diagnoses. However, under-reporting of symptoms has also been
described, particularly in older smokers (Lundback et al. 1993a).
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iv) Prevalence of chronic airflow obstruction
The inclusion of spirometry in epidemiological surveys gives an objective method
of detecting airflow obstruction. Measurement of PEFR, FEV\ and FVC does not
require complex equipment, and can be mastered by the majority of adults,
including the elderly (Connolly et al. 1988b). However, as asthma is defined in
terms of variable airflow obstruction, a single measurement of pulmonary function
provides only limited diagnostic information. Repeated measurements on separate
occasions (for example by measurement of peak flow variability over a period of
time (Higgins et al. 1989b)) will increase the sensitivity of the technique, but are
rarely feasible in large population surveys. Furthermore, simple spirometry will not
distinguish between asthma, chronic bronchitis, and other causes of chronic airflow
obstruction.
For this reason, assessment of response to bronchodilator has been included in some
surveys (Burr et al. 1979). However, reversibility of chronic airflow obstruction
does not reliably distinguish between asthma and chronic bronchitis (Kesten and
Rebuck 1994), and does not show consistent correlation with measurement of
bronchial responsiveness (Postma et al. 1988). Asthmatic subjects in remission with
normal lung function may not show a bronchodilator response. Moreover, opinions
differ on the best way of defining bronchodilator reversibility. Traditionally, a cut¬
off of 15% increase over baseline FEVj has been used to define reversible airflow
obstruction - but this fails to take into account short-term variability in repeated lung
function measurements, which may approach 15% in subjects with low baseline
FEV,. This has led some authors to define reversibility as an absolute increase,
rather than a percentage increase, in expiratory flow volume (Tweedale et al. 1987).
The prevalence of chronic airflow obstruction in some published cross-sectional
population surveys is summarised in table 1.6. In the majority of these studies,
spirometry has been performed prior to the start of bronchial challenge in order to
identify subjects excluded because of airflow obstruction. Varying definitions of






































































































studies difficult. The measured prevalence of chronic airflow obstruction varies
widely, from 1% to 18.2%.
Studies comparing lung function in different geographical areas using the same
methodology have suggested a relationship with environmental pollution. The UCLA
population study compared spirometry results in two different areas of Los Angeles:
the prevalence of impaired lung function was higher in a heavily polluted area than
in a relatively unpolluted area, but these differences were smaller than the difference
between smokers and non-smokers (Detels et al. 1981). In the first NHANES study,
a significant negative association was found between measurements of FEV) and
FVC and levels of total suspended particulates for over 6000 adults aged 25-75
living in 49 cities across the United States (Chestnut et al. 1991). This relationship
remained after adjustment for smoking and socio-economic characteristics.
Two of the surveys summarised in Table 1.6 actually set out to estimate the
population prevalence of chronic airflow obstruction. Isoaho et al measured the
prevalence of "chronic obstructive pulmonary disease" (COPD) in adults aged >64
years in Lieto, Finland, defining COPD as FEV1/FVC% <65% (Isoaho et al.
1994a). COPD was found in 3% of women and 12.5% of men; the majority had
only minimal reversibility following salbutamol inhalation. COPD was more
common in smokers: the prevalence in non-smokers was only 2%. Only 51%
percent of men and 33% of women with COPD had chronic productive cough, and
less than half had a diagnosis of airflow obstruction in their medical records. The
authors concluded that chronic airflow obstruction may have an insidious onset and
remain asymptomatic until considerable loss of respiratory reserve has occurred, and
that there may be a large amount of undiagnosed chronic airflow obstruction in
elderly populations. Similar conclusions were reached by a study of Busselton,
Australia, where the prevalence of "chronic airflow limitation" (CAL - defined as
FEV1/FVC% <65% or FEV^ <65% predicted) was found to be 18.2% (Peat et
al. 1990). Again, CAL was more common in smokers, and increased with
increasing age. Only 45% of subjects with CAL had either persistent cough or
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exertional breathlessness.
The fact that many subjects with chronic airflow obstruction do not describe typical
symptoms has also been noted in other populations. In Tucson, Burrows separated
subjects with airflow obstruction into 3 groups: heavy smokers, those with
diagnosed asthma, and others (Burrows 1990, 1991). There was no age difference
between the 3 groups. Respiratory symptoms were reported more frequently by the
"asthmatic" group than the heavy smokers. This suggests either that smoking-related
airflow obstruction produces fewer symptoms than airflow obstruction in asthma,
or that the smokers were under-reporting symptoms. The latter has previously been
noted in another study (Lundback et al. 1993a).
v) Prevalence of increased bronchial responsiveness
Nonspecific bronchial responsiveness to histamine or methacholine is the best
available objective measure of airways lability. In small studies, increased bronchial
responsiveness has been shown to be closely related to symptomatic asthma
(Cockcroft et al. 1977). Although requiring more complex equipment than
measurement of simple spirometry, shortened protocols using portable equipment
have been described and used successfully in large epidemiological surveys (Yan et
al. 1985; Peat et al. 1992b).
The results of epidemiological surveys of bronchial responsiveness are summarised
in Table 1.7. For ease of comparison, PD20 results initially reported in micromoles
of histamine or methacholine have been converted to micrograms. Different authors
have used different parameters to express the results of bronchial challenge: most
use the dose or concentration of challenge agent producing 20% fall in FEV\ (PD20
or PC20 - see page 19), but bronchial challenges in the Vlagtwedde/Vlaardingen
study were stopped after a 10% fall in FEV! (PD10) (van der Lende et al. 1973), and
Cerveri et al have reported the PD15 (Cerveri et al. 1988). Extrapolation of these
results to those expected from higher doses of challenge agent is probably








































































































possible: a PC20 of lmg/ml methacholine is approximately equivalent to a PD20 of
100 fig methacholine (Beach et al. 1993).
Unfortunately, there is no real agreement on what represents a normal bronchial
challenge result, and what defines increased bronchial responsiveness. In the
recommendations for standardisation of bronchial challenge testing published by the
European Respiratory Society (Sterk et al. 1993), it is suggested that PD20> 1500/xg
(> 7.8/xmol) of histamine or methacholine should be regarded as a normal result,
and that levels below this represent abnormally increased bronchial responsiveness.
However, the original studies of the relationship between asthma and bronchial
responsiveness suggested that this level of bronchial responsiveness had a low
positive predictive value for asthma. Cockcroft et al suggested that while
PC20 > 8mg/ml methacholine (equivalent to PD20 > 800/xg) made a diagnosis of
asthma extremely unlikely, only a PC20 < lmg/ml (PD20< 100/xg) gave a positive
predictive value approaching 100% (Cockcroft et al. 1985). Thus, while a
PD20< 1500/xg may not be "normal", this is unlikely to be a useful marker for the
identification of individuals with asthma in a population survey. Beach et al have
proposed that bronchial responsiveness be described as mildly increased if PD20 is
100-800/xg, moderately increased if PD20 is 12.5-100jUg, and greatly increased if
PD20< 12.5/xg. This leaves a large area of measurable but minimally increased
responsiveness (PD20=800-6400 /xg), the significance of which is unclear (Cockcroft
et al. 1977; Beach et al. 1993).
Using these definitions, most studies summarised in table 1.7 are reporting the
prevalence of very mildly increased bronchial responsiveness. As expected, these
prevalences are higher than those of self-reported asthma (Table 1.4). Few studies
have reported the prevalence of levels of bronchial hyper-responsiveness likely to
be associated with definite asthma. Bakke et al describe a 6.0% prevalence of
PC20<8mg/ml in Hordaland (Bakke et al. 1991a); PD20<200/xg (PC20 < 2mg/ml)
was found in 23.0% of the adult population of Surrey, and in 12.0% of those >65
years in the New Forest (Trigg et al. 1990; Horsley et al. 1993).
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Studies including a respiratory symptoms questionnaire as well as bronchial
challenge have shown that not all subjects with increased bronchial responsiveness
have symptoms suggestive of asthma. For example, over half of the subjects with
bronchial hyper-responsiveness (PC10< 16mg/ml) in the Vlagtwedde/Vlaardingen
study were asymptomatic; this may partly be a result of the definition of increased
bronchial responsiveness used in this study, which would be expected to include a
significant number of non-asthmatic individuals (Rijken et al. 1987). Asymptomatic
bronchial hyper-responsiveness has also been identified in populations of children
(Asher et al. 1988; Pattemore et al. 1990), and in adolescents and young adults
(Kolnaar et al. 1995).
The significance of bronchial hyper-responsiveness in asymptomatic subjects is
unclear (Cockcroft and Hargreave 1990). It may precede the onset of symptomatic
asthma, represent very mild "subclinical" asthma, represent asthma in subjects with
a high symptom threshold, or it may not be related to asthma at all. In a study of
adults with rhinitis and no symptoms of asthma, a subset were found to have levels
of peak flow variability and bronchial hyper-responsiveness typical of asthma
(Ramsdale et al. 1985a). The authors suggested that these individuals had
"subclinical" asthma, and either were completely unaware of the sensations
produced by variable bronchoconstriction, or regarded these as normal. Asthmatics
in remission may have persistent bronchial hyper-responsiveness despite being
asymptomatic for 2 or more years (Boulet et al. 1994).
An asymptomatic increase in bronchial responsiveness could also be transient: for
example, as the result of a viral upper respiratory tract infection (Empey et al.
1976; Trigg et al. 1994), or following allergen exposure. Longitudinal studies of
bronchial responsiveness confirm that this varies over time. In the
Vlagtwedde/Vlaardingen study, only half of the subjects who performed at least two
bronchial challenges had a measurable PCI0 on all occasions (Rijken et al. 1993b),
and two longitudinal surveys have shown seasonal variation in bronchial
responsiveness (Britton et al. 1988b; Trigg and Davies 1991; Trigg et al. 1994).
49
A study assessing recognition of methacholine-induced bronchoconstriction has shed
further light on the relationship between respiratory symptoms and bronchial
responsiveness (Stenton et al. 1995). Subjects with 20% fall in FEV\ during
bronchial challenge were asked "have you ever felt like this before?", and their
responses were then compared with their reports of wheeze, cough or breathlessness
on a questionnaire completed before the challenge. Recognition of broncho¬
constriction was more frequent in subjects with marked bronchial hyper-
responsiveness, but showed no relationship to reported respiratory symptoms,
suggesting that responses to respiratory symptoms questionnaires are poor predictors
of bronchial hyper-responsiveness. A similar study, comparing recognition of
methacholine-induced bronchoconstriction in old and young subjects, found that
awareness of bronchoconstriction in the elderly was not related to level of bronchial
responsiveness, and was lower than awareness of younger subjects (Connolly et al.
1992a). These results suggest that the relationship between increased bronchial
responsiveness and symptoms may be weaker in the elderly than the young.
However, published studies have not assessed whether asymptomatic bronchial
hyper-responsiveness is more common in the elderly.
Uncertainty about the significance of asymptomatic bronchial responsiveness has led
some authors to define asthma as increased bronchial responsiveness plus asthma¬
like symptoms (Toelle et al. 1992). In a population study of children, this definition
identified a group with greater peak flow variability, evidence of atopy, and use of
asthma medication than the rest of the population. In the Busselton population, a
definition of asthma as bronchial hyper-responsiveness plus wheeze or breathlessness
within the last year gave relatively constant prevalences of asthma in 1981 and
1990, despite large increases in the prevalence of wheeze and reported asthma
(Woolcock et al. 1987; Peat et al. 1992a).
Difficulties in interpreting bronchial challenge results have been demonstrated by
studies including examination by a physician. In one study of adults with asthma-like
symptoms but normal spirometry, physician diagnosis and bronchial challenge result
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disagreed in 39% of cases (Adelroth et al. 1986). Similarly, in two further studies
of adults with respiratory symptoms, bronchial challenge results showed little
relationship to physician-predicted probability of bronchial hyper-responsiveness
(Dales et al. 1988; Pratter and Irwin 1988). Moreover, in a cross-sectional
population survey, increased bronchial responsiveness was found in only 48% of
subjects reporting a diagnosis of asthma (Trigg et al. 1990).
However, in most populations the relationship between bronchial hyper-
responsiveness and reported asthma has been found to be relatively strong. Two
studies of male industrial workers have found increased bronchial responsiveness to
be related more strongly to reported asthma than to respiratory symptoms (Dales et
al. 1987; Enarson et al. 1987). In one cross-sectional population study, 79% of
subjects designated as asthmatic on the basis of a structured interview and
spirometry had PD20<8mg/ml (<800^g) methacholine (Lundback et al. 1993b).
Furthermore, in a general practice-based study, bronchial hyper-responsiveness was
found in 61.5% of those diagnosed as asthmatic by their doctor, but only 27.6% of
subjects reporting attacks of breathlessness and wheeze (Murray,SA and Graham
A further problem with the use of bronchial challenge in population surveys is that
of low response rate. The nature of the bronchial challenge technique, and the
degree of co-operation involved, have led to response rates lower than 50% in
several studies (Table 1.8). Older subjects, smokers, and those with no past history
of obstructive airways disease tend to be under-represented (Lebowitz et al. 1975;
Burney et al. 1987; Britton et al. 1994a). Moreover, not all of those who do attend
are able to perform satisfactory, reproducible spirometry readings, and this may be
a particular problem in studies of older populations (Isoaho et al. 1994a).
In the interests of safety, individuals with low pre-challenge FEY) (eg <60% of
predicted), and those with other medical conditions (for example ischaemic heart




methacholine. This further reduces the number of participants in surveys of
bronchial responsiveness, and adds another potential source of bias: older
individuals may be more likely to be excluded because of poor health (Table 1.8).
For all of these reasons, it is important that information is available to determine
whether or not those taking part in a population study are a representative sample.
Unfortunately, such information is not always included in published reports




























































































































D) FACTORS ASSOCIATED WITH INCREASED BRONCHIAL
RESPONSIVENESS
Epidemiological surveys have identified possible associations between bronchial
responsiveness and various factors, including age, sex, baseline lung function,
diagnosed asthma, respiratory symptoms, smoking and measures of atopy. The
relationships with respiratory symptoms and diagnosed asthma have been discussed
above; the other factors will be considered below.
i) Pre-challenge airways calibre
The relationship between bronchial responsiveness and baseline FEV! or FEVj/FVC
ratio in subjects with chronic airflow obstruction has been discussed above (page
10). Correlation between level of bronchial responsiveness and pre-challenge
airways calibre has also been seen both in random population samples and in
selected samples of non-asthmatic non-smokers (van der Lende et al. 1973; Malo
et al. 1983; Taylor et al. 1985b; Burney et al. 1987; Lim et al. 1988; Trigg et al.
1990; Horsley et al. 1993). In studies using multiple regression analysis to identify
factors independently associated with bronchial responsiveness, airways calibre
(FEVj or FEV1/FVC%) almost invariably shows a strong association (Kennedy et
al. 1990; Bakkeetal. 1991b; Peatetal. 1991, 1992b; Brittonetal. 1994a; Sparrow
et al. 1994). This relationship is not only seen in those with airflow obstruction, but
has also been found in populations of subjects (including asthmatics) with normal
FEV! (Rijken et al. 1988; Ulrik 1993; Sparrow et al. 1994).
There are several reasons why bronchial responsiveness may be directly related to
airways calibre. Firstly, the custom of expressing bronchial responsiveness in terms
of a percentage change in FEVj (PD20) incorporates the level of pre-challenge FEVj
in the calculation of bronchial responsiveness. Secondly, Poiseuille's law states that
resistance to gas flow through a tube is inversely related to the fourth power of the
radius of the tube (Benson 1975; Holgate et al. 1987). Thus as the airways become
narrower, the effect of smooth muscle contraction on airways resistance will
increase, and substantial bronchoconstriction may be triggered by a smaller
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stimulus: in other words, bronchial responsiveness will increase. Furthermore,
chronic airflow obstruction will tend to increase the proportion of an inhaled
stimulus that is deposited in the central airways, and so the response to centrally-
acting stimuli will be enhanced (O'Connor et al. 1989b). Alternatively, both
bronchial responsiveness and FEV! may be altered simultaneously by the same
disease process. For example, inflammation and oedema of the bronchial wall
epithelium will produce a greater decrease in airways calibre for any given degree
of smooth muscle contraction, and so will reduce FEV! and increase bronchial
responsiveness. Finally, it is possible that bronchial hyper-responsiveness itself is
a risk factor for the development of chronic airflow obstruction, as suggested by the
"Dutch hypothesis" (Orie et al. 1961).
Since some of the other factors thought to affect bronchial responsiveness (age, sex,
smoking, atopy) may also be associated with airways calibre, it is particularly
important to correct for FEV! when investigating the relationship between these and
bronchial responsiveness. Failure to do this makes the results of some published
surveys difficult to assess.
ii) Age
The relationship between age and bronchial responsiveness has been examined in
several population-based studies, with varying results. In some cases, failure to take
the baseline FEVi level into consideration makes interpretation of results difficult,
as FEVi is known to decline with age. The age range of the subjects included is also
relevant, as there is some suggestion that the relationship may be U-shaped, with
higher prevalence of bronchial hyper-responsiveness in very young and very old
subjects. In this case, studies including only middle-aged subjects may fail to detect
an association.
Four published studies have shown a decrease in levels of non-specific bronchial
responsiveness with increasing age. In a random sample of a Norwegian population
(age range 18-73 years, 28% aged >55 years), the prevalence of bronchial hyper-
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responsiveness fell with increasing age after adjustment for FEV!, sex and smoking
status (Bakke et al. 1991a). Similarly, in a large population sample from Nottingham
(age range 18-70 years, 14.4% >60 years), bronchial hyper-responsiveness was
negatively associated with age in a regression analysis which included 3 measures
of airways calibre (absolute FEV!, FEVi % predicted, and FEVi/FVC%) (Britton
et al. 1994a). In the latter study, initial analysis without adjusting for FEV,
suggested that bronchial hyper-responsiveness was more common with increasing
age.
Thirdly, a study of 652 working men (mean age 40 years, upper age limit 65 years)
also reported a negative relationship between age and bronchial responsiveness when
baseline FEV[ was included in the regression equation (Kennedy et al. 1990).
Finally, bronchial hyper-responsiveness to cold air hyperventilation was more
common in children than adults aged < 60 years in a study of 90 families (Weiss
et al. 1984).
A U-shaped relationship between bronchial responsiveness and age has been
suggested by the results of 3 studies. The first 2 of these did not include adjustment
for baseline airways calibre, making the results difficult to interpret. An increased
prevalence of bronchial hyper-responsiveness over the age of 55 was found in a
random population sample of 522 subjects aged 18-64; the increase in bronchial
responsiveness in older subjects was seen mainly in smokers (Burney et al. 1987).
Secondly, bronchial hyper-responsiveness was found to increase in prevalence over
the age of 60 in 148 non-asthmatic, non-atopic, non-smoking subjects aged 5-86 (18
subjects [12%] aged >65 years) (Hopp et al. 1985). Finally, when the results of 5
separate population studies in Australia (4 studies of children and one of adults)
were combined, the prevalence of bronchial hyper-responsiveness was highest in
children aged <10 years and adults aged >70 years (Peat et al. 1992c).
If it is true that the prevalence of bronchial hyper-responsiveness in adults increases
only above a "threshold" age, then studies including few (or no) subjects above this
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threshold will fail to detect an increase. The majority of studies showing no
association between bronchial responsiveness and age have contained few older
subjects (Cerveri et al. 1988; Davis and Byard 1988, 1990; Trigg et al. 1990;
Higgins et al. 1992). The first Busselton cohort contained 114 individuals aged > 70
years; however, this still represented only 12% of the study population (Woolcock
et al. 1987).
Several studies have documented increased prevalence of bronchial hyper-
responsiveness in older adults. In the Vlagtwedde/Vlaardingen study, an increase in
bronchial responsiveness with age was noted in the initial analysis (van der Lende
et al. 1973). The same relationship was reported again in an analysis of cumulative
results recorded over 18 years of follow-up, with adjustment for pre-challenge FEVj
(Rijken et al. 1993a). Information on the number of older individuals included in
this study is not available in the published reports. As part of the Normative Aging
study, bronchial challenge was performed by 914 healthy non-asthmatic men
between 1984-1987 (age range 41-86 years, 110 subjects [12%] aged >70 years).
Analysis of results showed an increase in the prevalence of bronchial hyper-
responsiveness with older age (Sparrow et al. 1994). However, when adjustment for
pre-challenge level of FEVj was included, this relationship only remained significant
for former smokers.
Two smaller studies of non-asthmatic subjects also showed an increase in the
prevalence of bronchial hyper-responsiveness with age. The first of these was a
Chinese study of 86 non-asthmatic non-smokers aged 11-68 years (You-ning et al.
1986). The second included 211 subjects aged 22-86, but did not adjust for pre-
challenge FEV[ in the multiple regression analysis (Lang et al. 1987).
In summary, it is not clear whether there is a relationship between bronchial
responsiveness and age. The different methods of analysis used in different studies,
failure of some authors to include pre-challenge FEV! level in regression equations,
and small numbers of older adults included in most surveys, have led to conflicting
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results in the published literature. Although an increase in bronchial responsiveness
as part of the ageing process is biologically plausible (see page 27), there is as yet
no firm evidence that this occurs.
iii) Gender
The published evidence for a relationship between bronchial responsiveness and
gender is confused. Bronchial hyper-responsiveness has been found by several
authors to be equally prevalent in both sexes (Malo et al. 1983; Weiss et al. 1984;
Hopp et al. 1985; Burney et al. 1987; Higgins et al. 1993; Britton et al. 1994a).
However, other studies have found increased bronchial responsiveness to be more
common in women (Rijken et al. 1987; Cerveri et al. 1988; Trigg et al. 1990;
Carrozzi et al. 1992; Peat et al. 1992a). Only one study has found it to be more
common in men (Bakke et al. 1991a). However, not all authors have included
adjustment for pre-challenge FEVj. In Vlagtwedde/Vlaardingen, initial analysis
suggested increased prevalence of bronchial hyper-responsiveness in men (Rijken
et al. 1987), but this trend was reversed when FEVj was taken into account (Rijken
et al. 1993a). Similarly, Britton et al found that a trend for increased bronchial
responsiveness in women became insignificant when FEVj was included in the
regression equation (Britton et al. 1994a). In contrast, in the Lieto population,
adjustment for pre-challenge FEV! revealed a relationship between increased
bronchial responsiveness and male sex which was not apparent from initial analysis
of the data (Bakke et al. 1991a).
iv) Smoking
Many studies have suggested a link between smoking and bronchial hyper-
responsiveness (Kabiraj et al. 1982; Buczko et al. 1984; Welty et al. 1984; Burney
et al. 1987; Sparrow et al. 1987, 1991a; Bakke et al. 1991a; Carrozzi et al. 1992;
Peat et al. 1992b; Higgins et al. 1993), but it is not clear whether this is a causal
relationship. In the long-term, smoking decreases airways calibre, and so this must
be taken into consideration when the effects of smoking on bronchial responsiveness
are considered. Thus in some cross-sectional studies, an apparent relationship
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between smoking habit and increased bronchial responsiveness has been removed
by inclusion of pre-challenge FEV\ in the analysis (Kennedy et al. 1990; Trigg et
al. 1990; Rijken et al. 1993a; Britton et al. 1994a).
Despite this, there is some evidence that smoking increases bronchial responsiveness
independently of its effect on FEV\. Three studies of subjects with normal FEVj
have found higher bronchial responsiveness in smokers than nonsmokers (Kabiraj
et al. 1982; Taylor et al. 1985b; Cerveri et al. 1989). Furthermore, cigarette
consumption and FEVj were both found to be independently associated with
bronchial hyper-responsiveness in a study of smokers undergoing surgery for
malignant disease (Mullen et al. 1986). A direct effect of smoking on bronchial
responsiveness is plausible: both inflammation and increased permeability of
bronchial epithelium have been demonstrated in human smokers, and both are also
implicated in the pathogenesis of increased bronchial responsiveness in asthmatics
(O'Connor et al. 1989b).
There are several potential sources of bias in research on smoking and bronchial
responsiveness. Firstly, since bronchial hyper-responsiveness is associated with
respiratory symptoms on exposure to inhaled stimuli, it could in theory reduce
tolerance to cigarette smoke (Mortagy et al. 1986). Thus individuals with increased
bronchial responsiveness may be more likely to develop symptoms and give up
smoking. This has been termed the "healthy smoker effect", and it would be
expected to reduce the strength of the relationship between smoking and increased
bronchial responsiveness. Secondly, evidence suggests that older smokers have a
tendency to deny respiratory symptoms and under-report diagnosed chronic
bronchitis in questionnaire surveys, reducing the estimated prevalence of respiratory
morbidity in a population (Lundback et al. 1993a). Furthermore, smokers may be
reluctant to take part in studies of pulmonary function: the prevalence of smoking
in one population survey was 10% lower than the estimated prevalence for the entire
population (Britton et al. 1994a). Alternatively, symptomatic smokers concerned
about their symptoms may be more likely to take part in respiratory health surveys,
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thus falsely increasing the measured prevalence of respiratory symptoms. Such
potential sources of bias may explain some of the conflicting results in the literature.
v) Atopy
Early studies of atopic subjects showed a high prevalence of bronchial hyper-
responsiveness, with significant correlation between the number of positive skin tests
and the level of bronchial responsiveness (Cockcroft et al. 1984). However, further
studies in large populations have not produced consistent results. One reason for this
may be the use of different measures of atopy, including skin testing, total IgE level
and eosinophil count. These different parameters may not measure the same aspects
of the atopic process. Indeed, individuals with positive skin tests may have normal
IgE level and eosinophil counts (Burrows et al. 1989). Some authors have suggested
that there may be different "atopic phenotypes", with different measures of atopy
being associated with different atopic manifestations (Tollerud et al. 1991).
The relationships between skin tests, total IgE levels, eosinophil counts and
bronchial responsiveness will be discussed below.
a) Skin tests
The results of several population studies confirm that positive skin tests are
associated with increased bronchial responsiveness (Burney et al. 1987; Lang et al.
1987; Trigg et al. 1990; Carrozzi et al. 1992; Peat et al. 1992b; Higgins et al.
1993; Britton et al. 1994a). Some authors have noted a reduction in the strength of
this relationship with increasing age (Burney et al. 1987; Peat et al. 1992c; Higgins
et al. 1993), which may be related to the general decline in skin test positivity seen
in older individuals (Hanneuse et al. 1978; Barbee et al. 1987; Cline and Burrows
1989; Tollerud et al. 1991).
No consistent relationship has been found between skin test positivity and smoking
status. Current smokers had fewer positive skin tests than never-smokers in the
Tucson epidemiological survey (Burrows et al. 1976; Barbee et al. 1987; Cline and
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Burrows 1989) but a higher prevalence of positive skin tests than ex-smokers in
another study (Welty et al. 1984). In contrast, two studies have found positive skin
tests to be more common in ex-smokers than in current- or never-smokers (Taylor
et al. 1985b; Barbee et al. 1987). This has led to the suggestion that smoking and
a highly atopic disposition may be incompatible, so that atopic individuals may be
more likely to give up smoking. If true, this may be another manifestation of the
"healthy smoker effect" previously discussed.
There is no evidence of a relationship between skin test positivity and baseline
airways calibre (O'Connor et al. 1989b).
b) Eosinophil count
Eosinophil counts decrease with increasing age (Hanneuse et al. 1978), and in some
studies have been higher in current smokers (Taylor and Luksza 1987; O'Connor
et al. 1989b; Tollerud et al. 1991). Both of these factors complicate studies of the
relationship between eosinophil count and bronchial responsiveness.
There have been conflicting reports of the relationship between eosinophil count and
baseline FEVi. A negative association (eosinophilia associated with low FEV!) has
been found in several populations (Kauffman et al. 1986; Taylor and Luksza 1987;
Burrows et al. 1988; Frette et al. 1991). However, in one population this
relationship was abolished by the exclusion of asthmatic subjects (Burrows et al.
1988). Other studies have found no association between FEV! and eosinophil count
(O'Connor et al. 1989a; Frette et al. 1991).
Several authors have reported an association between eosinophilia and bronchial
hyper-responsiveness (O'Connor et al. 1989a; Rijken et al. 1993a; Sparrow et al.
1994). In one study this relationship was found even in skin-test negative "non-
atopic" subjects, suggesting a role for eosinophils in the pathogenesis of bronchial
hyper-responsiveness independent of the atopic process (Taylor and Luksza 1987).
However, in the Normative Aging Study, exclusion of asthmatic subjects from the
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analysis removed the relationship between eosinophils and bronchial responsiveness
(Parker et al. 1990). Moreover, no relationship was found between bronchial
responsiveness and eosinophil count in a population of working men (Frette et al.
1991).
c) Serum IgE
Like skin test positivity and eosinophil count, total IgE level falls with increasing
age (Hanneuse et al. 1978; Barbee et al. 1981). There is definite evidence that
serum IgE is increased in smokers, but as yet this finding has not been explained
(Vollmer et al. 1986; O'Connor et al. 1989b; Tollerud et al. 1991; Dow et al.
1992a; Taylor et al. 1985a; Jensen et al. 1992). It is possible that smoking may
increase the likelihood of allergen sensitisation, although the lack of a definite
association between smoking and skin test positivity in cross-sectional population
surveys would not support this theory. There is some evidence, however, that
sensitisation to occupational allergens is more common in smokers than non-smokers
(O'Connor et al. 1989b), and so the raised IgE in smokers could relate to rare
antigens not included in standard skin test protocols (Cline and Burrows 1989).
Alternatively, components of cigarette smoke may affect various stages of the
immune response, including processing of inhaled antigens, or macrophage or
lymphocyte function (Casterline 1983).
The nature of the relationship between total IgE level and airways calibre is unclear.
Raised IgE has been associated with low pre-challenge FEV! or FEV^FVC ratio in
some studies (Vollmer et al. 1986; Burrows et al. 1988; Annesi et al. 1992; Dow
et al. 1992b), but not others (O'Connor et al. 1989a). Reported relationships
between IgE and rate of decline of FEV! also vary. Accelerated decline in FEVj has
been found in symptomatic non-atopic smokers with elevated IgE (Jensen et al.
1992), and in non- and ex-smokers with raised IgE in a working male population
(Annesi et al. 1992). However, other population studies have failed to confirm this
relationship (Vollmer et al. 1986; Parker et al. 1990).
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The relationship between serum IgE and bronchial responsiveness is similarly
uncertain. In the Normative Aging Study, bronchial hyper-responsiveness was
associated with increased IgE levels (O'Connor et al. 1989; Sparrow et al. 1994);
this relationship was also found in the Po River Delta population, with multiple
regression analysis revealing IgE level as an independent predictor of bronchial
responsiveness in subjects with respiratory symptoms (Carrozzi et al. 1992). In a
birth cohort of children, bronchial responsiveness was closely linked to serum IgE
level even after the exclusion of children with diagnosed asthma or atopy (Sears et
al. 1991). However, this association was not seen in either a Norwegian population
or in a cohort of working Parisian men (Bakke et al. 1991a; Annesi et al. 1992).
Some authors have suggested an interaction between smoking and atopy in their
effects on airways calibre and bronchial responsiveness. In a study of adults aged
>65 years, multiple regression analysis suggested a synergistic effect of IgE and
smoking on FEVj/FVC ratio, so that smokers with high IgE had the greatest degree
of airflow obstruction (Dow et al. 1992a). An interaction between smoking and skin
test positivity in their effect on bronchial responsiveness was reported by O'Connor
et al, who found that current smokers with positive skin tests had significantly
higher levels of bronchial responsiveness than non-atopic smokers (O'Connor et al.
1989a). Similarly, in a study of 654 working men, the only factors significantly
associated with increased bronchial responsiveness were pre-challenge FEV),
younger age, and a interaction between skin test positivity and current smoking
(Kennedy et al. 1990). However, no such interaction was found in the Busselton
cohort (Peat et al. 1992c).
In summary, skin tests, total IgE levels and eosinophil count are not interchangeable
as measures of atopy. Skin test positivity is associated with increased bronchial
responsiveness, but not with airflow obstruction. Total IgE levels (and possibly also
eosinophil counts) are increased in smokers, but the relationships between these
parameters and airways calibre or bronchial responsiveness are not clear.
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vi) Other factors affecting bronchial responsiveness
There has been considerable interest in the possible contribution of dietary factors
to the pathogenesis of asthma, and relationships between bronchial responsiveness
and various dietary components have been investigated. The initial observation that
mortality from asthma in England and Wales correlated with sales of table salt
(Burney 1987), led to the demonstration that urinary sodium excretion was
associated with airway responsiveness to histamine (Burney et al. 1986). However,
other studies have failed to confirm this relationship (Sparrow et al. 1991b; Britton
et al. 1993). Magnesium induces smooth muscle relaxation in vitro and can cause
bronchodilatation in vivo; hypomagnesaemia has been found in some individuals
with acute asthma. A large population study of bronchial responsiveness and diet
found that dietary magnesium intake was independently related to lung function,
bronchial responsiveness and self-reported wheezing (Britton et al. 1994b).
With the recent increases in both reported asthma morbidity and the levels of some
air pollutants, research has been performed investigating the effects of air pollutants
on bronchial responsiveness. Studies of experimental exposure to ambient levels of
S02, N02 and/or smoke have suggested detrimental effects on lung function and
increased symptoms in subjects with pre-existing airflow obstruction (Abramson and
Voigt 1991; Molfino et al. 1992). Air pollutants could affect bronchial
responsiveness either directly, or indirectly via increased response to specific
allergens (Devalia et al. 1994; Tunnicliffe et al. 1994). In general, however,
epidemiological studies have failed to identify a relationship between air pollution
and asthma. For example, asthma seems to be less common in industrial East
Germany than in West Germany, although levels of bronchial hyper-responsiveness
appear similar in both (Tattersfield 1996). In one cross-sectional population survey,
bronchial hyper-responsiveness was more common in ex-smoking men with a history
of exposure to dusts, chemicals or gases, but no convincing difference was seen in
women (Viegi et al. 1994b).
As smoking becomes less socially acceptable, interest has increased in the effects
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of passive exposure to cigarette smoke on health. Although parental smoking has
been implicated in the development of respiratory symptoms in children, there is no
evidence that passive smoking, at least in the short term, results in impaired lung
function or increased bronchial responsiveness (Weiss et al. 1983; Jorres and
Magnussen 1992).
Comparisons of levels of bronchial responsiveness in individuals of different ethnic
origins have suggested inter-racial differences, although the basis of these
differences has not been explained (Pattemore et al. 1989; Sherman et al. 1993).
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Chapter 2 : AIMS OF THESIS
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(1) To enlist a representative age-stratified random sample of white adults aged >45
years (including a large proportion of elderly adults) from the local (Central
Manchester) population.
(2) To measure the population prevalence of reported asthma, bronchitis and
respiratory symptoms by postal questionnaire.
(3) To measure the prevalence of chronic airflow obstruction using spirometry.
(4) To measure the prevalence of increased bronchial responsiveness by bronchial
challenge with methacholine.
(5) To investigate the relationships between bronchial responsiveness and age, atopy,
airways calibre and smoking.
(6) To assess the effects of chronic airflow obstruction and bronchial hyper-
responsiveness on quality of life.
(7) To assess the effects of bronchial challenge on oxygen saturation.
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Chapter 3: EQUIPMENT AND METHODS
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A) POPULATION SAMPLING
i) Selection of random population sample
The study aimed to recruit a representative population sample of adults, including
large numbers of older subjects (age-stratified random sample). A lower age limit
of 45 years was selected because of the hypothesis of a "U-shaped" relationship
between age and bronchial responsiveness, with the frequency of bronchial hyper-
responsiveness increasing in adults over the age of 55-60 years (Hopp et al. 1985;
Burney et al. 1987; Peat et al. 1992c) (see page 55). Non-Caucasian adults were
excluded because of suggested inter-racial differences in bronchial responsiveness
(Sherman et al. 1993). As the study protocol included completion of a questionnaire
and hospital attendance for bronchial challenge, housebound adults and those with
significant cognitive impairment were also excluded.
The study was approved by the Central Manchester Health Authority Ethical
Committee. Names, addresses and dates of birth of a random sample of adults aged
>45 years and registered with local General Practitioners (GPs) were taken from
computerised records of the Central Manchester Family Health Services Authority
(FHSA), using computerised generation of random numbers. Three hundred and
ninety-five patients of 101 GPs were selected in this way.
GPs were then contacted by post, informing them of the nature of the study and
listing patients who had been selected; patients themselves were not contacted until
the approval of their GP had been obtained. Twenty-two GPs replied, approving the
inclusion of 65 patients in the study. This low response was in part attributable to
GP dissatisfaction at the release of patient details by the FHSA without GP consent.
Seven of the 22 GPs responding to the initial letter subsequently agreed to the
recruitment of a further sample of their patients. Random number tables were used
to select patients from the computerised practice list of each of these GPs. Non-
Caucasian names were discarded at this point. A list of selected patients was then
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screened by the GP, who identified those excluded from the study, plus any felt to
be unsuitable for other reasons (eg psychiatric problems, malignant disease). All
other patients were contacted by post (see below).
Patient recruitment continued from December 1991-December 1993. In the last
months of recruitment, an increase in the number of older adults in the study
population was achieved by discarding the details of every second person selected
at random who was aged less than 70 years.
Eligible subjects were sent a short explanatory letter (Appendix 2.1), describing the
aims and nature of the project. This was accompanied by a questionnaire and a pre¬
paid envelope. Letters were printed on notepaper headed with details of the
appropriate GP practice, and informed subjects that their GP was aware that they
had been contacted. GP headed notepaper was used in an attempt to improve
response rates.
The questionnaire (Appendix 1) was designed for this study, and had two purposes:
a) to estimate the prevalence of asthma, chronic bronchitis and respiratory symptoms
in the population, and to provide information on smoking habits, and b) to identify
subjects suitable for bronchial challenge. Exclusion criteria for bronchial challenge
were: significant history of ischaemic heart disease (previous myocardial infarction,
heart failure, arrhythmias or symptomatic angina) and the use of medications
influencing the outcome of bronchial challenge - ie oral steroids, anticholinergic
drugs, and oral or topical beta-blockers). Respiratory symptoms questions were
adapted from the MRC respiratory symptoms questionnaire (Medical Research
Council 1960). The questionnaire was written in simple language, printed in large
type, and covered one side only of 5 sheets of paper. An early experiment with
questionnaires printed on both sides of the paper revealed that most subjects filled
in only one side.
Returned questionnaires were examined, and responses recorded. Incomplete
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questionnaire pages were returned to the subject with an explanatory note and a pre¬
paid envelope. Subjects not excluded from bronchial challenge by the criteria listed
above were contacted by telephone and invited to attend hospital on one occasion
for bronchial challenge. A suitable date was arranged, and the subject was requested
to refrain from caffeine-containing drinks for 12 hours before this. Those taking
bronchodilators were requested to omit these for 12 hours (inhaled preparations),
24 hours (oral medications) or 48 hours (sustained release preparations) before
attending. All potential attenders were asked if they had a recent upper respiratory
tract infection, or an exacerbation of wheezing: hospital attendance was delayed for
6 weeks after any such episode.
A confirmatory letter (Appendix 2.4) was sent to all subjects who had made an
appointment, reminding them of these instructions and the appointment time, and
requesting them to inform us if they would be unable to attend or developed an
upper respiratory tract infection. A map of the hospital was also included. Suitable
subjects who could not be contacted by telephone were allocated an appointment and
sent the confirmatory letter by post.
Subjects who failed to attend were contacted by telephone with the aim of arranging
another appointment, and answering any worries which may have led to non-
attendance. Non-attenders who could not be contacted by telephone were sent a
letter requesting that they indicate whether or not they wished to be sent a further
appointment. Subjects defaulting twice were not sent further appointments.
ii) Non-responder tracing
Subjects who failed to return the first questionnaire were sent a reminder letter and
second copy of the questionnaire after approximately 4-6 weeks. The reminder letter
incorporated an "opt-out" slip, allowing the subject to request not to be sent an
appointment for bronchial challenge (Appendix 2.2). This was intended to maximise
the response rate, so that subjects who did not wish to attend hospital would feel
able to return the questionnaire.
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A second reminder letter was sent to subjects failing to respond to the first reminder
after one month. This contained an abbreviated version of the questionnaire
(Appendix 2.3), and stated that no further participation in the project would be
required if the questionnaire was returned. There was also a request to return the
letter if the addressee was no longer living at that address.
The abbreviated questionnaire was designed to fit onto one page and contain only
simple questions, to encourage a response from subjects deterred by the length and
complexity of the original questionnaire. To this end, the respiratory symptoms
questions were omitted.
A list of persistent non-responders was returned to each GP, who checked to see
whether they had recently moved away or died. A random sample of those thought
still to be living locally was then contacted by telephone or home visit, and asked
to complete the abbreviated questionnaire.
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B) ATTENDANCE FOR BRONCHIAL CHALLENGE
All subjects signed an information/consent form, listing the procedures involved,
and the possible side-effects of methacholine inhalation (wheeze, headache, facial
flushing) (Appendix 3).
A 12-lead ECG was performed; subjects with ECG evidence of ischaemia were
excluded from methacholine challenge. A venous blood sample was taken for
measurement of serum sodium (Na), potassium (K), magnesium (Mg) levels,
differential white cell count, and total immunoglobulin E (IgE) level.
The subject was then taught how to perform spirometry, and baseline pulmonary
function was measured (mean of 6 recordings reproducible within 10%). Subjects
with baseline FEVj <60% predicted were excluded from bronchial challenge, but
had bronchodilator reversibility measured as described below. A few subjects unable
to perform reproducible spirometry manoeuvres were also excluded from bronchial
challenge. The challenge technique is described below.
Three questionnaires were completed during the hospital visit. The first of these was
an interview-administered questionnaire containing items omitted from the postal
questionnaire for reasons of brevity, including questions about symptoms of
"bronchial irritability" (Mortagy et al. 1986), symptoms of chronic bronchitis
(Medical Research Council 1960), and occupational exposure (Appendix 4).
Secondly, subjects completed the St George's Respiratory Questionnaire (Jones et
al. 1992), which aims to measure quality of life in people with obstructive airways
disease (see chapter 15).
For subjects completing the whole methacholine challenge (ie inhaling the maximal
dose of methacholine), the entire hospital visit lasted approximately 90 minutes.
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i) Bronchial challenge technique
a) Preparation of methacholine solutions
Crystalline methacholine chloride (Sigma pharmaceuticals) was stored at -20°C in
a desiccator until use. A stock solution of 64 mg/ml methacholine in 0.4% phenol
(BDH Chemicals Ltd, Blyth) was prepared using distilled water; sequential dilutions
were made on a daily basis using a diluent of 0.5% sodium bicarbonate in 0.4%
phenol. Both the stock solution and the diluent were suction filtered through a 0.22
/xm millipore membrane filter (Nalgene) to remove any particulate matter, rendering
the solutions effectively sterile. Solutions were protected from light at 4°C until use,
and replaced every 3 months (Pratter et al. 1982).
Doubling dilutions ofmethacholine chloride solution (3.125/xg/ml-3200/xg/ml) were
prepared daily from the stock solution and diluent. The alkaline diluent was
necessary to neutralise the natural acidity of methacholine in solution; the use of
unbuffered acidic solutions of histamine for bronchial challenge has been shown to
produce a slight enhancement of bronchial responsiveness at low levels of pH (ie pH
<5) (Cockcroft and Berscheid 1982). Phenol was included as a preservative. The
pH of all methacholine dilutions was tested with a pH meter: pH ranged from 6.99
(3200/xg/ml) to 8.42 (3.125/xg/ml).
Twelve nebulisers were calibrated as described below, and numbered 1-12.
Nebuliser 1 contained 3ml of sterile normal saline; aliquots of 3ml of increasing
doubling dilutions of methacholine solution were placed in nebulisers 2-12. As
nebuliser output is temperature dependent, solutions were allowed to warm to room
temperature prior to use. Each nebuliser was activated for 3 seconds before the start
of the first challenge, to ensure that all internal surfaces were wetted with nebulised
solution.
b) Function of Newcastle dosimeter
The Newcastle dosimeter is an electronic timing device, designed to allow activation
of a series of nebulisers for precise periods of time, to ensure accurate output of
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nebulised solution. It is controlled by a microprocessor, and triggering of nebuliser
activation at the start of each inhalation can be produced either manually, or
automatically by a pressure transducer. For the purposes of this study, the dosimeter
was triggered manually by the operator at the start of each inspiration, as it had
been observed that some older subjects were "startled" by automatic triggering.
Triggering of the dosimeter opens a valve for a exact time period, the length of
which is controlled by the micro-processor program. While the valve is open,
compressed air passes from a compressed air cylinder to the nebuliser; a pressure
gauge (Budenberg Gauge Co Ltd, Cheshire) attached to the dosimeter allows the
compressed air pressure to be maintained at 20 lb/in2. Nebulisation ceases when the
valve is closed; residual compressed air escapes via a venting device so that
nebulisation ceases immediately. The nebuliser is supported on a height-adjustable
retort stand.
The microprocessor program not only controls the time for which each nebuliser is
activated, but also displays the current dose and inhalation number throughout the
challenge. The program delivers 5 inhalations from each nebuliser, following which
the nebuliser is removed from the retort stand, and replaced by the nebuliser
containing the next doubling concentration of methacholine.
c) Measurement of lung function
For the Newcastle dosimeter technique, the mean of 6 measurements of FEVj is
usually recorded prior to the inhalation of each dose of methacholine (Hendrick et
al. 1986). To avoid fatigue in elderly patients, reproducible challenge results have
also been obtained using the mean of 3 FEV! measurements (Connolly et al. 1988b).
For the purposes of this study, 3 reproducible recordings of FEVj and PEFR were
made immediately before inhalation of each methacholine dose. FEF50 was recorded
for the first of each 3 blows (repeated measurements of FEF50 were not made, as
this parameter is known to be particularly affected by repeated forced expiration).
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Reproducibility of all spirometry measurements was ±10%. The use of a computer-
controlled spirometer (Compact, Vitalograph, Buckingham) allowed FEV\, PEFR
and FEF50 to be calculated from a single maximal forced expiration. Challenge
results were calculated using both the mean and the maximum measurement of each
of these parameters; the repeatability of these results is compared in chapter 5. All
readings were made in the seated position, with the subject wearing a nose-clip. The
spirometer was calibrated daily.
d) Monitoring of oxygen saturation
Studies of oxygenation during bronchial challenge in asthmatic subjects have
suggested that some subjects may experience relative hypoxia during the procedure
(Fontana et al. 1993). All subjects undergoing bronchial challenge as part of the
current study had oxygen saturation and pulse rate monitored using a finger
oximeter (Biox 3700e, Ohmeda, Louisville, USA). Because pulse rate and oxygen
saturation were observed to increase following spirometry, all readings were taken
immediately before each set of spirometry manoeuvres.
e) Inhalation of methacholine
Following 6 reproducible baseline spirometry readings, the subject inhaled nebulised
saline from the mouthpiece of the first nebuliser. Five inspiratory capacity breaths,
each lasting for 5 seconds (with breath-holding at total lung capacity), were taken
from the nebuliser mouthpiece (Hendrick et al. 1986). The dosimeter was triggered
at the start of each inhalation by the test operator, activating the nebuliser for the
exact period of time (usually 1.0-2.5 seconds) required to give an output of 10/xl of
solution. A total of 50/xl of nebulised solution was thus inhaled during the 5 capacity
breaths. At the end of 5 seconds the dosimeter produced an audible tone, signalling
that inhalation/breath-holding could cease. Subjects were encouraged to delay as
little as possible between the 5 inhalations.
Five minutes after the start of the first inhalation of saline, pulse rate and oxygen
saturation were recorded, and the subject then performed three spirometry
manoeuvres before inhaling the lowest dose of nebulised methacholine (again
delivered as five x five second inhalations). The test then continued in 5 minute
cycles: at the beginning of each five minute period, pulse rate and oxygen saturation
were recorded; the subject then performed three spirometry manoeuvres, followed
by inhalation of the next dose of methacholine. The subject then rested until the end
of the next five minutes, when the whole procedure would be repeated. The test
continued until either the final dose ofmethacholine had been inhaled, or the subject
developed bronchoconstriction sufficient to produce a 20% fall from the baseline
FEVj.
At the end of the test, all subjects who had experienced a 20% fall in FEVj were
given lmg of inhaled terbutaline (Bricanyl, Astra Pharmaceuticals, Herts) via a
metered dose inhaler and plastic spacer device (Nebuhaler, Astra Pharmaceuticals).
Subjects remained within the department until FEV! had increased to within 10%
of the baseline value. All nebulisers were emptied and washed carefully in warm
soapy water. To ensure the adequacy of this cleaning technique, swabs were taken
from all nebulisers; culture of these revealed no evidence of bacterial or fungal
contamination.
iii) Measurement of bronchodilator reversibility
Subjects with baseline FEVj <60% predicted did not undergo methacholine
challenge, but instead had assessment of bronchodilator reversibility. Inhaled
terbutaline (lmg) was given via a metered dose inhaler and plastic spacer device,
and spirometry was repeated after 10 minutes. To allow for variability in spirometry
recordings (which can be marked in subjects with low lung volumes), reversibility
was expressed in terms of a fixed volume increase in response to bronchodilator,
rather than a percentage increase (Tweedale et al. 1987). Thus, significant
reversibility was recorded if baseline FEV, increased by 160ml following terbutaline
inhalation.
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C) CALIBRATION OF NEBULISER OUTPUT
The Newcastle dosimeter method relies on knowledge of the precise output of each
individual nebuliser (/d/sec) to allow calculation of the exact time period for which
the nebuliser must be activated to nebulise 10/rl of solution per inhalation. These
timings are then included in the microprocessor program controlling the dosimeter.
Traditionally, nebuliser output has been measured in terms of weight loss, with the
nebuliser being weighed before and after activation for a specific time period.
However, this method assumes that all fluid lost from the nebuliser during activation
is the result of nebulisation, whereas in fact there is also simultaneous loss of
solvent as a result of evaporation (Cockcroft et al. 1989). This evaporative loss
leads to cooling and concentration of the solution in the nebuliser reservoir;
consequently, measurement of weight loss will lead to over-estimation of solute
output. A more accurate method of nebuliser calibration involves direct
measurement of output using a chemical (fluoride) tracer impacted onto filter papers
(Dennis et al. 1990).
i) Calibration method
A solution of 1.0% sodium fluoride (BDH Chemicals Ltd, Blyth) was prepared in
distilled water. Aliquots of 3ml of this solution were placed in each nebuliser
reservoir (Turret Turbo nebulisers, Medic-Aid, Pagham, W. Sussex) using a pipette
(Pressmatic, Bibby). Before the start of the calibration procedure, each nebuliser
was activated for 2 seconds to ensure that all internal surfaces were wet. A 47mm
glass fibre filter (Whatman GF/A; BDH Chemicals Ltd) held in a plastic holder (In¬
line filter holder; Nalgene) was then attached 5cm from the nebuliser outlet via a
rubber connector (Vacuum gasket, Nalgene). To maximise impaction of solute onto
the filter, and to simulate the effect of inhalation by the subject, a suction pump
(N035.1.2AN.18; KNF Neuberger UK Ltd, Oxon) was used to draw ambient air
through the filter paper and nebuliser outlet at 200mbar suction pressure . The
posterior outlet of the nebuliser was occluded during calibration.
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The dosimeter micro-processor was programmed to activate each nebuliser for 5
separate periods of 2 seconds, using compressed air at a pressure of 20 lb/in2. The
suction pump was switched on throughout each 2-second activation. After 5x2-
second activations, the filter was removed and placed in a Universal container
containing 20 ml of a 50% solution of total ionic strength adjustment buffer
(TISAB; BDH Chemicals Ltd) in distilled water. The container was then sealed and
left for at least 12 hours at room temperature to allow the fluoride to desorb.
Fluoride analysis was performed using a fluoride-specific ion electrode (Dennis et
al. 1990). A pH/ion meter (Delta 255, Ciba Corning Analytical, Halstead) fitted
with a fluoride-specific ion electrode and double junction reference electrode plus
an automatic temperature-compensation probe (Premium Electrodes, Ciba Corning
Analytical, Halstead) was calibrated using reference solutions of sodium fluoride.
These were prepared by adding known volumes of 1.0% sodium fluoride solution
to 20ml aliquots of 50% TISAB buffer in Universal containers.
Nebuliser output was expected to be approximately 5/d/s (ie 10/xl per 2-second
activation), thus each filter paper was estimated to contain approximately 5 x 10/xl
of 1 % fluoride solution following 5 x 2-second nebuliser activations. Consequently,
two-point calibration of the ion meter was established with reference solutions
containing 10/xl and 100/xl of 1 % sodium fluoride in 20ml buffer; a further reference
solution containing 50/xl of 1% fluoride was used to check the accuracy of the
calibration curve. The error of fluoride analysis was within the range +5%. All
solutions were agitated continually during analysis using an electromagnetic stirrer.
Calibration was re-tested after each 10 readings to maintain accuracy within +5%.
The buffer solutions containing nebulised fluoride desorbed from the glass-fibre
filters were then analysed using the same calibration curve. The ion meter reading
for each of these solutions represented the volume of 1.0% fluoride solution (/xl)
which had desorbed into the buffer solution, that is, the output of each nebuliser
during 5 x 2-second activations.
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To assess the variability of nebuliser output, the calibration procedure was repeated
3 times for each nebuliser. The mean output (/xl/sec) and output variability were
calculated: nebulisers with mean output <4/xl/sec or >8/zl/sec, or with output
variation >5% were discarded. Suitable nebulisers were numbered, and the
activation time producing an output of 10/xl was entered into the dosimeter micro¬
processor program for each nebuliser.
Nebuliser calibration was repeated at 6-month intervals using this technique;
nebulisers with mean output or variability falling outside the limits defined above
were replaced. The results of repeat nebuliser calibration are given in Appendix 5.
ii) Adaptation of calibration technique
Initial nebuliser calibration was performed by the author in Newcastle, under the
instruction of J. Dennis, who devised and described this method. Twenty-four
nebulisers were tested, 19 of which were found to have acceptable output and
variability. Twelve of these were selected for use in the methacholine challenge
protocol (Table 3.1).
Calibration of the 12 nebulisers used for methacholine challenge was repeated at 6
month intervals in Manchester, using similar apparatus. Initial results using the
Manchester apparatus suggested wide variability of nebuliser outputs, despite all
nebulisers previously having had variability <5% on initial calibration (Table 3.1).
Nebuliser outputs were also lower than initially calculated. Possible reasons for this
increase in output variability were thought to be: (1) loss of fluoride solution during
calibration procedure due to maximal saturation of filter papers; (2) alteration in
nebuliser output resulting from cooling of the fluoride solution during repeated
activation of the nebuliser; or (3) incomplete impaction of fluoride onto filter
because of insufficient suction pressure.
To further investigate these hypotheses, the calibration procedure was repeated using


























































made to the calibration method: (1) two filter papers were inserted simultaneously
into the filter-holder, and the fluoride content of each analysed either separately or
together; (2) the level of suction applied to the filter paper and nebuliser output was
increased to 250 mbar; (3) the fluoride solution in the nebuliser reservoir was
changed after each 5 x 2-second activations (Table 3.2).
When 2 filter papers were used, small amounts of fluoride were detected in the filter
paper positioned furthest from the nebuliser outlet, suggesting that use of only one
filter would lead to incomplete collection of nebulised fluoride. Output variability
was reduced when 2 filters were used instead of 1. In contrast, increasing suction
pressure and changing fluoride solution more frequently did not markedly improve
variability. Thus subsequent calibration was performed as originally described, but
using 2 filters in the filter holder and analysing the fluoride content of both
simultaneously.
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Filter 1 of 2 5.39 10
Filter 2 of 2 0.09 6
Filters 1 + 2 5.50 4
Increased suction 5.37 8




Data was stored on and analysed by a microprocessor statistics program (Ecstatic,
SomeWare in Vermont, USA). Where necessary, log transformation was used to
achieve normal distribution. Comparison of sub-groups was performed by grouped
t test and chi2 tables. Multiple regression analysis was used to assess inter¬
relationships between various parameters. In all cases significance was defined at
the 5% level.
Smoking history was expressed as number of packyears smoked, where 1 packyear
= 20 cigarettes per day for 1 year.
Further details of certain aspects of data analysis are included in the relevant
chapters.
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Chapter 4: QUESTIONNAIRE RESPONSE AND ATTENDANCE FOR
BRONCHIAL CHALLENGE; VALIDATION OF QUESTIONNAIRE
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i) Questionnaire response rate
Of 1025 names selected from GP lists and screened by GPs, 132 (12.8%) met
exclusion criteria or were thought to be unsuitable. Twenty-eight of these subjects
(21.3%) were housebound, 14 (10.7%) were confused, 13 (9.8%) had psychiatric
conditions, 5 (3.8%) had medical conditions precluding participation, 3 (2.2%) did
not speak English, and 3 had other reasons for non-inclusion. In the remaining 66
(50.0%), the reason for exclusion was not specified by the GP (this resulted from
2 GPs labelling excluded subjects as "unfit" or "unsuitable" without giving details;
the proportion of these subjects meeting agreed exclusion criteria is thus not clear).
These 132 subjects were not further included in the study. Questionnaires were sent
to 893 subjects, 110 of whom were subsequently excluded: 78 no longer lived
locally, 15 had died, 6 were non-Caucasian, 2 housebound, 3 cognitively impaired,
1 deaf-and-dumb, and 5 with other illnesses precluding participation. Mean age of
the 110 excluded subjects was 63.3 years; 46 (41.8%) were women. Mean age of
the eligible study population (n=783) was 66.1 years; 446 (57.2%) were women.
Full questionnaires were returned by 508 subjects (64.9% of the eligible
population). Abbreviated questionnaires were returned by 170 subjects, plus 18
visited at home and 27 contacted by telephone: total number of completed
abbreviated questionnaires was 215. Questionnaire data was thus available for 723
subjects (92.3% of the eligible population; 81.0% of the 893 subjects initially
contacted). Twenty-nine subjects refused to complete a questionnaire.
Subjects contacted at home by telephone or home visit comprised a random sample
of persistent non-responders. Thirty phone-calls were made: 27 subjects completed
the abbreviated questionnaire, 1 refused, and 2 had moved away before the start of
the study. Fifty visits were attempted: 18 subjects completed the abbreviated
questionnaire, 1 refused, 10 had moved prior to the study, 3 had moved during the
study (regarded as persistent non-responders), there was no reply at 15 addresses,
and a further 3 addresses could not be located. This left a total of 31 persistent non-
responders (4.0% of the eligible population), of mean age 58.5 years, 17 (54.8%)
86
of whom were women.
Of the 723 subjects returning a questionnaire, 47.7% responded to the first contact,
22.5% to the first reminder, 23.5% to the second reminder (abbreviated
questionnaire), and 6.2% were contacted by telephone or visit.
ii) Demographic details and smoking habits of responders
Table 4.1 compares responders and non-responders. The proportion of women was
similar in all subject groups. However, subjects refusing to participate were older
than questionnaire responders (t=2.8, p=0.005), whereas persistent non-responders
and non-responders contacted at home were younger than responders (persistent non-
responders: t=-4.0, p=0.0001; non-responders contacted at home: t=-3.2,
p=0.001). The 723 questionnaire responders were representative of the entire study
population in terms of age and sex distribution. 1991 Census data suggest that 53%
of the local population aged > 45 are women (Office of Population Censuses and
Surveys 1991a). Figure 4.1 shows the age distribution of all questionnaire
responders: 292 were aged <65 years and 431 >65 years; 411 were women and
312 men.
Details of smoking habits and history of ischaemic heart disease were available for
all subjects completing a questionnaire (Table 4.2). Almost one third (29.2%) of the
population were current smokers; a further third (37.3%) were ex-smokers. Table
4.3 shows differences in smoking habit between men and women, and between older
and younger adults. Women were less likely to be ex- and current-smokers than men
(chi2= 54.7; p<0.001); older adults were more likely to be ex-smokers and less
likely to be current smokers than younger adults (chi2= 13.9, p=0.001).
Younger women were more likely to be current smokers and less likely to be ex-
or never-smokers than older women (women <65 years: 39.1% never-smokers,
Table 4.1: Demographic details of responders and non-responders
Subject
number
Mean age (SD) % women
Entire population 783 66.1 (11.3) 57.2
All questionnaire responders 723 66.7 (11.3) 56.8
Full questionnaire 508 66.6 (11.3) 58.7
Abbreviated questionnaire 215 66.9 (11.3) 52.6
Refused 29 72.5 (11.7) 69.0
Nonresponders contacted
by phone or visit
45 61.3 (11.9) 48.9
Persistent non-responders 31 58.5 (11.1) 54.8
Table 4.2: Prevalence of ischaemic heart disease
and smoking habit in all questionnaire responders
number completing number (%) of
question positive responses
Ischaemic heart disease 720 113 (15.7)
Current smoker 719 210 (29.2)
Ex-smoker 713 266 (37.3)
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Figure 4.1: Age distribution of questionnaire responders
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Table 4.3: Differences in smoking habit between sexes and age-groups
smoking
status
all women all men age <65 age >65
never 182 (44.6%) 58 (18.8%) 88 (30.5%) 152 (35.6%)
ex 118 (28.9%) 148 (48.1%) 94 (32.5%) 172 (40.3%)
current 108 (26.5%) 102 (33.1%) 107 (37.0%) 103 (24.1%)







Age 64.5 67.8 66.1 p<0.05
% women 56.3 57.0 57.2 p>0.1
Current smoker(%) 33.6 30.7 29.2# p>0.1
Ex-smoker(%) 38.5 36.8 37.3# p>0.7
* attenders vs non-attenders or study population # questionnaire responders (n=723)
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contrast, smoking habits were similar in younger and older men, (men <65 years:
21.0% never-smokers, 40.6% ex-smokers, 38.4% current smokers; men aged >65
years: 17.1% never-smokers, 54.1% ex-smokers, 28.8% current smokers,
chi2=5.6, p=0.06).
Twenty-six men smoked cigars, pipe tobacco or roll-up cigarettes rather than
commercial cigarettes: 16 were current smokers, and 10 ex-smokers.
There was no difference between smoking habits of subjects completing full and
abbreviated questionnaires. However, non-responders contacted by telephone or
home visit had a higher prevalence of current smoking than other questionnaire
responders (20.0% never-smokers, 24.4% ex-smokers and 55.6% current smokers;
chi2= 16.0, p<0.001).
iii) Attendance for methacholine challenge
Of 508 subjects returning the full questionnaire, 113 were excluded from bronchial
challenge: 101 reported ischaemic heart disease and/or were using beta-antagonist
medications, one was using anticholinergic medication, and 11 oral steroids. The
remaining 395 were invited to attend; 247 did so (62.5% of those invited; 31.5%
of entire study population). Attenders were significantly younger than non-attenders,
but were otherwise representative of the study population (Table 4.4). The age
distribution of attenders is shown in figure 4.2: 117 were aged <65 years and 129
>65 years; 139 were women and 107 men.
Satisfactory spirometry results were recorded for 246 of the 247 adults attending for
bronchial challenge: one woman was unable to perform reproducible spirometry.
Twenty-nine attenders did not attempt bronchial challenge: two had ECG evidence
of ischaemia, one declined, and baseline FEV) was <60% predicted in 26 (the latter
had reversibility tested with inhaled terbutaline). Of the 217 subjects attempting the
challenge, 9 failed (excessive coughing in 4, fatigue in 3, 1 developed a "choking"
sensation, and 1 failed to master the inhalation technique). Full challenge results
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Figure 4.2: Age distribution of attenders
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were thus available for 208 subjects (118 [56.7%] women, mean age 63.7 years [SD
10.8]).
Side effects were reported by several subjects completing bronchial challenge: the
majority of these were minor sensations of flushing and headache, as previously
reported (Sterk et al. 1993; Carratala et al. 1995). One woman reported dysphonia
after completing a second challenge; both ENT and speech therapy assessment failed
to identify a cause for this, and it seemed unlikely to be the result of methacholine
inhalation. A second subject was reported by her GP to have developed oral thrush
following a challenge: samples of all challenge solutions and swabs from nebulisers
and dosimeter were examined by microscopy and culture for bacteria and fungi,
with negative results in all cases.
iv) Validation of postal questionnaire
Because some of the questions included in the interview-administered questionnaire
(completed by subjects attending for bronchial challenge) were similar to those in
the postal questionnaire, validation of the latter was possible.
Two questionnaires were completed by 244 subjects. Postal responses about wheeze
and sputum were incomplete in 2 cases (Table 4.5). Agreement between the 2 sets
of responses was calculated using Cohen's kappa statistic, which adjusts observed
agreement with agreement occurring by chance (Cohen, 1960).
Adjustment was made for differences in terminology between the questionnaires.
The postal questionnaire asked "does your chest ever sound wheezy", whereas the
supplementary questionnaire also asked about wheeze on exertion, with chest
infections or on exposure to environmental triggers. For the purposes of
questionnaire validation, subjects with wheeze occurring only following
exertion/infections/environmental triggers were regarded as "not wheezy". Similarly,
subjects reporting breathlessness only on exertion (walking uphill) on the postal
questionnaire, or only after exertion/infections/environmental triggers on the
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supplementary questionnaire were regarded as "not breathless".
One or more symptoms were reported by 126 subjects on the postal questionnaire,
compared with 114 at interview. There was highly significant agreement between
questionnaires (sputum: k=0.645, p<0.001; wheeze: k=0.460, p<0.001;
breathlessness: k=0.216, p<0.001; any symptom: k=0.622, p<0.001).
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TABLE 4.5 Comparison of symptoms reported on






Breathlessness* Absent 207 9
Present 22 6
Sputum Absent 133 20
Present 20 69
Wheeze** Absent 136 12
Present 46 48
Any Absent 100 29
Present 17 97
•Not including breathlessness on exertion or with infections
••Not including wheeze on exertion or with infections
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CHAPTER 5: REPEATABILITY OF METHACHOLINE CHALLENGE
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i) Introduction
Before assessing the influence of different factors on bronchial responsiveness, it is
necessary to demonstrate that our method of measuring bronchial responsiveness is
repeatable.
Repeatability is best assessed by calculation of the coefficient of repeatability (CR)
(Bland and Altman 1986). This then allows calculation of 95% limits of agreement
between which further repeated measurements would be expected to lie. This
method is more appropriate than that of regression analysis or calculation of
correlation coefficients, which have been used by some authors in this context
(Juniper et al. 1978), for the following reasons. Correlation assesses the relationship
between two readings rather than agreement between them, thus the correlation
between two measurements of the same parameter by the same method will always
be strong. For perfect agreement between two sets of measurements, the results
must lie along the line of identity, and not just along any straight line. Furthermore,
the correlation coefficient is influenced by the range of variation between the
readings being compared: for a given level of agreement the correlation coefficient
will increase with the variance between the two sets of readings (Bland and Altman
1986; Chinn 1991).
For the purposes of this study, repeatability of bronchial challenge was assessed in
subjects taking part in the epidemiological survey, and compared with a group of
younger volunteers. The results were used to ascertain the most repeatable method
of calculating PD20 or DRS from spirometry measurements made during the
challenge, and also to compare different pulmonary function parameters.
ii) Methods
All subjects completing bronchial challenge were invited to attend for a second time
on a separate day. Twenty-one agreed to do so (age 54-84 years [mean 68.3 years,
SD 7.4]; 10 women; reported asthma 4; reported bronchitis 4; current smokers 8;
ex-smokers 12). A group of young volunteers was recruited from hospital staff
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(n=19; age 24-35 [mean age 27.1 years, SD 3.14]; 7 women; reported asthma 4;
ex-smokers 3; current smokers 0).
Repeat methacholine challenge was performed in all cases at the same time of day
(within 1 hour) as the first challenge, although there is little evidence to suggest a
significant diurnal variation in bronchial responsiveness during the daylight hours
(Beach et al. 1995). The interval between challenges was 3-10 days, to minimise the
effects of refractoriness (demonstrated up to 24 hours following a methacholine
challenge) (Beach et al. 1995) and other factors affecting long-term variability, for
example viral infection (Empey et al. 1976). No subject reported the development
of upper respiratory tract symptoms between the two tests.
iii) Data analysis
Results of the bronchial challenge were expressed as PD20(FEV1) and DRS(FEV1).
Each of these parameters was calculated twice, firstly using the mean, and secondly
the best of the 3 FEVj manoeuvres performed after each dose of methacholine.
Further calculations of dose-response slope were made using measurements of FEF50
(DRS[FEF50]), and PEFR (DRS[PEFR]). All values for PD20 and DRS were log
transformed prior to further analysis.
Assessment of repeatability was performed as described by Bland and Altman (Bland
and Altman 1986). Graphs of the ratio between the two log measurements of
bronchial responsiveness (day 1/day 2) (equivalent to the difference between the
measurements on a linear scale) plotted against the geometric mean of the two
measurements (ie the nearest estimate of the true value) were used to look for
evidence of heteroscedasticity (that is, a relationship between repeatability and level
of bronchial responsiveness).
Geometric mean values for DRS or PD20 for day 1 and day 2 were compared by
paired t test. Coefficient of repeatability (CR) was calculated from the within subject
standard deviation using the equation CR = (2s), where s = V&tfJvL), d; = the
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difference in paired values of log PD20 or log DRS for the ith subject, and n =
number of subjects. The higher the value of CR, the poorer the repeatability.
Approximate 95 % limits of agreement for the result of the second of a further pair
of measurements were derived from the coefficient of repeatability (lower limit =
l/(antilog CR) x first measurement, upper limit = (antilog CR) x first
measurement).
To allow assessment of the effects of age on repeatability, CR was also calculated
separately for the 19 subjects aged less than 45 and the 21 subjects aged over 45.
iv) Results
Twenty-two of the 40 subjects had a measurable PD20 on both occasions, and 7 on
one occasion only. Results of bronchial challenge on day 1 and day 2 are listed in
Appendix 6. Comparison of results obtained using the mean or the best of 3 FEVi
recordings to calculate PD20 and DRS revealed superior repeatability using the mean
(Table 5.1). Because of this, all subsequent analyses used the mean of 3 spirometry
results.
Paired t test revealed no significant difference between the geometric mean reading
on the two days for either PD20(FEVj) or DRS calculated using FEV!, FEF50 or
PEFR (table 5.2). A graph of DRS(FEV!) on day 1 against day 2 showed strong
correlation between the two readings (figure 5.1).
Table 5.3 shows values of the coefficient of repeatability for PD20(FEV1) and for
DRS calculated using FEV!, FEF50 or PEFR. Maximum repeatability was achieved
by expressing bronchial responsiveness as PD20 rather than DRS, although the
number of individuals with two values for PD20 was smaller. Further calculation of
PD20 inserting a fixed value of 6450/xg for subjects with PD20 > 6400jUg gave a
similar result (CR^O.21). Both PEFR and FEF50 were found to give less repeatable
bronchial challenge results than FEV, (table 5.3).
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Table 5.1: Coefficient of repeatability for PD20 and DRS
using mean or best of 3 FEV1 measurements
Coefficient of
repeatability (CR)
95% limits of agreement
PD20# (mean) 0.20 0.40 - 2.48 x initial reading
(best of 3) 0.23 0.35 - 2.82 x initial reading
DRS* (mean) 0.24 0.33 - 3.07 x initial reading
(best of 3) 0.31 0.24 - 4.10 x initial reading
*n=40
#n=22
Table 5.2: Geometric mean values (95% limits of agreement)
for PD20(FEV1)1 DRS(FEV1), DRS(FEF50) and DRS(PEFR) on days 1&2
Day 1 Day 2 Paired t test
PD20(FEV1) 132.28 176.68 t=0.23, p=0.82
(48.79-358.67) (63.34-492.72)
DRS(FEV1) 29.58 30.23 t = -0.86, p = 0.39
(10.89-71.96) (12.04-75.94)
DRS(FEF50) 51.59 52.30 t = -0.15, p = 0.89
(21.56-123.45) (22.24-122.97)
DRS(PEFR) 32.11 28.99 t = -0.94, p= 0.35
(12.65-81.53) (11.81-71.12)
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Figure 5.1: Dose-response slope for day 1 vs day 2




Table 5.3: Repeatability of methacholine challenge using different
measures of airway calibre
Coefficient of
repeatability
95% limits of agreement
PD(FEV1) 0.20 0.40 - 2.48 x initial reading
DRS (FEV1) 0.24 0.33 - 3.07 x initial reading
DRS (FEF50) 0.26 0.31 - 3,25 x initial reading
DRS (PEFR) 0.31 0.24 - 4.23 x initial reading
Table 5.4: Repeatability of methacholine challenge in older
and younger subjects
Coefficient of repeatability
(95% limits of agreement)
AGE <45 AGE >45
PD20 (FEV1) 0.15* 0.21#
(0.50-2.00 x initial reading) (0.37-2.68 x initial reading)
DRS (FEV1) 0.21 0.27
(0.38-2.66 x initial reading) (0.29-3.46 x initial reading)
DRS (FEF50) 0.16 0.34
(0.47-2.11 x initial reading) (0.21-4.7 x initial reading)
DRS (PEFR) 0.28 0.33




The graph of ratio against mean for log DRS(FEV1) on the two days shows
increasing variability of results at lower values of DRS, implying poorer
repeatability at lower levels of bronchial responsiveness (figure 5.2). A similar trend
is not seen in the graph of ratio against mean for log PD^FEVj), although this
graph contains data from fewer subjects (figure 5.3). To further investigate this
apparent difference in repeatability of DRS(FEV1) between subjects with high and
low bronchial responsiveness, CR was calculated separately for the group of 22
subjects achieving a PD20 on both occasions and the 18 subjects with one or no PD20
measurements. Coefficient of repeatability was higher in subjects with one or no
PD20 readings (CR=0.26) than in those with two PD20 readings (CR=0.23),
confirming that repeatability of DRS was poorer for subjects with lower levels of
bronchial responsiveness.
Table 5.4 compares the values of CR for the two age groups. Reproducibility was
better for all parameters in the younger volunteers than in the older random
population sample, the difference being particularly marked for DRS(FEF50).
Measurements of PD20(FEV1) for subjects taking part in the epidemiological survey
were repeatable within 2 doubling doses of methacholine (CR=0.21).
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Figure 5.2: Geometric mean DRS(FEV1) vs ratio
of log DRS(FEV1) for days 1 & 2
log DRS(FEV1) day 1/log DRSfFEV,) day 2
10
0.1277 1.277
geometric mean log DRS(FEV1)
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Figure 5.3: Geometric mean PD20(FEV1) vs ratio
ratio of log PD20(FEV1) for days 1 & 2





Chapter 6: PREVALENCE OF SELF-REPORTED ASTHMA AND
BRONCHITIS
106
All 723 subjects completing full or abbreviated questionnaires answered the
questions "have you ever been treated for asthma?" and "have you ever been treated
for bronchitis?". One hundred and six (14.7%) reported treatment for asthma, and
164 (22.7%) treatment for bronchitis. However, 53 (32.3% of those with bronchitis;
50.0% of those with asthma) reported both asthma and bronchitis. Regarding these
separately gives prevalence of asthma 7.3%, bronchitis 15.4%, and asthma plus
bronchitis 7.3%. Only 10 subjects reported treatment for emphysema, 2 of whom
also reported bronchitis, and a further 3 asthma plus bronchitis.
Table 6.1 compares reporting of asthma and bronchitis by subjects completing full
and abbreviated questionnaires, the 45 non-responders contacted at home, and
attenders and non-attenders. Subjects with asthma were over-represented, and those
with bronchitis under-represented in the group completing the full questionnaire.
Similarly, the group of non-responders contacted at home contained fewer
asthmatics and slightly more bronchitics than other responders, although these
differences did not reach significance. However, asthma and bronchitis were equally
common in attenders and non-attenders.
More women reported a diagnosis: 137/411 women (33.3%) and 80/312 men
(25.6%) reported asthma, bronchitis or both diagnoses (chi2=5.0, p=0.03) (Figure
6.1). Women and men had similar prevalences of asthma alone or bronchitis alone
(asthma: chi2=0.7, p=0.4; bronchitis: chi2=0.1, p=0.7), but the combination of
asthma plus bronchitis was reported more commonly by women (chi2=9.8,
p=0.002) (Figure 6.1).
Prevalences of reported asthma and bronchitis were similar in adults aged < 65 and
those aged >65 years (Figure 6.2).
Figure 6.3 summarises smoking habits of subjects reporting asthma and bronchitis.
Asthma was reported less often by current smokers than ex- or never-smokers
(chi2 = 12.1, p<0.001). In contrast, bronchitis was reported more often by current
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Table 6.1: Prevalence of reported asthma and bronchitis








All responders 723 7.3 15.4 7.3
Full questionnaire 508 9.1 14.3 6.6 0.02
Abbreviated 215 2.9 18.0 9.2
Non-responders* 45 2.2 17.7 11.1 >0.05
Other responders 678 7.7 15.2 7.1
Attenders 247 8.5 16.7 6.9 >0.05
Non 476 6.7 14.7 7.5
* contacted at home by 'phone or visit
Figure 6.1: Prevalence of reported asthma and bronchitis
in women and men
%
CD asthma ED bronchitis C3 asthma + bronchitis
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Figure 6.2: Prevalence of reported asthma and bronchitis
in older and younger adults
%
□ asthma □bronchitis □ asthma + bronchitis
Figure 6.3: Prevalence of reported asthma and bronchitis
in current, ex- and never-smokers
%
□ asthma □ bronchitis □ as1J%raa + bronchitis
smokers (chi2=3.7, p=0.05). The combination of asthma plus bronchitis appeared
less common in never-smokers, but this difference was not significant (chi2=3.0,
p=0.08). Only 13.2% of those reporting asthma were current smokers, compared
with 38.7% of those reporting bronchitis and 39.6% of those with
asthma/bronchitis.
Of the 26 subjects smoking cigars or tobacco rather than cigarettes, 2 (7.7%)
reported asthma plus bronchitis, and three (11.5%) bronchitis alone.
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Chapter 7: PREVALENCE OF RESPIRATORY SYMPTOMS
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Information on respiratory symptoms (cough, sputum, wheeze and breathlessness)
was available from the 508 full questionnaires. Wheeze was reported by 178/496
subjects (35.9%), cough by 160/496 (32.3%); sputum production by 166/494
(33.6%); and 90/502 (17.9%) reported breathlessness at rest or walking on the level
(MRC grade 3+). A further 192 (38%) subjects described breathlessness walking
uphill: interpretation of this response was difficult because of standardisation
problems ("how steep is the hill?"). Thus, these were regarded as asymptomatic for
the remainder of the analysis. By this definition, 53.8% of subjects had respiratory
symptoms. Eighty-six (17.5%) reported 1 symptom, 74 (15.1%) 2 symptoms, 71
(14.5%) 3 symptoms, and 33 (6.7%) all 4 symptoms.
The 247 attenders completing the supplementary questionnaire were asked about
symptoms suggesting "bronchial irritability" (see pages 41-2) (Mortagy et al. 1986).
Breathlessness or wheeze on exposure to respiratory irritants was reported by 104
(42.4%), morning wheeze by 43 (17.6%) and nocturnal breathlessness by 18
(7.3%); 9 subjects (3.7%) reported all 3 of these symptoms. Fifty-one (20.7%) of
the subjects completing the supplementary questionnaire had symptoms compatible
with chronic bronchitis (Medical Research Council 1960). There was no difference
in the proportion of attenders and non-attenders reporting one or more symptoms
(attenders: 57.1%, non-attenders 50.8%; p=0.2).
Figure 7.1 shows symptoms reported by women and men. Sputum production was
more common in men (chi2=18.2, p<0.001), and women reported more
breathlessness (chi2=4.0, p=0.05). There was no difference between the sexes in
the mean number of symptoms reported (women: 1.1 symptoms, men: 1.3; t=-l .9,
p=0.06). Of subjects attending for bronchial challenge, 21/138 women (15.2%) and
30/107 men (28.0%) described symptoms compatible with chronic bronchitis
(chi2=6.0, p=0.01). Symptoms of bronchial irritability were reported equally by
men and women.
Figure 7.2 shows symptoms reported by older and younger subjects. There was no
112
Figure 7.1: Respiratory symptoms reported by women and men
%
n cough [EUsputum Hwheeze EZldyspnoea
Figure 7.2: Respiratory symptoms reported by different age groups
%
Qcough Elsputum Hwheeze EDdyspnoea
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difference in symptom prevalence between those aged <65 and >65 years.
Figure 7.3 shows symptoms reported by current, ex- and never-smokers. Both
wheeze and sputum were more common in ex- than never-smokers (wheeze:
chi2 = 3.7, p=0.05; sputum: chi2 = 9.0, p=0.003). Wheeze, cough and sputum were
all more common in current than ex-smokers (wheeze: chi2 = 8.2, p=0.004; cough:
chi2 = 17.4, p=0.001; sputum: chi2 = 8.0, p=0.005). Breathlessness was unrelated
to smoking habit. In attenders, symptoms of chronic bronchitis were strongly
associated with smoking habit (reported by 6/78 [7.7%] never-smokers, 15/93
[16.1%] ex-smokers and 30/73 [41.1%] current smokers [chi2=27.5, p<0.001]).
In contrast, symptoms of bronchial irritability showed no relationship with smoking.
The 26 cigar or tobacco-smoking men reported relatively high levels of symptoms:
50.0% described cough, 65.4% sputum, 38.5% wheeze and 23.1% breathlessness.
Number of symptoms reported was also associated with smoking habit. Four
symptoms were reported by 12% of current, 7.0% of ex- and only 2.4% of never-
smokers; 30.4% of current, 47.9% of ex- and 57.2% of never-smokers were
asymptomatic (chi2 = 34.5, p< 0.001).
The relationship between symptoms and smoking habit changed with age. The
proportion of never-smokers reporting one or more symptoms was 37.7% in
younger adults (age <65 years), and 46.4% in older adults (age >65) (p=0.26);
similar numbers of ex-smokers in the 2 age-groups were symptomatic, but
symptoms were more common in younger than older current smokers (age <65:
79.4% current smokers symptomatic, age >65: 59.7% current smokers
symptomatic; chi2=6.2, p=0.01).
Figure 7.4 shows symptoms in subjects reporting asthma or bronchitis. All
symptoms were more common in those reporting a diagnosis. Subjects reporting
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Figure 7.3: Respiratory symptoms reported by current,
ex- and never-smokers
EDcough dlsputum Hwheeze GUdyspnoea
Figure 7.4: Respiratory symptoms in subjects reporting asthma,
bronchitis, and asthma/bronchitis
%
□ cough □sputum □wheeze □dyspnoea
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asthma alone described less cough than those reporting bronchitis (chi2=5.1,
p=0.02), and less wheeze and breathlessness than subjects reporting
asthma/bronchitis (wheeze: chi2=9.3, p < 0.002, breathlessness: chi2=6.6, p=0.01).
Although cough was less frequent in subjects with asthma than those with
asthma/bronchitis, this difference did not reach significance (chi2 = 3.0, p=0.08).
Subjects reporting bronchitis alone reported more cough than those reporting asthma
(as above), and less wheeze and breathlessness than those reporting
asthma/bronchitis (wheeze: chi2 = 13.7, p<0.001, breathlessness: chi2= 12.2,
p<0.001).
Symptoms of chronic bronchitis were reported by 24/167 (14.4%) attenders not
reporting a diagnosis, 2/21 (9.5%) reporting asthma, 16/41 (39.0%) reporting
bronchitis, and 9/17 (52.9%) of those reporting asthma/bronchitis (chi2=24.8,
p<0.001). Of the bronchial irritability symptoms, wheeze/breathlessness on
exposure to irritants was more common in subjects reporting a diagnosis (diagnosis:
68.4%, no diagnosis: 29.9%; chi2 = 32.7, p<0.001), as was morning wheeze
(diagnosis: 30.4%, no diagnosis: 11.4%; chi2=23.4, p<0.001); nocturnal
breathlessness was not related to the presence of a diagnosis.
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Chapter 8: RESULTS OF SPIROMETRY
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Reproducible spirometry results were available for 246 of the 247 attenders.
Distribution of FEVj readings is shown in figure 8.1. For examination of the
relationship between lung function and age, spirometry results were standardised to
the mean height for women (1.58m) and men (1.71m), using the equation FEVj* =
FEV,/height2 x (mean height)2, where FEVf represents FEV) standardised to mean
height (Burr et al. 1985). There was significant negative linear correlation between
FEV^ and age in both sexes (women: r=-0.60, p<0.001; men: r=-0.47, p<0.001)
(figure 8.2). FVC* was also correlated with age (women: r=-0.62, p<0.001;
men:r=-0.43, p<0.001) (figure 8.3). The relationship between FEV^/FVC* ratio
and age was weaker, but still statistically significant (women: r=-0.19, p=0.01;
men: r= -0.21, p=0.01) (figure 8.4). Unlike FEVj* and FVC*, FEV^/FVC* ratio
was not lower in women than men.
The effects of smoking on lung function are summarised in figures 8.5-8.7. In
women, FEVj* was consistently lower in current and ex-smoking women than in
never-smokers (t=2.6, p=0.01) (figure 8.5). However, the effect of smoking on
FEVj* was less clear in men, with no difference between FEV^ in smoking and
never-smoking men (t=1.0, p=0.3). Neither men or women showed a significant
difference in FVC* between smokers and never-smokers (women: t=l.l, p=0.3;
men: t= 1.0, p=0.3) (figure 8.6). Comparison of FEV^/FVC* ratio in smokers and
never-smokers showed that in women, never-smokers had a higher ratio at all ages
(t=4.2, p< 0.0001), whereas in men ratios were similar in smokers and never-
smokers (t=0.6, p=0.6) (figure 8.7).
In order to compare lung function in the Central Manchester population with that
measured in other cross-sectional population studies, measured FEVj was compared
with values predicted by equations derived from 5 such studies (Cotes et al. 1966;
Burr et al. 1985; Dockery et al. 1985; Roberts et al. 1991; Enright et al. 1993). The
populations from which these prediction equations were derived are compared in
table 8.1; since most included only healthy never-smokers, current and ex-smokers
were excluded from the Central Manchester population.
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Figure 8.2: FEV1 vs age for Central Manchester adults
FEV1 (I)
age
FEV1 standardised to mean height
Figure 8.3: FVC vs age for Central Manchester adults
FVC (I)
age
FVC standardised to mean height
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Figure 8.4: FEV,/FVC vs age for Central Manchester adults
FEV,/FVC%
age
FEV, and FVC standardised to mean age
Figure 8.5: FEV, in smokers and never-smokers
FEV1 (I)
age
—Women non-smokers -FWomen smokers(-)
* Men non-smokers -"-Men smokers (—)
FEV, adjusted to mean height
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45-54 55-64 65-74 75-84 85 +
age
—Women non-smokers -I-Women smokers (—)
*Men non-smokers Men smokers (—)
FVC adjusted to mean height
Figure 8.7: FEV,/FVC% in smokers and never-smoke
FEV1/FVC%
age
—Women non-smokers -t-Women smokers (—)
* Men non-smokers ~Q~ Men smokers (--)
FEV, and FVC adjusted to mean height
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Table 8.1: Features of published reference ranges
Authors Sample n Age range Exclusions
Cotes et al, 1966 Random sample
working men
275 20-64 Dusty occupations
Lung disease
Breathlessness
Burr et al, 1985 Random sample 418 70 + Residents of
institutions#
Dockery et al, 1985 Random sample 2454* 25-74 Smokers
Symptoms
Roberts et al, 1991 Volunteers 179 18-86 Smokers
Symptoms
Lung disease




*30% of screened population; **15% of screened population
#smokers included but analysed separately; ##hypertension, diabetes, heart disease, obesity etc
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For women, measured FEVi in never-smokers was similar to values predicted by
Cotes (t= 1.1, p=0.3), Burr (t= 1.0, p=0.3) and Dockery (t=-0.6, p=0.5).
However, measured FEV! in women was lower than values predicted by Enright et
al (t=-2.6, p=0.02), and Roberts et al (t=-4.7, p<0.0001) (figure 8.8). In
contrast, measured FEV! for never-smoking men was lower than all 5 sets of
predicted values, with this difference being statistically significant for values
predicted by Dockery et al (t=-4.4, p =0.0006), Enright et al (t=-2.3, p=0.05) and
Roberts et al (t = -4.8, p=0.0001), but not for those predicted by Cotes (t=-1.8,
p=0.09) and Burr (t=-2.2, p=0.06) (figure 8.9). Removal of subjects with
respiratory symptoms from the comparison did not affect these results: in
asymptomatic never-smoking women, FEVj predicted by Enright (t=-4.5,
p=0.0001) and Roberts (t=-4.3, p=0.0002) was higher than measured FEVi, and
the same was true for values predicted by Dockery (t=-3.1, p=0.01), Enright (t=-
2.0, p=0.06) and Roberts (t=-3.0, p=0.01) in asymptomatic never-smoking men.
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Figure 8.8: Actual FEN^ vs predicted using equations of Cotes,
Enright, Dockery, Roberts and Burr - never-smoking women
0.5
0
45-54 55-64 65-74 75-84 85 +
age
-""Actual + Cotes (..) * Dockery (--)
H Enright (..) -*Burr (--) "♦ Roberts (--)
125
Figure 8.9: Actual FEVt vs predicted, using equations of Cotes,
Enright, Dockery, Roberts and Burr - never-smoking men
FEV, (I)
age
^-Actual + Cotes (..) * Dockery (--)
■■'Enright (..) -* Burr "♦ Roberts (--)
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Chapter 9: PREVALENCE OF CHRONIC AIRFLOW OBSTRUCTION AND
REVERSIBILITY
(Renwick and Connolly, 1996a)
127
Ratio of FEV,/FVC is frequently used as a measure of airflow obstruction, with a
ratio of 70-80% being regarded as normal. For the purposes of this study, chronic
airflow obstruction was defined as FEV1/FVC% <65%; this gave a prevalence of
29.3% (72/246 subjects performing spirometry). However, as FEV1/FVC%
decreases with age in this population (see Chapter 8), there was a risk that use of
this definition would lead to over-estimation of airflow obstruction in older subjects.
To prevent this, in subjects aged >65 a predicted value and lower limit of normal
(fifth percentile) for FEV1/FVC% were calculated using reference ranges derived
from the Cardiovascular Health Study (a recent cross-sectional survey of adults aged
>65 years) (Enright et al. 1993). Chronic airflow obstruction was then defined as
FEV1/FVC% <65% for subjects aged <65, and as FEV1/FVC% below lower limit
of predicted value for subjects aged >65. Using this composite definition, 65
subjects (26.4%) had chronic airflow obstruction.
Chronic airflow obstruction was equally prevalent in women and men (chi2=0.25,
p=0.6) (Figure 9.1), and in older and younger adults (chi2= 1.46, p=0.2) (Figure
9.2). There was a strong relationship with smoking, with chronic airflow obstruction
being more in common ex- than never-smokers (chi2 = 5.7, p—0.02). However, the
difference between ex- and current smokers did not reach significance (Figure 9.3).
Only 15.4% of subjects with airflow obstruction had never smoked, compared with
37.8% of those without airflow obstruction (chi2= 11.0, p=0.001).
Subjects with chronic airflow obstruction were more likely to report asthma and/or
bronchitis than those with no airflow obstruction (airflow obstruction: 55.4% asthma
and/or bronchitis, no airflow obstruction: 23.8% asthma and/or bronchitis;
chi2=26.1, p<0.001). The prevalence of chronic airflow obstruction was similar
in those reporting asthma alone and bronchitis alone. Although airflow obstruction
appeared to be more common in those with asthma/bronchitis than in those reporting
a single diagnosis, this difference was not statistically significant (Figure 9.4).
The validity of a questionnaire report of asthma/bronchitis for identification of
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Figure 9.1: Prevalence of chronic airflow obstruction
in women and men
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Figure 9.2: Prevalence of chronic airflow obstruction
in older and younger adults
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ED airflow obstruction ED no obstruction
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Figure 9.3: Prevalence of chronic airflow obstruction
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subjects with chronic airflow obstruction can be assessed by calculation of the
positive predictive value (the proportion of those reporting a diagnosis who have
proven airflow obstruction), sensitivity (the proportion of those with airflow
obstruction who report a diagnosis), and specificity (the proportion of those who do
not have airflow obstruction who do not report a diagnosis). The positive predictive
value of a reported diagnosis (asthma and/or bronchitis) for airflow obstruction was
45.6% (sensitivity 55.3%, specificity 76.2%); 48.1% of subjects reporting
bronchitis had chronic airflow obstruction (sensitivity 43.3%, specificity 80.3%).
Respiratory symptoms were reported more frequently by subjects with chronic
airflow obstruction: 50 (76.6%) of those with chronic airflow obstruction were
symptomatic, compared with 50.0% of those without airflow obstruction
(chi2 = 13.5. p<0.001). However, less than half of subjects reporting cough or
sputum had airflow obstruction (figure 9.5). Subjects with chronic airflow
obstruction were more likely to report multiple symptoms: 18.8% of those with
airflow obstruction and 3.4% of those without reported 4 symptoms (chi2=25.8,
p< 0.001). However, because symptoms were common in those with no airflow
obstruction, the positive predictive value of one or more symptoms for chronic
airflow obstruction was only 35.8% (sensitivity 76.6%, specificity 50.0%). The
positive predictive value of having 4 symptoms was 66.7% (sensitivity 18.8%,
specificity 96.6%).
Symptoms of chronic bronchitis were more common in attenders with airflow
obstruction (24/65 [36.9%] vs 27/181 [15.0%]; chi2 = 13.9, p<0.001), as were
symptoms of bronchial irritability (breathlessness/wheeze on exposure to irritants:
63.1% vs 35.0% [chi2=15.4, p<0.001]; morning wheeze: 29% vs 13% [chi2 = 8.3,
p=0.004]; nocturnal breathlessness: 13.9% vs 5.0% [chi2 = 5.5, p=0.02]).
Symptoms of chronic bronchitis (chronic productive cough) were related more
strongly to chronic airflow obstruction than were other symptoms (positive
predictive value 47.1%, sensitivity 36.9%, specificity 85.0%).
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Figure 9.5: Prevalence of chronic airflow obstruction
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Separate analysis of older and younger subjects revealed no difference in the
relationship between chronic airflow obstruction and respiratory symptoms;
predictive values of symptoms and reported diagnoses were similar in both age
groups.
Reversibility of airflow obstruction was assessed in 22 subjects with baseline FEVj
too low for bronchial challenge (ie < 60% predicted). Ten of these subjects (45.5%)
had > 160ml improvement in FEVj following terbutaline inhalation. There was no
significant difference in age or level of airflow obstruction between these subjects
and those with no reversibility; numbers were too small too allow comparison of
reversibility in those reporting asthma and/or bronchitis, or in smokers and never-
smokers. Elowever, there did appear to be a sex difference: 2/11 women (18%) and
8/11 men (73%) had reversible airflow obstruction (chi2=6.6, p=0.01).
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Chapter 10: PREVALENCE OF INCREASED BRONCHIAL
RESPONSIVENESS
134
Of the 208 subjects completing methacholine challenge, 148 (71.1%) achieved a
PD20 (ie had >20% fall in FEVj from baseline). Distribution of PD20 measurements
in the population is shown in figure 10.1. Bronchial responsiveness was slightly
increased (PD20 100-800/xg) in 52 subjects (25.0%), moderately increased (PD20
12.5-100/xg) in 42 (20.2%), and greatly increased (PD20< 12.5/ng) in 12 subjects
(5.8%).
Figure 10.2 shows levels of bronchial responsiveness in men and women; there was
no significant difference between the sexes. The prevalence of increased bronchial
responsiveness was similar in those aged <65 and >65 years (chi2 = 3.0, p=0.4)
(figure 10.3).
The prevalence of slightly and moderately increased bronchial responsiveness was
higher in current smokers than never-smokers (chi2 = 7.8, p=0.02) (Figure 10.4).
Ex-smokers had a similar prevalence of increased bronchial responsiveness to never-
smokers. PD20<12.5/xg was not associated with smoking habit.
The prevalence of increased bronchial responsiveness in subjects reporting bronchitis
alone was similar to those reporting no diagnosis (Figure 10.5). Subjects reporting
asthma alone had similar levels of increased bronchial responsiveness to those
reporting asthma/bronchitis. Both moderately and greatly increased bronchial
responsiveness were found more frequently in subjects reporting asthma or
asthma/bronchitis than those reporting bronchitis or no diagnosis (PD20< 100/xg:
chi2=41.9, p<0.001; PD20< 12.5/xg: chi2 = 34.1, p<0.001). Of subjects reporting
either asthma or asthma/bronchitis, 96.3% had at least slightly increased bronchial
responsiveness, and 77.8% had moderately or greatly increased bronchial
responsiveness. The positive predictive value of reported asthma for PD20<100/xg
was 77.8% (sensitivity 38.9%, specificity 96.1%).
All levels of bronchial hyper-responsiveness were more common in symptomatic
than asymptomatic subjects: PD20< 100/xg was found in 36.8% of symptomatic and
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Figure 10.4: Prevalence of increased bronchial responsiveness
in smokers and non-smokers
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Figure 10.5: Prevalence of increased bronchial responsiveness
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14.6% of asymptomatic subjects (chi2=25.0, p< 0.001). In all, 26.4% of those with
PD20<100/xg were asymptomatic. Asymptomatic bronchial hyper-responsiveness
was slightly more common in older subjects (age>65: 19/54 [35.2%] subjects with
PD<800/xg were asymptomatic vs 12/48 [25.0%] age <65), but this difference
failed to reach significance (chi2 = 1.2, p=0.3). Subjects with higher numbers of
symptoms were more likely to have increased bronchial responsiveness:
PD20<100/xg was found in 14.6% of asymptomatic subjects, and 83.3% of those
with 4 symptoms (chi2=20.1, p< 0.001).
Figure 10.6 shows bronchial responsiveness in subjects reporting different
respiratory symptoms. Whilst cough and sputum were reported commonly by
subjects with slightly increased bronchial responsiveness, moderately and greatly
increased bronchial responsiveness were particularly associated with the presence
of wheeze or breathlessness. The positive predictive value of reported wheeze for
PD20< 100/xg was 49.3% (sensitivity 64.2%, specificity 77.0%); breathlessness had
a positive predictive value for PD20< 100/xg of 50.0% (sensitivity 26.4%, specificity
90.9%). Symptoms of "bronchial irritability" were also more common in subjects
with bronchial hyper-responsiveness, but did not show a stronger association than
that of breathlessness or wheeze. The presence of one or more bronchial irritability
symptoms had a positive predictive value of 34.9% for PD20< 100/xg (sensitivity
55.6%, specificity 63.6%).
Bronchial hyper-responsiveness (PD20< 100/xg) plus wheeze or breathlessness was
present in 15.0% of the Central Manchester population, and was equally common
in women and men, and in subjects aged <65 and >65 years. This has been
suggested by some authors as a definition of asthma for use in epidemiological
surveys, as it removes the problem of how to interpret asymptomatic bronchial
hyper-responsiveness (Toelle et al. 1992). The positive predictive value of reported
asthma or asthma/bronchitis for asthma defined in this way was 47.4% (sensitivity
48.6%, specificity 90.4%).
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Figure 10.6: Prevalence of increased bronchial responsiveness
in subjects with respiratory symptoms
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Figure 10.7: Prevalence of increased bronchial responsiveness
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Increased bronchial responsiveness was more common in subjects with chronic
airflow obstruction (chi2= 19.4, p < 0.001) (Figure 10.7). There was a dose-response
relationship between degree of airflow obstruction and level of bronchial
responsiveness, with positive linear correlation between PD20 (log transformed to
achieve normal distribution) andFEVj/FVC ratio (n=148; r=0.35, p< 0.0001), and
negative linear correlation between log dose-response slope and FEV^FVC ratio
(n=208; r = -0.4, p<0.0001).
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Chapter 11: RELATIONSHIP BETWEEN BRONCHIAL RESPONSIVENESS
AND AGE: ANALYSIS BY MULTIPLE REGRESSION
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Analysis of the relationship between age and bronchial responsiveness with the latter
expressed as a categorical variable (increased vs not increased) fails to take into
account the effects of other variables associated with both age and bronchial
responsiveness (eg baseline FEV,, smoking habit). Furthermore, analysis using a
continuous measure allows the use of statistical tests which have increased power
for detecting inter-relationships between bronchial responsiveness and other
variables. The published literature suggests that nonspecific bronchial responsiveness
may be associated with age, sex, smoking habit, atopy, and baseline airways calibre.
Multiple regression analysis was used to assess whether age had an independent
relationship with bronchial responsiveness when the effects of these other variables
were taken into consideration.
i) Statistical methods
For multiple regression analysis, bronchial responsiveness was expressed as dose-
response slope, and values were log transformed to achieve normal distribution. One
subject had a slight increase in FEV! during bronchial challenge, producing a
negative dose-response slope; to allow logarithmic conversion of this result, a
constant of 0.43 was added to all dose-response slope values (Sparrow et al. 1994).
Several of the independent variables in the regression equation (age, sex, smoking,
airways calibre and atopy) showed inter-relationships. Where possible, these inter¬
relationships were removed by standardisation of variables for age and sex. Thus,
as eosinophil counts and total IgE levels are dependent on age and sex (Burrows et
al. 1980; Wittig et al. 1980; Barbee et al. 1981), they were converted to
standardised "Z-scores" (Burrows and et al. 1989). The Z-score indicates the
number of standard deviations by which each IgE level or eosinophil count differs
from the mean value of the appropriate sex and age group (age 45-54, 55-64, 65-74,
>75 years). To allow conversion to Z-scores, 46 subjects with IgE level reported
as <5 IU/ml were given the value of 0.1 IU/ml. Z-scores were log transformed to
achieve normal distribution.
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Measures of airways calibre are also strongly related to age and sex, and so FEV\
or FEV/FVC ratio are not suitable for use in regression analysis. Expression of
FEVj as % predicted values does not entirely remove age and sex bias: as FEV[
increases with height and decreases with age, the use of % predicted FEVj will lead
to an increase in the number of elderly and short individuals appearing to have
abnormal results (Miller and Pincock 1988). This is obviously relevant in the
current study, which contains many elderly subjects. To avoid this bias, the use of
standardised residuals (SR) has been recommended (Miller and Pincock 1988).
These are calculated using the equation SR = (recorded value - predicted
value)/RSD, where RSD is the residual standard deviation about the regression
equation used to calculate the predicted values (Miller et al. 1985). For the current
study, standardised residuals were calculated using prediction equations derived
from a study of urban white UK adults over a wide age range (Roberts et al. 1991).
The distribution of standardised residuals is shown in figure 11.1.
Where inter-relationships between independent variables persisted (eg between
airways calibre and smoking habit), interaction terms were included in the
regression equation (Sparrow et al. 1994).
ii) Results
Table 11.1 summarises the results of stepwise multiple regression analysis with
bronchial responsiveness (expressed as log dose-response slope) as the dependent
variable, and age, sex, packyears smoked, airways calibre (expressed as FEV,
standardised residuals), IgE (expressed as log Z-score) and eosinophils (log Z-score)
as independent variables. Bronchial responsiveness was positively associated with
IgE and with age; there was a negative relationship between bronchial
responsiveness and airways calibre. Packyears smoked, sex, and eosinophils were
not independently associated with bronchial responsiveness. The inclusion of
interaction factors for the relationship between airways calibre and packyears
smoked, and between sex and packyears smoked, did not alter either the value of
R2 or the relationships between other variables. The interaction factors themselves
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Table 11.1: Factors associated with bronchial responsiveness:
stepwise multiple regression analysis
Independent
variable
B SE t P % var
FEV1 * -0.49 0.07 -7.42 <0.0001 21
IgE# 0.22 0.07 3.28 0.001 3
age 0.01 0.006 2.39 0.02 3
sex -0.16 0.13 -1.23 0.22
packyears 0.005 0.003 1.81 0.07
eosinophils# 0.08 0.07 1.08 0.28
R2=0.29
* standardised residuals # log Z-score
%var=percent of variation in dependent variable attributable to independent variable
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were not significantly associated with bronchial responsiveness.
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Chapter 12: RELATIONSHIP BETWEEN BRONCHIAL RESPONSIVENESS
AND ATOPY
148
The strong relationship between atopy and asthma in children and young adults is
undisputed, and measures of atopy have been shown to correlate with bronchial
responsiveness in young populations (Cockcroft et al. 1984). However, it is
generally assumed that the role of atopy is less important in adult-onset asthma (so-
called "intrinsic" asthma). As far as chronic bronchitis is concerned, this has been
regarded as a consequence of smoking rather than an atopic disease, although a
relationship between measures of atopy and airways calibre in smokers with chronic
airflow obstruction was predicted by the "Dutch Hypothesis" (see page 12). We
have investigated the links between atopy, airways calibre and bronchial
responsiveness in our random population sample.
i) Methods
Questions about personal or family history of atopy (hay fever, contact dermatitis
or eczema) were included in the full questionnaire. A venous blood sample was
taken from subjects attending for bronchial challenge, and was sent to the hospital
laboratories for measurement of total IgE and eosinophil count. Skin tests were not
performed due to lack of time and staff. Both IgE levels and eosinophil counts were
converted to age- and sex-adjusted Z-scores as described on page 142; log values
of Z scores were used to achieve normal distribution. Relationships between
IgE/eosinophils and lung function were assessed by t test and multiple regression
analysis.
ii) Results
Atopy was reported by 132 subjects (26.1%) completing the full questionnaire, and
163 (32.4%) reported atopy in a first degree relative. Of the 247 subjects attending
for methacholine challenge, total IgE measurements were available for 235, and
eosinophil counts for 231. Missing results represent refusal of blood testing, and
problems with delivery or laboratory analysis of samples.
The distribution of total IgE level and eosinophil counts are shown in figures 12.1
and 12.2. Geometric mean IgE level was 9.76 i.u./ml; 33 subjects had levels falling
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above the laboratory "normal" range (< lOOi.u./ml). Geometric mean eosinophil
count was 0.13xl09/l; 6 subjects had counts above the "normal" range of 0.04 - 0.4
x 1071.
Geometric mean IgE Z-score was higher in ex- than never-smokers (ex-smokers 1.0
[SD 8.1], never-smokers: 0.5 [SD 10.8]; t=-2.1, p=0.04), and in current than ex-
smokers (current smokers 2.13 [8.6]; t=-2.1, p=0.03). There was also a dose-
response relationship between packyears smoked and log IgE Z-score (r=0.18,
p<0.001). Eosinophil count was not related to smoking habit. Subjects reporting
a personal or family history of atopy did not have significant elevation of IgE or
eosinophil Z-scores.
Subjects reporting asthma, bronchitis or asthma/bronchitis had higher geometric
mean log IgE Z-scores than those with no diagnosis. However, the differences
between the three diagnostic groups did not reach statistical significance (no
diagnosis: 0.7 [SD 11.0], asthma: 2.5 [SD 6.3; t=-2.8, p=0.01], bronchitis: 1.7
[SD 6.7; t=-2.4, p=0.02], asthma/bronchitis: 2.1 [SD 5.6; t = -2.6, p-0.01]).
Geometric mean log eosinophil Z-scores were higher in subjects reporting asthma
and asthma/bronchitis than those without a diagnosis (no diagnosis: 0.8 [SD 8.6],
asthma: 3.2 [SD 15.7; t=-2.3, p=0.02]; asthma/bronchitis: 2.5 [SD 7.9; t=-1.9,
p=0.04]). In contrast, mean log eosinophil Z-scores of those reporting bronchitis
were similar to those with no diagnosis (1.3 [SD 9.7]). Again, there were no
significant differences between the three diagnostic groups.
Both IgE and eosinophil Z-scores were higher in symptomatic subjects, particularly
those with cough or wheeze (Table 12.1).
In multiple regression analysis with baseline FEV) as the dependent variable, there
was a significant independent negative relationship with eosinophil Z-score, but no
relationship with IgE Z-score (Table 12.2). Over 60% of the variation in FEVj was
explained by the independent variables (R:=0.61).
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Cough 2.2 [6.9]* 2.2 [10.0]*
No cough 1.6 [10.0]* 0.7 [8.5]*
Sputum 1.4 [9.3]# 1.6 [10.0]#
No sputum 0.8 [9.5]# 0.8 [8.7]#
Wheeze 1.6 [10.0]$ 1.6 [10.0]$
No wheeze 0.7 [9.1]$ 0.7 [8.5]$
Dyspnoea 1.7 [6.8]# 1.4 [12.6]
No dyspnoea 0.9 [10.0]# 0.9 [8.9]
*p<0.001; #p<0.05; $p<0.01
Table 12.2: Factors associated with baseline FEV,:








Age -0.033 0.004 <0.0001
Height 3.438 0.515 <0.0001
Packyears smoked -0.008 0.002 <0.0001
Eosinophils Z-soore -0.091 0.036 0.01
IgE Z-score -0.066 0.04 0.07
Sex* 0.348 0.099 0.0005
n = 211, R2 = 0.61
*female = 1, male = 2
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To investigate whether the relationship between FEV\ and eosinophils was different
in subjects reporting asthma, an interaction term for reported asthma and eosinophil
Z-score was included in the regression. This removed the significant relationship
between eosinophils and FEV,; the interaction term itself was negatively associated
with FEV! (B = -0.074, SE=0.028, p= 0.007).
Similarly, the addition of an interaction factor for the relationship between age and
eosinophil count removed the independent association between eosinophils and
FEV!; again the interaction factor was negatively associated with FEVi (B=-0.001,
SE=0.0005, p=0.0008). When regression analysis was performed separately for
subjects aged <65 and >65 years, the negative relationship between eosinophils
and FEVi was significant only in those aged >65 years (Table 12.3).
An interaction factor for the relationship between smoking (packyears) and
eosinophils did not affect the results of the regression analysis, implying that the
relationship between eosinophils and FEVi is not affected by smoking habit.
Multiple regression with log dose-response slope as the dependent variable showed
an independent positive relationship between bronchial responsiveness and log IgE
Z-score (Table 11.1). Addition of an interaction term for the association between
reported asthma and IgE level did not alter the regression results; the relationship
between IgE and bronchial responsiveness remained when subjects reporting asthma
were omitted from the analysis.
Inclusion of an interaction term for age and IgE level removed the independent
relationship between IgE and log DRS; the interaction term itself was significantly
associated with log DRS (B=0.0025, SE=0.001, p=0.01). This suggested that the
relationship between IgE and log DRS was stronger in older subjects; this was
confirmed by separate analysis of younger and older subjects, which revealed that
IgE was associated with bronchial responsiveness only in subjects aged >65 (Table
12.4).
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The effect of smoking habit on the relationship between IgE and bronchial
responsiveness was assessed by the inclusion of an interaction term for the
relationship between IgE and packyears smoked. This did not alter the results of the
regression analysis.
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Table 12.3: Factors associated with baseline FEV.,





age -0.04 (0.0001) -0.03 (0.0004)
height 0.04 (<0.0001) 0.03 (0.0001)
packyears -0.01 (0.04) -0.01 (<0.0001)
eosinophils* -0.05 (0.30) -0.13 (0.007)
sex 0.32 (0.02) 0.39 (0.009)
igE -0.05 (0.40) -0.08 (0.11)
Age <65: R2=0.48; age >65: R2=0.51
* log Z-score
Table 12.4: Factors associated with bronchial responsiveness





FEV1 * -0.56 (<0.0001) -0.41 (<0.0001)
IgE# 0.13 (0.16) 0.30 (0.002)
sex -0.19 (0.29) -0.15 (0.45)
packyears 0.01 (0.14) 0.01 (0.24)
age 0.02 (0.31) 0.03 (0.15)
eosinophils# -0.04 (0.66) 0.20 (0.05)
Age <65: R2= 0.30; age >65: R2=0.25
* standardised residuals # log Z-score
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Chapter 13: USE OF INHALED MEDICATIONS
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Five hundred and six of the 508 subjects completing the full questionnaire answered
the question "do you use inhalers ("puffers") for your chest?". Seventy-four subjects
(14.5%) were using inhaled medications: 23 were using inhaled bronchodilators
alone, and 51 were also using inhaled steroids. Four of those using inhalers were
also taking oral steroids, two were also taking theophylline, and 2 were taking both
oral steroids and theophylline. Only one subject was taking an oral beta agonist
preparation.
More women than men used inhalers (chi2=5.8, p=0.02) (Figure 14.1), but there
was no difference between older and younger adults (chi2=2.6, p=0.1) (Figure
14.2). Those taking oral steroids were older (age range 60-83 years, mean 73.0
years), as were those taking theophylline (age range 77-81 years, mean 79.8 years).
The subject taking an oral beta-agonist was aged 58 years. There was no difference
between the proportion of attenders and non-attenders using inhaled medications.
Use of inhaled medications by smokers and non-smokers is shown in Figure 14.3.
Although smokers were slightly more likely to be using inhalers, this difference was
not significant.
Asthma or bronchitis was reported by all but 4 of the subjects using inhaled
medications. However, only 70 (46.4%) of the 151 subjects reporting asthma or
bronchitis were using inhalers. Subjects describing asthma or asthma/bronchitis were
more likely to be using inhalers than subjects reporting bronchitis alone (chi2=45.5,
p < 0.001) (Figure 14.4). Although there was a tendency for increased use of inhaled
steroids by those reporting asthma or asthma/bronchitis compared with those
reporting bronchitis, this difference did not reach significance (asthma or
asthma/bronchitis: 72.4% using inhaled steroids, bronchitis alone: 58.3% using
inhaled steroids; chi2 = 1.6, p=0.4). Overall, 82.4% of inhaled bronchodilators plus
steroids and 69.6% of bronchodilators alone were used by subjects reporting
asthma.
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Figure 13.1: Use of inhaled medications by women and men
%
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Figure 13.2: Use of inhaled medications by younger and
older adults
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Figure 13.4: Use of inhaled medications by subjects reporting
asthma, bronchitis and asthma/bronchitis
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Inhaled medications were used more often by symptomatic subjects (figure 14.5).
Only 2.2% of asymptomatic subjects reported used inhalers, compared with 10.5%
of those with one respiratory symptom, 20.3% of those with two, 32.9% of those
with three, and 54.6% with four symptoms (chi2=98.4, p<0.001). Breathlesness
was the symptom most strongly linked with inhaler use. In subjects attending for
bronchial challenge, 30.0% of those with symptoms of chronic bronchitis and
10.0% without were using inhalers (chi2= 12.5, p< 0.001); 37.5% of those with one
or more symptom of bronchial irritability were using inhalers (chi2=23.2,
p<0.001).
Subjects reporting wheeze were asked as part of the full questionnaire whether they
had ever received treatment for this: 44.6% claimed to have been treated by their
GP and 9.7% in hospital. Of those reporting treatment for wheeze (either by GP or
in hospital), 63.1% were using inhaled beta-agonist + steroid.
Use of inhaled medications by subjects with chronic airflow obstruction is
summarised in figure 14.6. Those with airflow obstruction were more likely to be
using inhalers (chi2 = 33.3, p<0.001); however, over 60% of those with chronic
airflow obstruction were not using inhaled medications. Treated subjects had more
severe airflow obstruction (treated subjects: mean [SEM] FEV1/FVC% =48.6%
[1.8], untreated subjects: 57.5% [0.7]; t=5.3, p<0.001). Seventy percent of
subjects with chronic airflow obstruction who were not using inhaled medication
described one or more respiratory symptoms.
Figure 14.7 shows inhaled medication use by subjects with bronchial hyper-
responsiveness. Use of inhalers was more common in subjects with greater bronchial
hyper-responsiveness (chi2 = 10.0, p=0.007). However, two thirds of those with
greatly increased bronchial responsiveness and over three quarters of those with
moderately increased bronchial responsiveness were not on inhaled therapy.
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Figure 13.6: Use of inhaled medications by subjects with
chronic airflow obstruction
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Chapter 14: QUALITY OF LIFE IN SUBJECTS WITH CHRONIC AIRFLOW
OBSTRUCTION AND BRONCHIAL HYPER-RESPONSIVENESS
(Renwick and Connolly, 1996b)
163
Studies in groups of patients with asthma and chronic airflow obstruction have
shown that these illnesses have substantial impact on quality of life, impairing not
only physical, but also psychological and social function (Guyatt et al. 1987; Schrier
et al. 1990). However, the relationship between quality of life impairment and
severity of airflow obstruction has generally been found to be weak (Guyatt et al.
1987; Quirk and Jones 1990; Schrier et al. 1990; Quirk et al. 1991). The effect of
age on the relationship between quality of life and chronic airflow obstruction has
not been examined, although some studies have suggested that the impact of
obstructive airways disease on quality of life may be less in older subjects (Guyatt
et al. 1987; Quirk and Jones 1990; Juniper et al. 1992).
i) Methods
Subjects attending for bronchial challenge completed the St George's Respiratory
Questionnaire (Jones et al. 1992). This is a self-complete questionnaire designed for
patients with asthma and chronic airflow obstruction, and validated in patients up
to the age of 75 years. Separate scores are derived for 3 different components of
quality of life: symptoms (frequency and severity), activities (causing or limited by
breathlessness) and impacts (on employment and emotions, feelings of panic or
control). The sum of these three scores represents the total quality of life score; this
is expressed as a percentage of the total possible questionnaire score. Higher scores
indicate greater morbidity; the maximum possible score is 100. Questions mostly
take a "multiple-choice" format, and the questionnaire can be completed in
approximately 10 minutes.
St George's Questionnaire scores were log transformed to achieve normal
distribution. To allow log transformation of all scores, the value 0.5 was allocated
to those subjects with scores of 0. Relationships between quality of life scores and
pulmonary function were analysed by linear correlation and multiple regression.
Subgroups were compared by grouped t test.
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ii) Results
Two hundred and twenty-seven attenders performed reproducible spirometry and
completed the St George's Questionnaire. Bronchial challenge results were available
for 190 of these.
The distribution of total St George's Questionnaire scores is shown in Figure 15.1.
Sixteen subjects had a score of zero (indicating no quality of life impairment), and
geometric mean score was 8.5 (SD 3.5). Geometric mean quality of life scores were
similar for men and women. There was no correlation between quality of life scores
and age. However, the geometric mean Activities score was significantly higher for
subjects aged >65 than for those <65 years (age >65: 11.0 [SD 5.1], age <65:
6.5 [SD 5.6; t=-2.34, p=0.02]).
Total quality of life scores were significantly higher (indicating greater quality of
life impairment) in subjects with chronic airflow obstruction (table 15.1). Similarly,
all quality of life scores except Impacts score were higher in those with bronchial
hyper-responsiveness (PD20^ lOO^g) (table 15.1).
There was significant linear correlation between total quality of life scores and both
airways calibre and bronchial responsiveness (figures 15.2 and 15.3). Multiple
regression analysis was performed with quality of life score as the dependent
variable and baseline FEY) (expressed as standardised residuals), bronchial
responsiveness (log dose-response slope), age and sex as independent variables. As
there was significant correlation between baseline FEV, and log dose-response
slope, an interaction term was included in the regression. This was not significantly
related to quality of life in any of the analyses, and did not alter the value of R2.
For the whole subject group, both total and separate component quality of life scores
showed independent negative relationships with baseline FEVj. Only symptoms
score showed a significant association with log dose-response slope (Table 15.2).
The addition of baseline oxygen saturation and haemoglobin level to the regression
failed to show significant relationships between these variables and quality of life.
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Table 14.1: Quality of life scores in subjects with and without
chronic airflow obstruction or bronchial hyper-responsiveness
TOTAL ACTIVITIES IMPACTS SYMPTOMS
mean (sd) mean (sd) mean (sd) mean (sd)
airflow obstruction 15.1 (3.1) 15.1 (4.5) 5.8 (5.4) 25.7 (3.6)
no obstruction 6.9 (3.4) 7.1 (5.6) 2.2 (4.9) 8.3 (5.9)
t= -4.2 t=-3.0 t= -3.9 t= -4.5
p<0.0001 p = 0.003 p = 0.0001 p<0.0001
bronchial hyper- 9.5 (3.0) 10.7 (4.4) 2.5 (5.0) 16.2 (5.0)
responsiveness*
no hyper- 6.5 (3.2) 6.3 (5.4) 1.9 (5.0) 7.8 (5.5)
responsiveness
t= -2.0 t = -1.9 t = -0.9 t = -2.6
p = 0.05 p = 0.05 p = 0.4 p = 0.01
*defined in text
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Figure 14.2: Linear correlation between quality of life
and airways calibre
log total quality of life score
4T
3-
-1 i 1 1 1 1 1 1 1 1 1 1 1 1 r
-4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1 1.5 2
baseline FEV, (standardised residuals)
-0.47 p<0.001
Figure 14.3: Linear correlation between quality of life
and bronchial responsiveness





Table 14.2: Factors associated with quality of life scores:









FEV1 $ B=-0.15 B=-0.18 B=-0.16 B=-0.13
SE=0.04 SE = 0.05 SE = 0.05 SE = 0.06
p<0.0001 p<0.0006 p<0.002 p = 0.03
bronchiai B=0.04 B = 0.06 B = 0.06 B=0.11
responsiveness# SE=0.04 SE = 0.06 SE = 0.05 SE = 0.06
COoIIQ_ p = 0.2 COoIIQ. p = 0.05
age B = 0.0003 B = 0.0003 B = 0.002 B=-0.006
SE = 0.003 SE = 0.005 SE = 0.004 SE = 0.005
p = 0.9 oIIQ_ h-ollQ_ p = 0.2
sex B = -0.05 B=-0.16 B=0.02 B=0.10
SE=0.07 oIILUCO SE = 0.01 OIILUCO
p = 0.5 OIICL p = 0.8 p =0.4
* log transformed values $ standardised residuals # log dose-response slope
total: R2=0.08 activities: R2=0.05 impacts: R2=0.05 symptoms: R2=0.07
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The effect of smoking on quality of life was assessed by comparing total St
George's Questionnaire scores of smokers of < 10 and >10 packyears. Quality of
life was significantly impaired in smokers of >10 packyears (total score 11.7 [SD
3.8) vs 5.8 [SD 2.9]; t=-3.3, p=0.001). However, when smoking status (packyears
smoked) was added to the multiple regression for the whole subject group, there was
no independent relationship with total quality of life score. The addition of an
interaction factor for smoking and airways calibre did not alter these results.
The effect of age on the relationship between quality of life and lung function was
assessed by repeating the regression analysis separately for subjects aged < 65 years
and >65 years (table 15.3). This revealed differences between the age groups: in
subjects aged <65, total quality of life score was significantly associated with log
dose-response slope but not baseline FEVj, whereas in the older group the opposite
was true.
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Table 14.3: Factors associated with quality of life scores
in older and younger adults
Log total quality
of life score






bronchial AGE<65 B= 0.1 7





Younger group: R2=0.15; older group: R2=0.11
* standardised residuals # log dose-response slope
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Chapter 15: CHANGES IN OXYGEN SATURATION DURING
METHACHOLINE CHALLENGE
(Renwick and Connolly, 1996c)
172
i) Methods
Oxygen saturation (Sa02) was monitored during bronchial challenge using a finger
oximeter (Biox 3700e, Ohmeda, Louisville, USA). The 95% confidence limits for
background variability of Sa02 in our laboratory (measured in young controls over
2 minutes) are ±2.7% (Zaidi et al. 1995). Sa02 was observed to increase following
spirometry, presumably secondary to a reduction in ventilation-perfusion mismatch
resulting from repeated maximal inhalations. Consequently, all Sa02 measurements
were recorded immediately before each set of FEV, manoeuvres; this point was
chosen arbitrarily. Multiple regression analysis was used to assess the influence of
various parameters on oxygen saturation.
ii) Results
Baseline oxygen saturation was recorded in 238 subjects performing spirometry, and
change in saturation was monitored during 208 methacholine challenges. Mean
baseline Sa02 was 96.8% (SD 1.6). Baseline Sa02 was higher in women than men
(women 97.0% ±1.3, men 96.5% ±1.8; t=2.2, p=0.03).
There was no difference in baseline Sa02 between subjects with or without a
diagnosis of asthma or bronchitis. Baseline Sa02 was lower in subjects with
spirometric evidence of chronic airflow obstruction (airflow obstruction: 96.7% [SD
1.4], no obstruction: 97.1% [SD 1.2]; t—3.2, p=0.002). Subjects reporting one or
more respiratory symptoms had lower baseline Sa02 than asymptomatic subjects
(symptomatic: 96.5% [SD 1.8], asymptomatic: 97.2% [SD 1.2]; t=3.5, p=0.0005).
Multiple regression analysis with baseline Sa02 as the dependent variable showed
an independent positive relationship with airways calibre (FEV, standardised
residuals), and independent negative relationships with age and with packyears
smoked (Table 16.1). Baseline Sa02 was also independently associated with gender.
Interaction factors for the relationships between age and packyears, and sex and
packyears, did not alter the results. However, an interaction factor for the
relationship between FEV, and packyears was strongly associated with baseline Sa02
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Table 15.1: Factors affecting baseline oxygen saturation
Coefficient SE p value
FEV1 (standardised residuals) 0.45 0.08 <0.0001
AGE -0.03 0.008 0.0003
PACK YEARS -0.01 0.004 0.003
SEX -0.42 0.19 0.03
No relationship was found between baseline saturation and bronchial responsiveness,
haemoglobin, reported asthma or bronchitis, or respiratory symptoms
R2=0.25
Table 15.2: Factors affecting change in oxygen saturation
Coefficient SE p value
% FALL IN FEV1 0.11 0.03 <0.0001
LOG METHACHOLINE DOSE 0.95 0.21 <0.0001
BASELINE SATURATION 0.35 0.14 0.01
FEV1 (standardised residuals) -0.41 0.2 0.04
No relationship was found between fall in saturation and bronchial responsiveness (log DRS),
age, sex, packyears, reported asthma/bronchitis, or respiratory symptoms
R2=0.18
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(B=0.02, SE=0.002, t=8.9, p<0.0001), removing the independent relationships
of baseline Sa02 with FEV, and packyears. The square of the coefficient of multiple
regression (R2) was 0.25.
Mean percentage fall in FEVi during bronchial challenge was 20.6% (SD 7.9);
mean fall in Sa02 was 3.2% (SD 2.4). Fall in Sa02 was >10% in only 4 subjects
(Figure 16.1), and was similar in subjects reporting asthma, bronchitis, and those
with no reported diagnosis. There was no difference in the fall in Sa02 between
subjects with and without chronic airflow obstruction, or between symptomatic and
asymptomatic subjects.
Multiple regression analysis showed fall in Sa02 to be positively associated with
baseline Sa02, % fall in FEV!, and log methacholine dose given (Table 16.2). Fall
in Sa02 was negatively associated with baseline FEV! (standardised residuals). R2
was 0.16. Interaction factors for the relationships between fall in FEVi and log
methacholine dose, and between baseline saturation and baseline FEVi were both
significantly associated with fall in Sa02 (fall in FEVi x log methacholine dose:
B=0.04, SE=0.007, t=5.6, p=0.008; baseline Sa02 x baseline FEVi: B=-0.003,
SE=0.002, t=-2.0, p=0.05). Inclusion of these interaction factors removed the
significant relationships of the individual determinants with fall in Sa02. R2 was now
0.18. There was no relationship between fall in Sa02 and age, sex, pack years,
bronchial responsiveness, or haemoglobin.
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The response rate to our postal questionnaire was high, and compares favourably
with other studies in this area (Dow et al. 1991; Horsley et al. 1993). Factors
which may have contributed to this success include the use of GP's headed
notepaper; repeated mailings for non-responders (which accounted for 46.0% of the
total response); the "opt-out" slip allowing subjects to return the questionnaire
without risk of being requested to attend hospital; simplification of the questionnaire
sent to persistent non-responders; and tracing of non-responders by telephone or
home visit (accounting for 6.2% of the total response).
Many subjects in the intial random sample were found to have left the area or died
(93/893 subjects). Similar or higher prevalences of untraceable or deceased patients
(10-20%) have been described in other studies taking information from GP records
(Milne et al. 1971; Trigg et al. 1990). This seems to be an unavoidable consequence
of using such data. Screening of selected subjects by GPs prior to inclusion in the
study was necessary to ensure GP co-operation with the study. It was reassuring that
the majority of subjects thought unsuitable by GPs met the agreed exclusion criteria.
We are confident that responders were representative of the selected population in
terms of age and sex. Population statistics for this area suggest that women are
over-represented in our population (Office of Population Censuses and Surveys
1991); the high proportion of men amongst subjects initally selected but found to be
ineligible may be responsible for this difference.
Persistent non-responders were younger than responders, and contained a higher
proportion of males. This may reflect increased mobility of the younger male
population. In contrast, subjects refusing to participate were older, and more likely
to be women. Difficulties in persuading older people, particularly women, to
participate in research projects have been previously described (Cochrane 1954;
Milne et al. 1971; Bakke et al. 1990), although one study found higher response
rates in subjects aged >85 than in those aged 65-74 years (Rockwood et al. 1989).
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Differences in health status have also been reported between responders and non-
responders in epidemiological surveys. Different studies have found responders
either more or less likely to use medical services than non-responders (Milne et al.
1971; Rockwood et al. 1989). Non-smokers, asthmatics, and middle-aged women
have been over-represented in some epidemiological surveys of bronchial
responsiveness (Burney et al. 1987; Trigg et al. 1990; Britton et al. 1994a). In the
current study, very few asthmatics were found in the non-responders contacted by
telephone or visit. This suggests that our estimate of the prevalence of reported
asthma may be slightly high. Conversely, bronchitis was reported by a relatively
large number of contacted non-responders, and so our estimate of the prevalence of
reported bronchitis may be slightly low. However, the high questionnaire response
rate means that these effects would be small.
Furthermore, subjects reporting asthma were more likely, and those reporting
bronchitis less likely, to complete the full (rather than the abbreviated)
questionnaire. This could in theory have led to over-representation of asthmatics in
the group attending for bronchial challenge. However, reported asthma, bronchitis
and respiratory symptoms were all equally common in attenders and non-attenders,
confirming that the attenders were a representative group.
Over half of our responder population was aged >65 years, as were over 40% of
those performing bronchial challenge. This is the highest proportion of older adults
included in a population study of bronchial responsiveness (except for studies
including only elderly subjects (Dow et al. 1991; Horsley et al. 1993)). In all other
published population studies, less than 15% of those included have been in this age
group. The inclusion of this high proportion of elderly people may have aided the
detection of the subtle relationship between bronchial responsiveness and age, and
the persistence of the relationship between bronchial responsiveness and atopy in the
elderly.
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The very high prevalence of current and ex-smoking in Central Manchester is
noteworthy. Our "current smoker" figures are higher than General Household
Survey estimates for this region (Office of Population Censuses and Surveys 1991b).
However, there was a particularly high prevalence of current smoking in the non-
responders contacted by telephone or visit; if these are representative of the
remaining non-responders, our estimate of smoking prevalence may still be low.
Smokers have been under-represented in some other population studies of bronchial
responsiveness (Burney et al. 1987; Britton et al. 1994a). These high levels of
smoking probably reflect the nature of this relatively deprived inner-city population;
our results are likely to be representative of the urban Caucasian population
elsewhere in Britain.
The low attendance rate for bronchial challenge was disappointing. Older people
were particularly reluctant to take part, resulting in a small age difference between
attenders and non-attenders. Attendance rates of less than 50% have been described
in several other epidemiological surveys of bronchial responsiveness (Table 2.4)
(Mortagy et al. 1986; Trigg et al. 1990; Higgins et al. 1993). However, the fact that
reported asthma/bronchitis, respiratory symptoms, smoking habit and use of inhaled
medications were all similar in our attenders and non-attenders confirms that we
have studied a representative sample of the responder population.
In the interests of safety in this elderly random population sample, we excluded
subjects with symptomatic ischaemic heart disease or ECG abnormalities from
bronchial challenge. However, methacholine challenge has been performed in
patients with symptomatic cardiac failure (Cabanes et al. 1989), and published
guidelines suggest that only those within 3 months of myocardial infarction, or with
uncontrolled hypertension should be excluded (Sterk et al. 1993).. In total, 16.7%
of responders were excluded on these grounds.
The exclusion of subjects with low baseline FEVj from bronchial challenge is
accepted practice (Sterk et al. 1993). In our study 10.5% of attenders were excluded
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for this reason. Four percent of adults were unable to complete bronchial challenge.
These figures are comparable with other published epidemiological surveys (Table
2.4). The vast majority of adults attending for bronchial challenge were able to
perform spirometry reproducible to within +10%; this contrasts with a study of
elderly adults in which 14% failed to produce results within +5% (Dow et al.
1992b). The fact that so few subjects (<5%) were unable to complete bronchial
challenge supports the assertion that this technique is practical even in elderly
populations (Connolly et al. 1988b).
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B) REPEATABILITY OF BRONCHIAL CHALLENGE
Repeatability of bronchial challenge is dependent on both subject and technique-
related factors (Sterk et al. 1993; Weeke et al. 1987). Careful standardisation of the
challenge protocol, calibration of nebuliser output and the performance of all tests
by a single operator increases repeatability (Ryan et al. 1981a; Britton et al. 1986;
Chinn et al. 1987). Subjects with previous experience of the bronchial challenge
technique produce more repeatable results than inexperienced subjects (Knox et al.
1991).
In general, most published studies have found repeatability of bronchial
responsiveness to be within 1-3 doubling doses of challenge agent (Weeke et al.
1987; Sterk et al. 1993), with better results being obtained in small selected groups
than in larger epidemiological surveys (Ryan et al. 1981b; Chinn et al. 1987;
Higgins et al. 1988). In one study, subjects with "obstructive lung disease"
(FEV1<80% predicted or past history of airflow obstruction) had lower
reproducibility than healthy subjects (Bakke et al. 1991a).
Other studies of repeatability of the Newcastle Dosimeter method of bronchial
challenge have been published. In a group of 20 asthmatic subjects with
reproducible baseline FEV! and previous experience of bronchial challenge, 95%
limits of agreement for repeated measurements were 0.5-2.0 x initial PD20 for both
methacholine and histamine (Connolly et al. 1988a). Subsequent studies in older
subjects (aged 65-82) showed poorer, although still acceptable, repeatability for
PD20(FEV1) (95% limits of agreement 0.39-2.57 x initial reading) (Connolly et al.
1988b). A comparison of the Newcastle dosimeter technique with the Wright
nebuliser tidal breathing method in 20 asthmatic subjects found superior repeatability
for the Newcastle dosimeter method (95% limits of agreement 0.3-3.0 x initial PD20)
(Beach et al. 1993). These values are comparable with those for the current study
(95% limits of agreement 0.4-2.7 x initial reading).
Our results confirm that repeatability is better in younger than older subjects.
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However, the two age groups in the current study are not strictly comparable: the
younger group were hospital personnel (mostly medical and nursing staff), and so
might be expected to be more familiar with spirometry than the older subjects
recruited at random from the population. A decrease in repeatability with increasing
age could result either from greater variability in spirometry performance by older
subjects, or from an intrinsic variability in the response to methacholine.
We have shown that using the mean of 3 FEVj recordings produces more repeatable
results than does the best of 3. This may be because the mean is less affected by the
"deep breath bronchodilatation" that occurs as a result of performing repeated
spirometry (Orehek et al. 1981; Beach et al. 1993). Our results also suggest
superior reproducibility for FEVj than for PEFR or FEF50. This confirms published
studies comparing bronchial challenge results using FEV) and PEFR (Connolly et
al. 1988b), or FEVj and FEF50 (Dehaut et al. 1983).
Two other studies have shown lower reproducibility of DRS(FEV1) in subjects not
achieving a PD20 (Seppala 1991; Trigg et al. 1994), and several authors have
expressed concern that repeatability of DRS may be unsatisfactory in subjects with
low levels of bronchial responsiveness (Cockcroft and Berscheid 1983; Higgins et
al. 1989a; Chinn et al. 1992). This may be the result of log transformation of
calculations based on small changes in FEVj, which will magnify the effect of
within-subject variation and random technical errors.
This observation limits the application of DRS in the laboratory setting. However,
the use of DRS allows the inclusion of data from many more subjects than have a
calculable PD20. In the context of epidemiological surveys or large cross-sectional
study designs, where repeated testing of the same subjects is not planned, this latter
advantage may outweigh the disadvantage of reduced reproducibility at lower levels
of bronchial responsiveness. In our population, the difference between repeatability
in those with and without a calculable PD20 was small, and repeatability was within
2 doubling doses in both groups.
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C) PREVALENCE OF REPORTED ASTHMA, BRONCHITIS AND
RESPIRATORY SYMPTOMS
The questionnaire used in the current study was designed specifically for this study,
but used questions about respiratory symptoms and diagnosed asthma similar to
those in included in other widely used and well validated questionnaires (Medical
Research Council 1960; Ferris 1978; Burney and et al. 1989). Using Cohen's kappa
statistic to assess agreement between postal and interview responses showed slightly
lower agreement than reported for comparisons between two interview-administered
questionnaires (Abramson et al. 1991). This may reflect the fact that more subjects
reported one or more symptoms on the postal questionnaire than at interview, which
confirms the findings of other comparisons between postal and interview
questionnaires (Toren et al. 1993). Agreement was lowest for breathlessness, which
is perhaps the most difficult of these symptoms to define, due to its dependence on
level of exertion (ie speed of walking, incline of hill).
The classification of subjects reporting both asthma and bronchitis is difficult. This
problem has been encountered in other studies, and probably reflects the lack of
clear diagnostic criteria for asthma and chronic bronchitis (see page 33). Inclusion
of subjects reporting both diagnoses as either "asthma" or "bronchitis" substantially
increases reported disease prevalence (from 7.3% to 14.6% for asthma, and from
15.4% to 22.7% for bronchitis).
In the Tucson study, 46% of patients aged >65 years reporting asthma also
reported chronic bronchitis, and 63% reported emphysema (Burrows et al. 1991).
Those with asthma/emphysema were mostly male heavy smokers, and the authors
classified them as "non-asthmatic"; those with asthma/bronchitis were classified as
"asthmatic" (Burrows et al. 1991). However, in the current study, subjects reporting
asthma/bronchitis appear to be a distinct group, differing from those reporting either
asthma or bronchitis alone. Thus, asthma/bronchitis was more common in women,
but asthma alone and bronchitis alone were equally common in both sexes.
Furthermore, although the strong relationship of reported asthma/bronchitis with
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current smoking resembles that of bronchitis alone, the high prevalence of bronchial
hyper-responsiveness in the group reporting asthma/bronchitis is more similar to
those with asthma alone. Given this overlap, it is not surprising that this group has
received multiple diagnostic labels.
It is possible that subjects reporting asthma/bronchitis may represent smokers who
initially had asthma, but have subsequently developed concurrent smoking-related
airflow obstruction. This would account for the presence of features of both asthma
and chronic bronchitis in these individuals. If these subjects with asthma/bronchitis
are regarded as a separate group, then the prevalence of self-reported asthma in
Central Manchester falls within the range reported by most other studies (see table
2.5), but reported bronchitis is still more common than elsewhere. Alternatively,
including asthma/bronchitis with the group reporting asthma alone gives a higher
prevalence of reported asthma than that found in other populations. The diagnosis
of emphysema was reported only rarely in Central Manchester; this may reflect
local diagnostic practices, and a reluctance to use a term which the public associates
with poor prognosis.
Respiratory symptoms were reported more frequently in Central Manchester than
in other published studies (table 2.6). Although the prevalence of one or more
symptoms was similar (53.8% in Central Manchester, 30-60% in other studies
(Dow et al. 1991; Horsley et al. 1991; Lundback et al. 1991; Viegi et al. 1991a)),
individual symptoms were all more common in our population than in several others
(Milne 1978; Samet et al. 1982; Rijken et al. 1987; Woolcock et al. 1987;
Krzyzanowski et al. 1990; Viegi et al. 1991a; Peat et al. 1992a; Isoaho et al.
1994a). Perhaps significantly, the only other study reporting levels of reported
cough and sputum similar to the current study was a survey performed in Glasgow
(Milne 1978); this may reflect similarities between the populations of these two
large industrial cities. Prevalences of breathlessness similar to that found in Central
Manchester have been reported by the Tucson study (Lebowitz et al. 1975), and by
a recent Dutch population survey (Boezen et al. 1995).
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The prevalence of respiratory symptoms in the current study was higher than that
of reported asthma or bronchitis. This finding is particularly surprising for chronic
bronchitis, which is a diagnosis based purely on the presence of symptoms. In the
current study, only 39.0% of subjects reporting bronchitis fulfilled MRC criteria for
this diagnosis, and only 49.0% of those fulfilling the diagnostic criteria reported
having bronchitis. Our terminology ("bronchitis" rather than "chronic bronchitis")
is unlikely to account for this discrepancy, which has been noted by others
(Lebowitz et al. 1975; Lundback et al. 1991).
Our data show no change in the prevalence of reported asthma or bronchitis with
increasing age. Both increasing and decreasing prevalences have been suggested by
other studies (Lebowitz et al. 1975; Lundback et al. 1991; Neukirch et al. 1995).
Others have also suggested that symptom frequency increases with age (Lebowitz
et al. 1975; Burr et al. 1979; Mortagy et al. 1986; Rijken et al. 1987; Lundback et
al. 1991; Viegi et al. 1991a); again, our results do not support these findings.
We have also found no evidence of higher prevalence of reported asthma in women
than men, or of reported bronchitis in men than women, as has been reported by
others (Samet et al. 1982; Schachter et al. 1984; Isoaho et al. 1994b). However,
reported asthma/bronchitis was more common in women than men in the current
study. Our results confirm differences found in other populations between symptoms
reported by men and women; sputum production was more common in men, and
breathlessness in women (Caird and Akhtar 1972; Milne and Williamson 1972;
Lebowitz et al. 1975; Burr et al. 1979; Krzyzanowski et al. 1990; Isoaho et al.
1994a).
The strong link between smoking and reported bronchitis is expected, and confirms
other reports (Samet et al. 1982; Lundback et al. 1991). However, the relative lack
of current smokers in subjects reporting asthma is interesting, and may suggest that
smokers receiving a diagnosis of asthma are more likely to give up smoking. If so,
this would represent another manifestation of the "healthy smoker effect" (see page
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59). However, those reporting asthma/bronchitis had smoking habits resembling
those reporting bronchitis, rather than those reporting asthma.
The relationship between symptom prevalence and smoking habit in our population
again confirms previous reports (Milne and Williamson 1972; Samet et al. 1982;
Rijken et al. 1987; Horsley et al. 1991; Lundback et al. 1991; Viegi et al. 1991a;
Menezes et al. 1994). However, the stronger relationship between symptoms and
smoking habit in younger than older adults has not been previously described. The
reason for the higher prevalence of symptoms in older never-smokers, and lower
symptom reporting by older current smokers is unclear. Many older adults in
Central Manchester have lived in the same urban area for many years; chronic
exposure to an environmental agent (eg airborne pollution) could be implicated in
the production of symptoms independent of smoking (Viegi et al. 1991a). Under¬
reporting of respiratory symptoms by older smokers has been noted in another
population study (Lundback et al. 1993a).
Although we have found respiratory symptoms to be more common in subjects with
increased bronchial responsiveness, over one quarter of those with bronchial hyper-
responsiveness were asymptomatic. High prevalences of asymptomatic bronchial
hyper-responsiveness have been previously noted in both young and older
populations (Kolnaar et al. 1995; Rijken et al. 1987). However, the significance of
an asymptomatic increase in bronchial responsiveness is unclear (see page 49). The
relationship between bronchial hyper-responsiveness and respiratory symptoms in
our population is further discussed on page 190.
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D) RESULTS OF SPIROMETRY
A decline in pulmonary function with age is accepted, and most studies suggest
linear relationships between FEVl5 FVC, FEVj/FVC and age (Cotes 1993). Our
figures confirm these relationships, although the correlation was weaker for
FEV1/FVC% than for other spirometric parameters. This is partly the result of an
increase in FEVj/FVC in women over the age of 85, which may represent the
reluctance of less robust subjects in this age-group to take part. Alternatively, it may
be the result of "survival of the fittest": poor lung function is a marker of increased
mortality from various causes, and so subjects surviving into the older age groups
are likely to be those with better lung function (Cook et al. 1989).
The detrimental effect of smoking on lung function is undisputed (Dockery et al.
1988). We have confirmed significantly lower FEVj and FEV1/FVC% in women
smokers, but have failed to show a difference in men. This is surprising, and
suggests either unexpectedly low FEVj in never-smoking men, or unexpectedly high
FEVj in smokers. Alternatively, it may represent a survival effect: the increased
mortality of male smokers with airflow obstruction may have falsely increased the
mean FEV! of smoking men in this relatively elderly population. Smoking appeared
to have little effect on FVC in either women or men; this finding is in agreement
with other population studies (Burrows et al. 1977; Miller et al. 1986).
Further assessment of our results has been made by comparison with 5 reference
ranges, derived from the results of other cross-sectional population surveys by
regression analysis (Cotes 1993). Reference equations are calculated separately for
men and women; the effect of smoking on lung function is accounted for by
excluding smokers, or by producing separate equations for smokers and never-
smokers. Since the decision of an individual whether or not to start or give up
smoking may be influenced by his or her lung function and/or the presence of
symptoms, exclusion of all smokers from the analysis may introduce bias into the
reference population (Cotes 1993).
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Several reference ranges for lung function have been published from the 1960s
onwards, representing studies of various different populations (Cotes 1993).
Composite equations have also been calculated, combining the results of different
studies (Quanjer 1983). However, the relevance of studies performed 30 years ago
in predicting lung function in the 1990s is debatable. Environmental changes over
time may cause lung function to be affected by year of birth; this has been termed
a "cohort effect" (Cotes 1993). Furthermore, some studies have included both
smokers and non-smokers, whereas others have excluded not only smokers but also
those with respiratory symptoms (table 8.1). Few reference ranges have included
subjects over a wide age-range such as that included in the current study;
extrapolation of results from younger to older subjects assumes a constant rate of
decline in FEV, with age, and is probably not valid. In one study, values of FEVj
measured longitudinally differed considerably from values predicted by a cross-
sectional analysis of the same population, and it has been suggested that reference
ranges calculated from a study of one particular population cannot give accurate
predictions for another (Burrows et al. 1986).
Comparison of measured FEVj in Manchester never-smoking men and women with
values predicted by the published reference ranges identifies some important
differences. Measured values are similar to reference ranges predicted by Cotes et
al (who included smokers in their population) (Cotes et al. 1966) and Burr et al
(who did not exclude symptomatic subjects or those with asthma or chronic
bronchitis) (Burr et al. 1985). However, more recent studies which have excluded
both smokers and symptomatic subjects have produced higher predicted values;
comparison of asymptomatic never-smoking Manchester men and women with these
shows significantly lower lung function in the Manchester population (Dockery et
al. 1985; Roberts et al. 1991; Enright et al. 1993). The reason for this is unclear;
it may reflect environmental exposure (for example to airborne pollution), or result
from general poor health in the Central Manchester population. It may also
represent a cohort effect, perhaps following exposure of this adult population to high
levels of ambient air pollution in childhood (in the 1920s-1940s). The fact that this
189
difference is more marked in men than women raises the possibility that a work-
related factor may be involved; unfortunately, comprehensive occupational histories
were not taken in the current study.
Alternatively, the difference may merely reflect differences in population selection:
the study by Roberts et al was based on volunteers rather than a random population
sample (Roberts et al. 1991), and Enright et al incorporated particularly stringent
screening to ensure that only healthy subjects were included (Enright et al. 1993).
However the Central Manchester population attending for spirometry excluded
subjects with ischaemic heart disease, and removal of symptomatic subjects from the
analysis failed to remove the difference between measured and predicted lung
function.
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E) PREVALENCE OF CHRONIC AIRFLOW OBSTRUCTION AND
INCREASED BRONCHIAL RESPONSIVENESS
We have found high prevalences of both chronic airflow obstruction (26.4%), and
moderately/greatly increased bronchial responsiveness (PD20< 100/xg methacholine;
prevalence=26.0%). This level of bronchial responsiveness has been shown to have
a positive predictive value for symptomatic asthma of almost 100% in young
populations (Cockcroft et al. 1985). Comparison with other studies suggests that
both chronic airflow obstruction and increased bronchial responsiveness are more
common in Central Manchester than in other populations (table 2.7, 2.8).
However, comparisons between studies are hampered by the use of different
definitions of chronic airflow obstruction and bronchial hyper-responsiveness. Two
studies have used a similar definition of chronic airflow obstruction to the current
study, and both report a lower prevalence (12.5% (Isoaho et al. 1994a), and 18.2%
(Peat et al. 1990); Central Manchester 26.4%). PD20<800/zg was found in 6% of
the population of Hordaland (Bakke et al. 1991a), and 51.0% of Central Manchester
adults; no other authors have reported the prevalence of PD20< 100/xg, but
PD20<200jug was reported in 12% adults over 65 in the New Forest (Horsley et al.
1993), and in 23% adults in Surrey (Trigg et al. 1990), compared with 34.6% in
Manchester.
Our data confirms a strong inter-relationship between bronchial responsiveness and
baseline airways calibre. Although this relationship has previously been reported to
be stronger in subjects with chronic airflow obstruction than in those with asthma
(Woolcock et al. 1991), we found it to be strongest in those with the most marked
increase in bronchial responsiveness (PD20< 12.5/xg).
Other studies have suggested that chronic airflow obstruction is more common in
men (Isoaho et al. 1994a) and bronchial hyper-responsiveness in women (Rijken et
al. 1987; Cerveri et al. 1988; Trigg et al. 1990; Carrozzi et al. 1992; Peat et al.
1992a). Our data supports neither of these associations; sex was not independently
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associated with bronchial responsiveness in multiple regression analysis.
Furthermore, chronic airflow obstruction has been found to be more common in
older people (Krzyzanowski et al. 1986; Peat et al. 1990; Isoaho et al. 1994a).
Although our data confirms this finding, the difference did not reach statistical
significance, perhaps because of a type II error. Simple categorical analysis also
showed no relationship between age and bronchial responsiveness in our population.
We have found a strong relationship between smoking and chronic airflow
obstruction, as described in other populations (Peat et al. 1990; Isoaho et al. 1994a).
However, the prevalence of chronic airflow obstruction in never-smokers is higher
in the current study than in other populations (Central Manchester 12.8%; Finland
2%; Busselton 7% (Peat et al. 1990; Isoaho et al. 1994a)). The increased frequency
of bronchial hyper-responsiveness in current smokers has also been previously
reported (Kabiraj et al. 1982). Ex-smokers in the current study had levels of
bronchial responsiveness similar to those of never-smokers, suggesting that the
effects of smoking on bronchial responsiveness may be short-lived, although
bronchial hyper-responsiveness has been shown to persist for at least 3 months after
giving up smoking (Buczko et al. 1984).
Respiratory symptoms were more common in subjects with chronic airflow
obstruction and those with increased bronchial responsiveness than in other subjects.
As expected, chronic productive cough was the symptom most strongly related to
chronic airflow obstruction, whilst wheeze and breathlessness were more predictive
of moderately and greatly increased bronchial responsiveness. However, the
predictive values of these symptoms for either chronic airflow obstruction or
bronchial hyper-responsiveness was low. This concurs with other population studies,
which have found that up to 50% of subjects with airflow obstruction reported
neither symptoms nor a diagnosis (Peat et al. 1990; Isoaho et al. 1994a), and that
over 50% of bronchial hyper-responsiveness may be asymptomatic (Rijken et al.
1987; Kolnaar et al. 1995). Like others, we have found that questions about
diagnosed asthma have higher positive predictive value for bronchial hyper-
responsiveness than questions about symptoms (Dales et al. 1987; Enarson et al.
1987).
The significance of asymptomatic chronic airflow obstruction and bronchial hyper-
responsiveness is unclear. It has been suggested that airflow obstruction may remain
asymptomatic until a relatively advanced stage, or alternatively that symptoms of
chronic airflow obstruction may develop insidiously and be tolerated by patients.
Denial of symptoms by smokers has been reported in a questionnaire study
(Lundback et al. 1993a). Asymptomatic bronchial hyper-responsiveness may
represent asymptomatic, pre-clinical or quiescent asthma, or may be the temporary
result of viral infection or exposure to an inhaled allergen or irritant. Despite the
apparent increase in tolerance of methacholine-induced bronchoconstriction in older
adults (Connolly et al. 1992a) we have not shown higher prevalence of
asymptomatic bronchial hyper-responsiveness in older subjects. However, our data
confirms the finding of others that symptoms of "bronchial irritability" are not
strongly associated with increased bronchial responsiveness in older adults (Dow et
al. 1992b; Horsley et al. 1993).
The low prevalence of diagnosed asthma or bronchitis amongst subjects with chronic
airflow obstruction or bronchial hyper-responsiveness may represent failure of
patients to report symptoms to their doctors, or failure of doctors to investigate or
treat these. Reluctance of geriatricians to perform spirometry in elderly people with
respiratory symptoms was described in a small questionnaire study (Ghosh et al.
1992).
Because of doubts about the significance of asymptomatic bronchial responsiveness,
it has been proposed that asthma should be defined as bronchial hyper-
responsiveness plus appropriate symptoms (Toelle et al. 1992). Using this definition
gives a prevalence of asthma in Central Manchester of 15.0%. This is still higher
than the prevalence of reported asthma, but similar to that of asthma plus
asthma/bronchitis.
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The very high prevalences of chronic airflow obstruction and bronchial hyper-
responsiveness in the Central Manchester population are consistent with the finding
of lower than predicted levels of FEV). As discussed above, factors such as relative
poverty in childhood (leading to poor diet and over-crowding, and increasing the
risk of viral respiratory tract infection and passive cigarette smoke exposure),
exposure to high levels of ambient air pollution, and occupational exposure may all
be implicated.
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F) USE OF MULTIPLE REGRESSION ANALYSIS TO INVESTIGATE
FACTORS ASSOCIATEDWITH BRONCHIAL HYPER-RESPONSIVENESS
Several of the factors potentially affecting bronchial responsiveness are inter-related
(for example airways calibre and age or smoking habit); multiple regression analysis
allows assessment of the joint influence of these variables, taking into account the
correlations between them.
i) Baseline airways calibre, smoking, age and sex
Multiple regression confirms the strong relationship between baseline airways
calibre and bronchial responsiveness suggested by analysis with bronchial
responsiveness expressed as a categorical variable. This relationship has been found
in many other population surveys (van der Lende et al. 1973; Malo et al. 1983;
Burney et al. 1987; Kennedy et al. 1990; Trigg et al. 1990; Bakke et al. 1991a;
Peat et al. 1991, 1992b; Horsley et al. 1993; Britton et al. 1994a; Sparrow et al.
1994). Possible mechanisms of the association between airways calibre and
bronchial responsiveness have been discussed above (page 53).
Multiple regression analysis failed to show an independent effect of smoking on
bronchial responsiveness in the current study, despite the fact that analysis with
bronchial responsiveness expressed as a categorical variable suggested increased
prevalence of bronchial hyper-responsiveness in current smokers (see chapter 10).
This suggests that smoking does not affect bronchial responsiveness directly, but
indirectly via its effects on airways calibre. Inclusion of airways calibre in
regression analysis has been shown to eliminate the relationship between smoking
and bronchial responsiveness in other population studies (Kennedy et al. 1990; Trigg
et al. 1990; Rijken et al. 1993a; Britton et al. 1994a) (page 58).
Studies of the relationship between bronchial responsiveness and sex have provided
conflicting results; where a difference has been found, this has usually been
increased bronchial responsiveness in women (page 58). Our results do not support
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a difference in bronchial responsiveness between women and men.
More interesting is our finding of a positive relationship between bronchial
responsiveness and age, although this accounts for only 3% of the population
variation in bronchial responsiveness. Other published population surveys have
disagreed on the presence or absence of such a relationship, which may have been
obscured by the small numbers of older adults included in most other studies (page
57). In the current study, the relationship between age and bronchial responsiveness
was only apparent in analysis of the entire population, and was not seen when older
and younger subjects were examined separately.
A second factor allowing our demonstration of a relationship between age and
bronchial responsiveness may have been the expression of pre-challenge airways
calibre as standardised residuals to remove age and sex-bias. Other studies have
either failed to take airways calibre into account, or have included FEV), %
predicted FEV!, or FEVj/FVC, all of which retain age and sex bias. The residual
age bias associated with the use of these parameters may have obscured the
relationship between age and bronchial responsiveness.
An increase in bronchial responsiveness with age is biologically plausible; several
of the abnormalities in the beta-adrenergic system seen in asthmatics are similar to
changes occurring as part of the normal ageing process (see page 27). Measurement
of both bronchial responsiveness and beta-adrenoceptor density and function in a
longitudinal study of older adults would be necessary to confirm an association
between increasing bronchial responsiveness and decreasing beta-adrenoceptor
function with increasing age.
ii) Atopy
Our results show an association between airways calibre and eosinophil count. This
confirms the results of other population surveys (van der Lende et al. 1969;
Burrows etal. 1980, 1983, 1988; Kauffman et al. 1986; Vollmeretal. 1986; Frette
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et al. 1991; Annesi et al. 1992). Only one population study has failed to show a
relationship between airways calibre and measures of atopy: this study excluded
asthmatic individuals (O'Connor et al. 1993). Removal of subjects reporting asthma
eliminated the relationship between FEV\ and eosinophil count in both the current
study and another population study (Kauffman et al. 1986). This suggests a role for
eosinophil-mediated airways inflammation in the development of chronic airflow
obstruction in asthmatics. We have found no evidence of a relationship between
airways calibre and total IgE, although such a relationship has been reported in
some populations (Burrows et al. 1980, 1983, 1988; Kauffman et al. 1986; Vollmer
et al. 1986; Frette et al. 1991; Annesi et al. 1992). The very high value of R2 for
the regression equation with FEVj as the dependent variable is worthy of note: over
60% of the variation in FEVj in our population can be explained on the basis of
variation in age, sex, height, packyears smoked and measures of atopy.
Our results also show a relationship between bronchial responsiveness and IgE level,
but not eosinophil count. Other population studies have also reported associations
between bronchial responsiveness and IgE (Carrozzi et al. 1992), eosinophils
(Rijken et al. 1993a), or both (O'Connor et al. 1989a; Parker et al. 1990), although
some have contradicted this (Annesi et al. 1988, 1992; Bakke et al. 1991a). The
relationship between IgE and bronchial responsiveness in the current study was
independent of reported asthma.
We have not shown a change in the association between measures of atopy and
baseline airways calibre or bronchial responsiveness with increasing smoking habit.
This suggests that atopic mechanisms are involved in the pathogenesis of chronic
airflow obstruction and bronchial hyper-responsiveness both smokers and non-
smokers. Thus our data does not support the theory that bronchial hyper-
responsiveness in smokers with chronic airflow obstruction is merely the
consequence of reduced airways calibre (Ramsdale and Hargreave 1990). Although
our results confirm that total IgE is elevated in smokers (Taylor et al. 1985a;
Vollmer et al. 1986; O'Connor et al. 1989b; Dow et al. 1992a; Jensen et al. 1992),
197
we have failed to show an interaction between the effects of atopy and smoking on
FEVj, as suggested by others (Orie et al. 1961; O'Connor et al. 1989a; Dow et al.
1992a). Several authors have also reported eosinophilia in current smokers (Taylor
and Luksza 1987; O'Connor et al. 1989b; Tollerud et al. 1991); this was not the
case in our population.
The raised serum IgE and eosinophils in subjects reporting asthma confirms
expectations (Kauffman et al. 1986; Burrows and et al. 1989), and has been noted
even in elderly asthmatics (Burrows et al. 1991). Elevated IgE levels and eosinophil
counts in subjects describing respiratory symptoms have also been previously
reported (Weiss et al. 1984; Mensinga et al. 1990; Barbee et al. 1991; Tollerud et
al. 1991). However, we have been unable to confirm links between different
symptoms and different measures of atopy. It is interesting that reported atopy was
not associated with raised IgE or eosinophils in this population. Results of skin tests,
IgE and eosinophil counts showed only weak correlation with questionnaire reports
of allergy in another study (Burrows et al. 1980).
Our finding that measures of atopy are more strongly associated with airflow
obstruction and bronchial responsiveness in older than younger adults is surprising,
and contradicts accepted teaching. Other studies of older adult populations have
shown relationships between IgE and airways calibre (Dow et al. 1992a) and
between IgE, eosinophils and bronchial hyper-responsiveness (O'Connor et al.
1989a). However, the prevalence of positive skin tests decreases with age (Skassa-
Brociek et al. 1987), and two population surveys have shown a decline in the
association between skin test positivity and bronchial hyper-responsiveness with
increasing age (Burney et al. 1987; Higgins et al. 1993).
It is possible that the effect of atopy on lung function has a "U-shaped" association
with age, being stronger in children/younger adults (not included in the current
population) and in the elderly than in "middle-aged" adults. The small numbers of
elderly people included in other studies may have obscured this relationship. Our
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results suggest that atopic mechanisms should not be overlooked as a significant
factor in older adults with asthma or chronic airflow obstruction.
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H) USE OF INHALED MEDICATIONS
Few epidemiological surveys of obstructive airways disease have considered use of
medication. Those that have suggest that many subjects with symptoms or
spirometric evidence of airflow obstruction are untreated (Banerjee et al. 1987).
Surveys of medications used by nursing home residents have shown low numbers
using bronchodilators (Nolan and O'Malley 1989; Hatton 1990).
A general practice-based study in the North of England found that 5% of the
population aged 0 to >85 years was using inhalers (Roberts and Bateman 1994).
This is lower than the prevalence of inhaler use in our population, perhaps because
of the different age ranges involved. The use of inhalers by patients with a
respiratory diagnosis was similar in both studies (Northern region 38%, Central
Manchester 46.4%), although fewer subjects with bronchitis were treated in the
Northern region (6%, vs 16.9% in Central Manchester). In the Northern region,
inhalers were more commonly used by men and by patients aged less than 70; these
findings were not confirmed by the current study. This may relate to differences in
either disease prevalence or diagnostic criteria between the two study populations.
It may be significant that there were wide (up to two-fold) variations in rates of
diagnosed asthma and bronchitis between separate general practices within the
Northern region, which were unlikely to reflect variations in actual disease
prevalence (Roberts and Bateman 1994).
Over half of the subjects in our population reporting asthma or bronchitis, and over
half with proven chronic airflow obstruction were not using inhaled drug therapy.
Although those using inhalers had more severe airflow obstruction and bronchial
hyper-responsiveness, 70% of untreated subjects with airflow obstruction described
respiratory symptoms. We do not know, however, how many of these untreated
subjects had reported their symptoms to a doctor. Thus, the low use of inhalers in
this population may reflect either tolerance of respiratory symptoms by patients, or
therapeutic nihilism by their GPs.
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Subjects reporting a diagnosis of asthma or asthma/bronchitis were more likely to
be using inhaled medications than those reporting bronchitis alone. This seems
appropriate, since those reporting asthma or asthma/bronchitis had a higher
prevalence of bronchial hyper-responsiveness, which may imply better response to
treatment (Connolly et al. 1988b). The use of oral steroids more frequently in older
than younger asthmatics has been previously reported (Bailey et al. 1992). The very
small number of patients receiving theophylline in this population is surprising; this
may reflect poor patient compliance or local prescribing habits.
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I) QUALITY OF LIFE IN SUBJECTS WITH CHRONIC AIRFLOW
OBSTRUCTION AND BRONCHIAL HYPER-RESPONSIVENESS
Our results confirm that obstructive airways disease impairs quality of life. We have
found no independent relationship between quality of life and age, sex, or smoking
status but have shown significant relationships with baseline FEV! and with
bronchial responsiveness. However, the value of R2 for the multiple regression
calculations was low, indicating that variation in lung function explains only a small
amount of the variation in quality of life, as previously reported (Guyatt et al. 1987;
Quirk and Jones 1990; Schrier et al. 1990; Quirk et al. 1991; Malo et al. 1993;
Ketelaars et al. 1996). Psychological assessment of patients with obstmctive airways
disease has shown that illness attitudes and beliefs are stronger predictors of
breathlessness and exercise tolerance than are measures of airflow obstruction
(Morgan et al. 1983; King and Cotes 1989; Jones 1991). Quality of life was
associated with partial pressure of oxygen in a small group of patients with severe
chronic obstructive pulmonary disease, but an independent relationship with oxygen
saturation was not found in the current study (Okubadejo et al. 1996).
The St George's Questionnaire has not been validated in a general population
sample, or in subjects aged >75 years (Jones et al. 1992). In the current study,
some subjects with no airways disease recorded very little quality of life
impairment, producing a skewed distribution of scores. The lack of correlation
between quality of life scores and age in the current study suggests that the
questionnaire is valid in the elderly. However, the mean Activities score was higher
for older subjects, indicating reduced activity levels with age.
It has been suggested that the quality of life impairment associated with obstructive
airways disease decreases with increasing age (Guyatt et al. 1987; Quirk and Jones
1990; Quirk et al. 1991; Juniper et al. 1992). It has also been shown that older
adults describe less severe acute symptoms than younger adults when exposed to the
same degree of methacholine-induced bronchoconstriction (Connolly et al. 1992a).
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However, there is no evidence for a general decrease in the reporting of distressing
chronic symptoms by the elderly: indeed the opposite may be true (Woods and
Britton 1985). The results of the current study do not confirm a reduction in the
impact of obstructive airways disease on quality of life in older people.
Our results show that quality of life is associated with bronchial responsiveness in
adults aged <65, but with baseline FEV! in older adults. The reasons for this
difference are not clear. Increased bronchial responsiveness is associated with
symptoms of "bronchial irritability" in young adults but not the elderly (Mortagy et
al. 1986; Dow et al. 1992b); the lack of these symptoms may diminish the effect of
increased bronchial responsiveness on quality of life. Alternatively, our results may
reflect a change in the interaction between baseline FEV! and bronchial
responsiveness with age, rather than a change in their interaction with quality of
life.
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J) CHANGES IN OXYGEN SATURATION DURING METHACHOLINE
CHALLENGE
Previous smaller studies have shown a relationship between the change in
oxygenation during nonspecific bronchial challenge and either the change in FEVj
(Baldini et al. 1991; van Broekhoven et al. 1991; Fontana et al. 1993), the dose of
challenge agent inhaled (Reed and Calhoun 1991), the pre-challenge level of
oxygenation (Rodriguez-Roisin et al. 1991), or none of these parameters (Poppius
and Stenius 1977). In the current study we have shown that the change in saturation
is related to all of the above parameters, as well as the baseline FEVj. However,
the low coefficient of multiple regression indicates that only 18% of the variation
in Sa02 is attributable to the measured parameters, and so other unidentified factors
must be involved.
No other study of oxygen saturation during bronchial challenge has included adults
with chronic airflow obstruction. Asthma and chronic bronchitis might be expected
to have different effects on oxygen saturation, but we found no difference during
methacholine challenge between subjects reporting these diagnoses. However, subtle
differences might be detected using a more sensitive technique for the measurement
of oxygenation.
Monitoring of saturation is relatively insensitive in well oxygenated subjects because
of the sigmoid shape of the oxygen saturation curve (West 1990). However, use of
this technique during bronchial challenge gave similar results to measurement of
partial pressure of oxygen (Ptc02) using a transcutaneous electrode in one study
(Hoffarth et al. 1990), but not another (Wilson et al. 1991). Similarly, measurement
of Ptc02 during bronchial challenge gave comparable results to direct measurement
of partial pressure of oxygen (Pa02) in arterial blood samples (Dal Negro and
Allegra 1989). Almost all studies of Sa02 during bronchial challenge have shown
a statistically significant mean fall in Sa02 of around 3%, which is consistent with
the results of the current study (Poppius and Stenius 1977; Burke et al. 1989; Dal
Negro and Allegra 1989; Stewart et al. 1989; Wilson et al. 1991).
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The fact that the fall in Sa02 during bronchial challenge is not related only to fall
in FEV, but also to methacholine dose suggests that methacholine may be altering
Sa02 both indirectly, via reduction in airways calibre, and also directly, by some
other mechanism. Such mechanisms could include alteration of ventilation-perfusion
distributions, as have been recorded during nonspecific bronchial challenge
(Rodriguez-Roisin et al. 1991). For example, methacholine-induced vasodilation in
poorly ventilated areas of lung could reduce oxygen saturation.
We had hoped to identify baseline factors which could be used to identify subjects
at risk of hypoxia during methacholine challenge. Flowever, although fall in Sa02
is associated with baseline FEVj (confirming the expectation that subjects with
chronic airflow obstruction may become hypoxic during methacholine challenge),
there is also a positive association with baseline Sa02. This unexpected relationship
has been previously noted in a study of Pa02 during methacholine challenge in
asthmatic patients (Rodriguez-Roisin et al. 1991), and may represent a form of
regression to the mean.
Elderly subjects in our population, despite having lower baseline FEVi and oxygen
saturation, were not at increased risk of desaturation during methacholine challenge.
This reinforces the assertion that nonspecific bronchial challenge with methacholine
is a safe and useful technique in this age group (Connolly et al. 1988b). A fall in
Sa02 with increasing age has been previously reported (Sorbini et al. 1968; Blom
et al. 1988), but was not demonstrated in adults aged >65 years with chronic
bronchitis (Delclaux et al. 1994). However, it is not clear whether our results can
be extrapolated to subjects excluded from the study, for example those with baseline




(1) A random sample of 893 white adults aged >65 years was selected from local
GP lists using random number tables. Of these, 110 were found to have moved
away, died, or were excluded from the study (exclusions: non-Caucasian,
housebound, confusion, other major illness). The remaining 783 were sent a
questionnaire; 723 responded (response rate 92.3%). Responders were representative
in terms of age and sex. Smoking was very common in this population (29.2%
current and 37.3% ex-smokers).
(2) Twenty-two percent of responders were excluded from bronchial challenge
(exclusions: ischaemic heart disease, oral steroids, beta-blockers or anticholinergic
medication). Two hundred and forty-six attended and performed reproducible
spirometry (62.5% of those invited; 31.5% of eligible population). Attenders were
slightly younger than non-attenders, but were representative in terms of sex,
smoking habit, reported asthma and bronchitis, and prevalence of respiratory
symptoms.
(3) Methacholine challenge was performed using the Newcastle dosimeter technique.
Nebulisers were calibrated by direct measurement of output using a fluoride tracer
impacted onto filter papers. Repeatability of methacholine challenge results was
within 2 doubling doses.
(4) Prevalence of reported asthma was 7.3%, bronchitis 15.4%, and a further 7.3%
reported both asthma and bronchitis ("asthma/bronchitis"). Subjects reporting
asthma/bronchitis showed similarities both to those reporting asthma (high
prevalence of bronchial hyper-responsiveness) and to those reporting bronchitis
(strong association with current smoking). These subjects may represent asthmatics
who have developed smoking-related lung disease. If they are regarded as asthmatic
then reported prevalence of asthma in this population exceeds that of other
populations. The prevalence of reported bronchitis is higher in Central Manchester
whether or not those with asthma/bronchitis are included.
(5) One or more respiratory symptoms were reported by 53.8% of subjects. This
is comparable with other populations, but prevalences of individual symptoms were
higher in Central Manchester than in most other studies.
(6) Neither reported diagnoses nor symptoms were more common in older subjects,
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and both were equally common in women and men. Smokers were more likely to
report bronchitis, asthma/bronchitis or symptoms than never-smokers; in contrast,
few subjects reporting asthma were current smokers.
(7) The relationship between smoking and symptom prevalence was stronger in
younger than older adults. This was the result of a lower prevalence of symptoms
in older than younger smokers, and a slightly higher prevalence of symptoms in
older than younger never-smokers. Possible reasons for this include under-reporting
of symptoms by elderly smokers, a cohort effect (eg exposure of older adults to
adverse environmental or occupational factors in younger life, leading to respiratory
symptoms even in non-smokers), or reduced survival of symptomatic smokers into
older age.
(8) As expected, FEV[, FVC and FEVj/FVC showed a linear decline with age.
Women smokers had lower FEY) than never-smokers; however, there was no
difference in spirometry results between smoking and never-smoking men.
(9) Comparison of measured FEVj with values predicted by reference equations
derived from published cross-sectional surveys showed that measured values were
significantly lower than those predicted by 2 of 5 reference equations in women, and
by 3 of 5 equations in men.
(10) Chronic airflow obstruction was present in 26.4% of the population (22.9% of
those aged <65, and 29.7% of those aged >65 years). This prevalence is higher
than that reported for other populations. Only 44.6% of subjects with airflow
obstruction reported a diagnosis of bronchitis and/or asthma, although three quarters
(76.6%) reported one or more respiratory symptoms. Chronic airflow obstruction
was equally common in men and women, and in older and younger adults. There
was a strong association with smoking: only 15.4% of those with airflow obstruction
had never smoked.
(11) Mildly increased bronchial responsiveness was found in 25.0% of subjects
tested; a further 26.0% had levels of bronchial hyper-responsiveness compatible
with asthma (PD20^ 100/xg). Increased bronchial responsiveness was more common
than has been reported in other populations. Categorical analysis showed no
difference in the prevalence of bronchial hyper-responsiveness between women and
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men, or between older and younger adults.
(12) Increased bronchial responsiveness was more common in current smokers; ex-
smokers had levels of bronchial responsiveness similar to those of never-smokers.
There was no increase in the prevalence of bronchial hyper-responsiveness in
subjects reporting bronchitis alone; however, subjects reporting asthma and
asthma/bronchitis had significantly higher prevalence. The positive predictive value
of reported asthma for bronchial hyper-responsiveness was 77.8%.
(13) Although symptoms (particularly breathlessness and wheeze) were more
common in subjects with bronchial hyper-responsiveness, 26.4% of subjects with
PD20 < 100/xg were asymptomatic. Symptoms of bronchial irritability were not
particularly strongly associated with bronchial hyper-responsiveness in this
population.
(14) Multiple regression analysis with bronchial responsiveness as the dependent
variable and age, gender, baseline airways calibre, smoking status and measures of
atopy as independent variables revealed an independent negative relationship
between bronchial responsiveness and airways calibre, and independent positive
relationships with age and total IgE level.
(15) The relationship between bronchial responsiveness and age explained only 3%
of the population variation in bronchial responsiveness. This association has not
been found consistently in other populations, perhaps because of the small
proportion of elderly individuals included in other studies.
(16) The relationship between bronchial responsiveness and IgE has been previously
reported, and was found both in subjects reporting asthma and in non-asthmatics.
This suggests that IgE-mediated processes are involved in the pathogenesis of
increased bronchial responsiveness.
(17) Multiple regression analysis with baseline FEVj as the dependent variable and
age, gender, height and measures of atopy as independent variables identified an
independent relationship between airways calibre and eosinophil count. This was
abolished by removal from the analysis of subjects reporting asthma. Eosinophil-
mediated inflammatory processes may be involved in the development of airflow
obstruction in asthmatics.
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(18) Relationships between IgE and bronchial responsiveness, and between
eosinophils and airways calibre were stronger in older than younger adults. This
contradicts suggestions that atopy plays no part in the pathogenesis of asthma in the
elderly.
(19) Inhaled medications (bronchodilators + steroids) were used by only 46.4% of
those reporting asthma or bronchitis. Subjects reporting bronchitis were less likely
to be using inhaled medications than those reporting asthma. Only 36.9% of those
with chronic airflow obstruction, and 54.7% of those with PD20< 100/ig were using
inhaled medications.
(20) Quality of life (assessed by a disease-specific quality of life questionnaire) was
significantly impaired in subjects with chronic airflow obstruction and increased
bronchial responsiveness. Both baseline airways calibre and bronchial responsiveness
were significant predictors of quality of life impairment.
(21) Changes in oxygen saturation during bronchial challenge were small, and were
not higher in older subjects or those with airflow obstruction.
(22) The reasons for the high prevalence of reported asthma and bronchitis,
respiratory symptoms, chronic airflow obstruction and bronchial hyper-
responsiveness, and for the lower-than-predicted FEV! in this random population
sample are not clear. Possible explanations include childhood experience of
overcrowding, poor nutrition, exposure to high levels of ambient pollution,
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BRONCHIAL RESPONSIVENESS AND ASTHMA STUDY
QUESTIONNAIRE
Please answer the following questions by putting
a tick next to the answers that apply to you.







Can we contact you by telephone? YES/NO
Telephone number:
2.PREVIOUS HEALTH.
Have you ever been treated by your doctor for any
serious illness in the past? YES/NO
If yes, please give details:






Have you ever had HEART TROUBLE? YES/NO
If yes,please give details:
3.MEDICATIONS.
Do you take any medications or tablets prescribed
by your doctor? YES/NO
If yes,please list them here:
Do you use inhalers ("sprays" or "puffers") for
your chest? YES/NO
If yes,please list them here:
Do you take any medications or tablets bought
from the chemist? .YES/NO
If yes, please list them here:
4.SMOKING.
Have you ever been a smoker? YES/NO




ounces tobacco per week
How old. were you when you started smoking?
If vou are an EX-smoker:
How old were you when you started smoking?
How old were you when you stopped?
On average,how much did you used to smoke?
cigarettes per day
cigars per day
ounces tobacco per week
5.OCCUPATION
What is or was your main occupation?
I
6-ALLERGIES
Are you allergic to anything? YES/NO
If yes,please give details:









If so,please give details:
3.COUGH/PHLEGM ("flem")/SPUTUM ("spit")
Do you have a cough? YES/NO
If yes, do you cough mostly AT NIGHT?
IN THE MORNING?
AT ANY TIME?
How long have you had the cough?
Do you cough up phlegm ("flem" or "spit") from
your chest? " YES/NO
9.BREATKLESSNESS
Do you get breathless at night? YE3/N0
Do any of the following activities make you
breathless:
WALKING UPHILL?
WALKING ON THE LEVEL?
WALKING AROUND THE HOUSE?
TALKING?
SITTING AT REST?
10.WHEEZE AND CHEST TIGHTNESS
Does your chest ever sound wheezy or "whistling"
when you breathe? YES/NO
Does your chest ever feel "tight"? YES/NO





If you get a cold,does it go to your chest?
YES/NO
If yes,how often has this happened in the last
year?
THANKYOU FOR COMPLETING THE QUESTIONNAIRE
APPENDIX 2: LETTERS SENT TO SUBJECTS
1. Explanatory letter accompanying postal questionnaire
2. First reminder
3. Second reminder and abbreviated questionnaire
4. Appointment confirmation
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MANCHESTER CENTRAL HOSPITALS AND COMMUNITY CARE NHS TRUST
THE ROBERT BARNES MEDICAL UNIT
The Robert Barnes Medical Knit Tel No 061 - 491 - 2300
Barnes Hospital Fax No 061 - 491 - 4479
Kingsway, Cheadle SK8 2NY
Dear
We are doctors working in the Manchester
Royal Infirmary. We are setting up a research study on Asthma,
and hope that you may be able to help. We have discussed this
study with your General Practitioner, who has agreed to us
getting in touch with you.
Most people think that Asthma only affects children - but in
fact it can affect adults as well. Recently, a new breathing test
has been developed, which shows us whether a person has any
tendency towards having Asthma. This test is very safe, and is
not painful or unpleasant. It is widely used in other hospitals,
and has no lasting effects.
As part of our research study, we are going to measure exactly
how common Asthma is in adults and older people, by using the new
breathing test in groups of people both with and without Asthma.
This is where you can help. All we are asking you to do is to
fill in the questionnaire that is enclosed with this letter, and
possibly to come to the new Clinical Physiology Department at the
Manchester Royal Infirmary for a short visit. This would last for
about 1-2 hours, and would involve a free medical checkup, a
small blood sample, and perhaps the breathing test. All your
travel costs would be refunded - and if necessary we would
arrange for a Taxi to bring you to and from the hospital.
At the end of the study, we should know a lot more about Asthma
and the way it affects adults and older people. Taking part may
not be of any immediate benefit to your own health, but with your
permission we would inform your General Practitioner of the
results of the breathing tests, if you had these performed. We
hope that the results of this study will improve the treatment
for other people with chest diseases in the future.
There is a prepaid envelope enclosed, so that you can send the
completed questionnaire back to us. We hope to hear from you
shortly. If you would like to know any more about the study,
please feel free to contact us by post at Barnes Hospital, or by
telephone at the Manchester Royal Infirmary.
With many thanks for your help.
Yours faithfully,
Dr.Deborah S.Renwick MRCP
(Clinical Lecturer in Medicine)
MANCHESTER CENTRAL HOSPITALS AND COMMUNITY CARE NHS TRUST
THE ROBERT BARNES MEDICAL UNIT
The Robert Barnes Medical Unit
Barnes Hospital
Kingsway, Cheadle SK8 2NY
Tel No 061 - 491 - 2300
Fax No 061 - 491 - 4479
Dear
We recently wrote to you about a
Research Project based at the Manchester Royal Infirmary, and we
sent you a Questionnaire to fill in. We are writing to you again
because we have not yet had a reply from you.
We are studying breathing problems in adults and older people,
but you can take part whether you have any breathing problems or
not. There are two parts to the project:
1. A questionnaire about your general health, and whether
you take any medicines or smoke cigarettes.
2. A visit to the Manchester Royal Infirmary (lasting 90
minutes), for a basic medical check-up, some breathing
tests, and a small blood sample.
Not everyone who fills in a questionnaire would need to come for
the hospital visit. If you did come, we would refund your travel
expenses.
In case you have lost the questionnaire, we are sending another
copy with this letter, as well as a postage paid envelope to send




(PLEASE CROSS OUT THE PARTS WHICH DO NOT APPLY TO YOU)
I AM RETURNING THE COMPLETED QUESTIONNAIRE YES/NO
I AM WILLING TO COME FOR THE HOSPITAL VISIT IF REQUIRED
YES/NO
MANCHESTER CENTRAL HOSPITALS AND COMMUNITY CARE NHS TRUST
THE ROBERT BARNES MEDICAL UNIT
The Robert Barnes Medical Unit Tel No 061 - 491 - 2300
Barnes Hospital Fax No 061 - 491 - 4479
Kingsway, Cheadle SK8 2NY
Dear
Research Project on Asthma in Adults
We have written to you twice about this
project, but have received no reply from you. We assume that you
do not wish to be included in the project. However, it is very
important for us to get some basic information about all of the
people that we have written to. This is so that we can check that
there is no difference between the people who have replied to our
letters and the people who have not.
If the person to whom this letter is addressed no longer lives
at your address, please return this letter to us so that we know
the address is incorrect.
We would be grateful if you could answer the few simple
questions on the next page, and send it back to us in the
addressed envelope. All of the information we receive is
completely confidential. If you send this information back to us,
we will not need to contact you again about this project.
Thank you for your help.
Yours sincerely.
Name
How old are you? years
Have you ever had ASTHMA? yes/no
Have you ever had BRONCHITIS? yes/no
Have you ever had HEART TROUBLE? yes/no
Have you had any other serious illnesses...yes/no
(if yes, what were they?
)
Do you smoke? yes/no
If not, are you an ex-smoker? yes/no
MANCHESTER CENTRAL HOSPITALS AND COMMUNITY CARE NHS TRUST
THE ROBERT BARNES MEDICAL UNIT
The Robert Barnes Medical Unit Tel No 061 - 491 - 2300
Barnes Hospital Fax No 061 - 491 - 4479
Kingsway, Cheadle SK8 2NY
Dear
RESEARCH PROJECT ON ASTHMA IN ADULTS
Thank you for returning the Questionnaire that
we sent you a few weeks ago, and for agreeing to take further
part in this Research Project. An appointment has been made for
you to come to the Manchester Royal Infirmary for some breathing
tests on
The appointment will last for approximately 90 minutes. IF YOU
ARE NOT ABLE TO COME PLEASE LET US KNOW, BY TELEPHONING 276 8608
- we can then use the time for someone else.
Please come to the Department of Clinical Physiology. This is
on the ground floor in Phase 2 of the Infirmary, which is the new
part of the Hospital. I am enclosing a map to show you the way.
If you are not sure how to get there, if you come to the new Main
Entrance (off Nelson Street), there is a reception desk where you
can get directions. We will refund your bus or taxi fares if
necessary.
Dos and don'ts for the breathing tests:
1. DON'T keep the appointment if you have had a chest infection
or "cold" within the last 6 weeks - please let us know, and we
will delay your appointment to let your chest recover fully.
2. DON'T drink any tea, coffee or Coca-Cola for 12 hours before
you come for the test - the caffeine interferes with the
resultsi
DO feel free to eat or drink anything else!
3. If you use inhalers or "puffers" for your chest, please DON'T
use them for 12 hours before you come for the test.
4. If you take any tablets or medicines for your chest (eg
Ventolin/ Theophylline/ Phyllocontin/ Nuelin tablets) please
DON'T take these for the 24 hours before you come for the test.
Missing these tablets for one day is not dangerous in any way.
DO phone and ask us if you are not sure about your medicines.
Thank you again for taking part in this study. If you have any
questions, please feel free to contact me at the Manchester Royal
Infirmary.
Yours sincerely,
Dr Deborah S Renwick MRCP
APPENDIX 3: CONSENT FORM
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BRONCHIAL RESPONSIVENESS AND ASTHMA STUDY - CONSENT FORM
AIMS OF STUDY
This is a research study to measure how common asthma is in
adults and older people, and to try to improve the way in which
we diagnose asthma in this age group.
WHAT IT INVOLVES
1.You will be asked to fill in a questionnaire about symptoms of
asthma.
2.You may be asked to perform the new breathing test. This
involves blowing into a special machine several times, to measure
your breathing capacity. In between these measurements, you will
be asked to inhale a medicine called Methacholine through a
mouthpiece, for a few seconds at a time.
3.A blood sample will be taken.
SIDE EFFECTS
The breathing test has been used in adults (both young and old)
and children, and is known to be safe. It produces a mild degree
of airways wheeze, which is reversed at the end of the test. Most
people do not experience any side effects - but a small number
may notice some flushing of the face, or a mild headache for a
short time. There are no lasting side effects.
CONSENT
I have read the information given
above,and have had an opportunity to discuss it with one of the
doctors involved.I agree to take part in this research study,and




I confirm that I have explained the nature and purpose of this
research project, and answered any questions fully.
Signature Name Date
APPENDIX 4: SUPPLEMENTARY QUESTIONNAIRE
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6.Breathlessness
Do you feel breathless at any of the following times?
- in the morning
at night
after exercise
when you have a chest infection or cold












Do you bring up sputum (spit/flem/phlegm) from your chest?
If yes, when does this happen? - mostly in the morning
mostly at night
at any time
Do you bring up sputum/spit/phlegm most days? (eg 4 days per
week)
If yes, for how many months of the year do yo bring up the
sputum/spit/phlegm?
For how many years have you been bringing up sputum/phlegm?
NSBR PROJECT: SUPPLEMENTARY QUESTIONS
NAME
1.Passive smoking
FOR NON-SMOKERS ONLY: Does anyone else in your household smoke?
- if yes, please give details
2.Occupational exposure







aluminium production or processing
soldering or welding
- if yes, please give details
3.Airways Infection
Have you had an airways infection or chest cold in the last 6
weeks?
4.Menopause
FOR WOMEN ONLY: Do you still have monthly periods?
IF NOT: How long ago did they stop?
Are you taking Hormone Replacement Therapy (HRT)?
5.Wheeze/Chest tightness
Does your chest feel wheezy or tight at any of the following
times? - in the morning (for how long?...minutes/hours)
at night
after exercise
when you have a chest infection or cold
Do any of the following things make your chest feel wheezy or

















1 4.44 (4%) 3.92 (8%)* 3.89 (7%)*
2 4.02 (2%) 4.18 (4%) 4.07 (4%)
3 4.11 (3%) 3.68 (11%)* 4.05 (6%)*
4 4.52 (8%)* 3.92 (10%)* 4.20 (4%)
5 3.65 (6%)* 4.03 (4%) 4.08 (5%)
6 4.27 (6%)* 4.01 (5%) 3.91 (8%)
7 4.07 (4%) 4.04 (1%) 4.07 (2%)
8 4.85 (5%) 4.25 (5%) 3.99 (7%)*
9 4.42 (7%)* 4.12 (5%) 4.11 (3%)
10 4.39 (4%) 3.80 (9%)* 3.92 (8%)*
11 3.56 (8%)* 4.01 (5%) 4.51 (3%)
12 4.08 (5%) 4.01 (5%) 4.51 (3%)
^denotes nebulisers discarded and replaced
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29 80 75 239 249
24 - - 2.62 3.71
25 7.50 5.00 2169 4030
25 170 110 112 192
27 - - 1.39 0.78
26 - - 1.39 1.30
24 - - 2.56 2.74
25 6000 3500 3.53 7.08
26 5000 - 3.41 2.02
33 7.00 6.00 2557 3257
24 - 6400 1.85 3.30
28 - 6400 1.55 2.98
24 2500 - 6.59 3.77
35 - - 0.17 0.34
28 - - 0.31 0.78
26 - - 2.48 2.92
29 - - 3.13 2.23
26 - - 2.58 2.98
31 6.00 6.00 3095 3289
63 180 270 110 64.9
71 - 6400 2.37 3.02
66 120 120 167 112
76 170 230 117 86.6
73 160 250 245 103
70 2800 1580 10.61 25.7










57 12.5 11 1084 1670
74 1100 1700 15.4 11.8
58 46 30 440 604
66 2340 - 34.7 10.2
70 440 1100 34.0 14.2
74 - - 2.24 2.59
64 - 2000 3.94 7.46
70 - 4000 1.26 3.58
61 56.0 46.0 333 418
84 2.30 1.30 9406 17080
75 12.0 25.0 1810 778
64 3.20 6.00 4554 3397
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Mechanisms of SO2 responsiveness 163
In conclusion, the airway response to S02
involves the release of inflammatory mediators.
In addition, the parasympathetic reflexes which
play a part in the S02-induced broncho-
constriction have the potential to be modulated
by opioids.
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Prevalence and treatment of chronic airways
obstruction in adults over the age of 45
Deborah S Renwick, Martin J Connolly
Abstract
Background - Chronic airways ob¬
struction is common in adults and the
elderly. To investigate the possibility that
older adults with obstructive airways dis¬
ease frequently do not receive appropriate
treatment, the respiratory symptoms,
medication use, and pulmonary function
were studied in a random sample ofwhite
adults aged over 45 living in central Man¬
chester, UK.
Methods - A postal questionnaire survey
was performed on 783 men and women
aged 45 years and over selected from GP
lists by random number tables. Subjects
completing the questionnaire were invited
to attend for pulmonary function testing
and methacholine challenge (Newcastle
dosimeter method).
Results - The questionnaire response rate
was 92-3% (723 subjects). The mean age of
the population was 66*1 years and 57-2%
were women; 29-2% were current smokers
and 37-3% were ex-smokers. Asthma or
bronchitis was reported by 30*0%. Two
hundred and forty seven representative
subjects attended for pulmonary function
testing and spirometric evidence of
chronic airways obstruction was found in
26-4%. Respiratory symptoms were re¬
ported by 76*6% of subjects with chronic
airways obstruction; 55-0% had features
which may predict potential improvement
on treatment (increased non-specific
bronchial responsiveness or significant
bronchodilator reversibility). However,
only 55*4% of subjects with airways ob¬
struction had received a diagnosis of
asthma or chronic bronchitis and only
36-9% were using inhaled bronchodilators
or steroids.
Conclusions - Chronic airways ob¬
struction is very common in adults in this
inner city population, but is frequently
overlooked. Most subjects with chronic
airways obstruction are not receiving ap¬
propriate treatment.
(Thorax 1996;51:164-168)
Keywords: chronic airways obstruction, inhaled bron¬
chodilators, epidemiology.
Chronic airways obstruction is common; sur¬
veys give a prevalence in the elderly of ap¬
proximately 16% (asthma plus smoking-related
airways obstruction).12 However, studies often
contain few elderly people.34
It was our clinical impression thatmany older
people with chronic airways obstruction do not
receive appropriate drug treatment. In a study
of older adults attending day hospitals and
living in local authority homes, Banerjee et
al found a prevalence of reversible airways
obstruction of >40%, although only 3% were
using respiratory medications.5 Two surveys of
elderly nursing home residents found that 10%
or less were prescribed bronchodilators67; this
is probably much less than the proportion with
chronic airways obstruction given the estimate
for the general elderly population.2 There have
been no assessments of the proportion ofpeople
with chronic airways obstruction receiving ap¬
propriate drug treatment among the com¬
munity dwelling elderly. We have investigated
respiratory symptoms, medication use, and pul¬
monary function in an age stratified random
population sample of adults over the age of 45.
Methods
POPULATION SAMPLING
The study was approved by Central Man¬
chester Health Authority ethical committee.
We aimed to study a random sample of the
local population aged ^45 years including
large numbers of elderly people. Between Jan¬
uary 1992 and February 1994 names and ad¬
dresses were taken using random number tables
from practice lists of 22 local general prac¬
titioners. Non-white subjects were excluded
because of interracial differences in bronchial
responsiveness.8 General practitioners ex¬
cluded those who were confused or house¬
bound, plus the few unsuitable for other
reasons. In order to increase the numbers of
older subjects only those aged ^70 were se¬
lected during the final months of recruitment.
Subjects were sent an explanatory letter and
questionnaire concerning previous diagnoses
of asthma, chronic bronchitis, and ischaemic
heart disease; current medication; smoking his¬
tory; and respiratory symptoms. Questions on
respiratory symptoms were adapted from the
MRC respiratory symptoms questionnaire."
Non-responders were sent a repeat ques¬
tionnaire, followed if necessary by an ab¬
breviated questionnaire containing only
questions about previous diagnoses and smok¬
ing habits. Half of the persistent non-re-
sponders were randomly contacted by
telephone or home visit.
PULMONARY FUNCTION TESTING
Patients were excluded from the methacholine
challenge if they had a history of ischaemic
heart disease or were receiving current med¬
ication with (3 blockers, anticholinergic med-
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ications, or oral steroids. Subjects not excluded
on these grounds were invited to attend Man¬
chester Royal Infirmary. Attendance was de¬
layed for six weeks after respiratory tract
infection or exacerbation ofwheezing. Subjects
were requested to refrain from caffeine for 12
hours, and to omit bronchodilators for 12 hours
(inhalers), 24 hours (oral preparations), or 48
hours (sustained release preparations) before
attendance.
Written informed consent was obtained
from all subjects. Resting 12-lead electro¬
cardiography (ECG) was performed, and if
this showed evidence of myocardial ischaemia
subjects were also excluded from methacholine
challenge. Baseline pulmonary function was
measured (Compact, Vitalograph, Buck¬
ingham, UK) (mean of the best six readings
reproducible within 10%).1011 Methacholine
challenge was performed by subjects with base¬
line forced expiratory volume in one second
(FEV,) of ^60% predicted12; if FEV, was
<60% predicted (3 agonist reversibility was as¬
sessed.
(3 AGONIST REVERSIBILITY
FEV, measurements were repeated 10 minutes
after inhalation of 1 mg terbutaline via a
metered dose inhaler and large volume spacer
(Nebuhaler, Astra Pharmaceuticals, Hert¬
fordshire, UK). A positive result was defined
as an increase in FEV, of 5=160 ml.13
Table 1 Demographic details of study population
Mean age (years) 66-1
% women 57-2
% reporting asthma 7-3
% reporting bronchitis 15-4
% reporting asthma plus bronchitis 7-3
% current smokers 29-2
% ex-smokers 37-3
to take part. Forty five randomly selected non-
responders agreed to complete the abbreviated
questionnaire; a further 12 were found to have
moved away before the start of the study and
were therefore not included. Thus, ques¬
tionnaire information was available for 723
(92-3%) of the 783 eligible subjects. The age
and sex of all subjects was obtained from GP
records. Demographic details of the study
population are summarised in table 1; the age
distribution of the population is shown in the
figure.
Fifty three subjects reported asthma, 111
bronchitis, and a further 53 both asthma and
bronchitis; overall, 217 of the 723 (30-0%)
reported asthma or bronchitis. This proportion
was not significantly different in subjects aged
less than 65 years (94 of 292 subjects (32-2%))
or 65 years and over (123 of 431 subjects
(28-5%)). Of the 508 subjects returning the
full questionnaire 15% were using inhaled med¬
ications. The prevalence of inhaler use by sub¬
jects reporting asthma or bronchitis was 46-4%
(72-0% for subjects reporting asthma, 39-9%
for those reporting bronchitis).
METHACHOLINE CHALLENGE
This was performed by the Newcastle dosi¬
meter method.101114 Briefly, doubling doses
of nebulised methacholine were inhaled at five
minute intervals by the subject while seated
and wearing a noseclip. FEV, (mean of three
recordings reproducible within 10%) was meas¬
ured before each subsequent dose. End points
were a 20% decrease in FEV, or administration
of a maximum cumulative dose of 6-4 mg
methacholine. Results were expressed as the
methacholine dose producing a 20% fall in
FEV, (PDjo)-11 Increased non-specific bronchial
responsiveness was defined as a PD20 of <400
pg methacholine.11 Repeatability of metha¬
choline challenge was assessed in 21 subjects
who agreed to attend on a second occasion
3-10 days after the initial challenge.
DATA ANALYSIS
Subgroups were compared by grouped t test
and y2 tables. Significance was defined at the
5% level.
Results
DEMOGRAPHIC DETAILS OF STUDY POPULATION
AND RESPONSE RATE
Of 893 subjects contacted, 110 were ineligible
(78 incorrect address, 15 dead, six non-white,
11 housebound/confused/disabled). This left
783 eligible subjects, 508 of whom returned
the full questionnaire and 170 the abbreviated
questionnaire. Twenty nine subjects declined
PULMONARY FUNCTION, REVERSIBILITY AND
METHACHOLINE CHALLENGE
Of the 508 subjects returning the full ques¬
tionnaire, the responses of 113 excluded them
from methacholine challenge (ischaemic heart
disease 83; P blockers/anticholinergics/oral
steroids 48). The remaining 395 were invited to
attend for methacholine challenge: 247 subjects
actually attended (62-5% of those invited to
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Table 2 Mean (SD) results of spirometric tests
All attenders Subjects with Subjects without
(n= 246) chronic airways chronic airways
obstruction obstruction
(n = 65) (n = 181)
FEV,/FVC% 69-2 (11-6) 54-2 (7-7) 74-6 (7-2)
FEVj (% 86-9 (24-5) 63-6 (24-0) 94-6 (18-9)
predicted)
Age (years) 64-5 (10-8) 66-3 (10-0) 63-8 (11-1)
% women 56-7 53-8 57-4
FEV, = forced expiratory volume in one second; FVC = forced
vital capacity
lation). The mean age of attenders was 64-5
years (range 45-86 years); this was younger
than the population as a whole (p = 0-02,
grouped t test). There was no significant differ¬
ence between the 247 attenders and the 783
eligible subjects in sex distribution (56-7%
women in attender group), reporting of asthma
or bronchitis, reporting of respiratory symp¬
toms, or smoking habits (33-6% of attenders
were current smokers and 38-5% were ex-
smokers).
One subject was unable to perform re¬
producible measurements of baseline spir¬
ometry and thus data were available for 246
attenders (table 2). Chronic airways ob¬
struction was defined as an FEV,/FVC% of
<65% for subjects aged <65 years; for those
aged ^65 years a predicted value and lower
limit of normal for FEV,/FVC% was calculated
as described by Enright et alP Using these
criteria, the prevalence of chronic airways ob¬
struction was 26-4% (22-9% in 118 attenders
aged <65 years and 29-7% in the 128 attenders
aged ^65 (x2=T46, p = 0-2)). Airways ob¬
struction was equally common in men and
women, but more common in current (39-7%)
and ex-smokers (27-7%) than in those who had
never smoked (12-8%; x2= 14-1, p = 0-001).
In 22 subjects with chronic airways ob¬
struction baseline FEV! was <60% predicted,
and thus (3 agonist reversibility was measured.
Ten of these subjects (45-5%) had ^160 ml
improvement in FEV, following terbutaline. Of
the remaining 43 subjects with chronic airways
obstruction five were unable or unwilling to
complete the methacholine challenge. Non¬
specific bronchial responsiveness was increased
in 23. Thus, overall 33 of 60 (55-0%) subjects
with chronic airways obstruction had either
increased non-specific bronchial re¬
sponsiveness or significant P agonist re¬
versibility. In 21 subjects attending twice, PD20
measurements were repeatable within two
doubling doses of methacholine.
For the whole attender group multiple re¬
gression analysis with log PD20 as the dependent
Table 3 Number (%) of symptoms reported
Subjects with Subjects without y2 (p value)
chronic airways chronic airways
obstruction obstruction
VOII (n= 181)
Cough (%) 33 (50-8) 50 (27-6) 10-7 (0-001)
Sputum (%) 36 (55-4) 53 (29-3) 14-4 (<0-001)
Wheeze (%) 39 (60-0) 55 (30-4) 17-0 (<0-001)
Breathlessnessf (%) 19 (29-2) 26 (14-4) 7 0 (<0-01)
One or more symptoms (%) 49 (76-6) 88 (50-0) 13-5 (<0 001)
t Breathless when walking on the level or at rest (equivalent to MRC grade 3 +).9
Table 4 Proportion of subjects receiving inhaled ft
agonists or steroids
Chronic airways No chronic airways
obstruction obstruction
(n = 65) (n—181)
No treatment 41 (63-1%) 169 (93-4%)
P agonist only 9 (13-8%) 4 (2-2%)
Steroid + (1 agonist 14 (21-5%) 8 (4-4%)
variable and age, sex, smoking habit, and base¬
line FEV, (% predicted) as independent vari¬
ables showed a significant positive relationship
between log PD20 and baseline FEV, (p =
0-0001; R = 0-3), but no relationship between
log PD20 and the other independent variables.
RESPIRATORY SYMPTOMS AND USE OF
BRONCHODILATORS
Subjects with chronic airways obstruction re¬
ported significantly more respiratory symptoms
than those without, and wheeze was the com¬
monest symptom (table 3); 76% of subjects
with airways obstruction reported one or more
symptoms. However, as symptoms were also
common in those without chronic airways ob¬
struction, the positive predictive value of symp¬
toms for "obstructive" pulmonary function test
results was low: only 35-8% of symptomatic
subjects had chronic airways obstruction on
pulmonary function testing. The symptom with
the highest positive predictive value for airways
obstruction was breathlessness (MRC grade
3+)9: 19 (42-2%) of the 45 subjects reporting
breathlessness had evidence of airways ob¬
struction. Combinations of two or more symp¬
toms were reported less frequently, but were
more commonly associated with airways dis¬
ease. For example, only 21 patients reported
cough plus wheeze plus breathlessness, but
14 of them had airways obstruction (positive
predictive value 66-7%).
Asthma or bronchitis was reported by 55-4%
of subjects with airways obstruction and 23-7%
of those with "normal" FEV,/FVC (x2 = 21-9,
p<0-001). The positive predictive value of re¬
ported asthma or bronchitis for evidence of
chronic airways obstruction on pulmonary
function testing was 45-6%.
Twenty three (35-4%) of the 65 subjects with
chronic airways obstruction were using inhaled
treatment (table 4), most commonly both in¬
haled steroids and P agonists. Only two subjects
were taking oral P agonists and none theo¬
phylline. Age did not significantly affect the
likelihood of treatment: eight of 27 (20-6%)
subjects of <65 years and 15 of 38 (39-5%)
of ^ 65 years were using treatment. Treated
subjects had significantly worse baseline air¬
ways obstruction (mean (SE) FEV,/FVC% =
48-6 (1-8)%) than those on no treatment (57-5
(0-7)%; t= 5-3, p<0-0001). Respiratory symp¬
toms were reported by 70-0% of untreated
subjects with chronic airways obstruction.
Discussion
Our data confirm the high prevalence ofchronic
airways obstruction in white adults in central
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Manchester. However, it is relevant to ask
whether our study sample is representative.
Many subjects initially selected had died or left
the area. This problem has been described in
other studies using information from GP lists
and seems unavoidable.16 Nonetheless, the high
response rate (>90%) makes it likely that our
figures are accurate. The preponderance of
women in our population is expected in a
sample containing many elderly people and
agrees with OPCS estimates for central Man¬
chester (53% women in the population aged
>45).17 Our figures for current and ex-smoking
were higher than recent OPCS estimates (29%
current smokers in a population aged >50
years).18 It is probable that our results represent
the situation in other urban white populations
in Britain.
Unfortunately, only 31-5% of the eligible
population attended for methacholine chal¬
lenge. Although 113 subjects were excluded
because of ischaemic heart disease or med¬
ications, most non-attenders were simply not
prepared to undergo tests. This was particularly
true of older subjects, and so attenders were
younger than non-attenders. Similar problems
have been reported in other studies ofbronchial
responsiveness.2 1920 Nonetheless, attenders
were representative of the study population in
terms of sex distribution, smoking, diagnosed
asthma/bronchitis, and reported respiratory
symptoms.
Other studies of adults aged ^65 years have
found a lower prevalence of airways ob¬
struction. In a postal survey 8-4% reported
asthma and 16-4% chronic bronchitis1; chronic
airways obstruction has been found in 6-9%
(FEV,/FVC <65%)21 and 15-6% (FEV,/FVC
<60%) in population studies.2 This variation
may reflect differences in smoking habits or
environmental influences between populations.
The proportion of subjects with diagnosed
asthma or chronic bronchitis prescribed inhaled
medications has been assessed in a study in the
northern region ofEngland using computerised
GP records.22 In that study inhalers were pre¬
scribed for 6% of patients with chronic bron¬
chitis and 66?/o of those with asthma (38% of
patients with a recorded diagnosis); prescribing
rates were higher for patients aged 65-74. Our
figures for prescribing in central Manchester
are higher, perhaps because of differences in
the population age range, data source, and
diagnostic practices.
The problems of self-reported diagnoses as
a measure of asthma prevalence have been
discussed.23 The lack of agreed diagnostic cri¬
teria for asthma and chronic airways ob¬
struction means that physicians vary in their
diagnostic labelling and may be influenced by
non-clinical parameters such as age and sex.24
As a result, patients may acquire multiple diag¬
noses25; this is demonstrated by the number
of subjects in our population reporting both
asthma and bronchitis. Some studies have
found evidence of overreporting of un¬
confirmed diagnoses326; others have suggested
underreporting, particularly by older men with
chronic bronchitis.27
We have objectively assessed the prevalence
of chronic airways obstruction by spirometric
testing in a representative sample. Since FEV,/
FVC% decreases with age, we calculated pre¬
dicted levels and lower limits of normal for
subjects aged ^65 years.15 To avoid over-
estimation of airways reversibility in patients
with low baseline FEV, we defined reversibility
as a fixed volume increase in FEV,, rather than
a percentage increase over baseline.13 Measure¬
ment of bronchial responsiveness by the New¬
castle dosimeter method usually includes six
measurements ofFEV, after each methacholine
dose.11 To avoid fatigue in our elderly popu¬
lation this was reduced to three; this adapted
method has been shown to be reproducible in
older adults.10 As is customary for this method
of bronchial challenge, PD20 was calculated
using the mean rather than the maximum of
the three FEV, recordings1011; we confirmed
that this gave better repeatability.
The prevalence of reported asthma or bron¬
chitis was similar to that of measured chronic
airways obstruction. However, both reported
diagnoses and symptoms were poor predictors
of chronic airways obstruction. This has im¬
plications for other epidemiological studies of
asthma or chronic airways obstruction, some
of which have relied solely on self-reporting of
diagnoses and symptoms.2829
Only one third of subjects with airways ob¬
struction were using inhaled medications. This
may reflect tolerance of respiratory symptoms
by elderly people or therapeutic nihilism on
behalf of their doctors. The lack of patients
taking theophylline is surprising; this may re¬
flect either poor patient compliance or local
prescribing habits. The need for serum moni¬
toring and the incidence of side effects has
decreased the popularity of theophylline.30
Over halfofour subjects with chronic airways
obstruction had bronchodilator reversibility or
increased bronchial responsiveness. The latter
has been shown to predict spirometric im¬
provement on treatment in elderly asthmatic
subjects.10 A single measurement of bron¬
chodilator reversibility is less reliable as a pre¬
dictor of response to treatment.31 The
significance of increased bronchial re¬
sponsiveness in patients with chronic airways
obstruction is also unclear; a strong correlation
between baseline FEV, and PD20 in these
patients has led to the suggestion that increased
bronchial responsiveness is merely the result of
reduced airway calibre rather than an indication
of airways lability.3233 We have confirmed the
relationship between baseline FEV, and PD20,
but the low coefficient of multiple regression
suggests that the high prevalence of increased
bronchial responsiveness in our subjects is not
merely the result of low FEV,.
In summary, we have found high levels of
untreated chronic respiratory morbidity in the
adult white population of central Manchester,
but no evidence of age bias in the proportion
of patients receiving treatment. Adults with
respiratory symptoms should have pulmonary
function formally assessed; those with airways
obstruction may benefit from bronchodilator
treatment.
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increase in renal blood flow in these animals.
However, other studies have found no change
in systemic arterial pressure during infusions
of L-arginine.1' In our study we have shown
that the increase in renal blood flow seen with
infusions of L-arginine in humans is in¬
dependent of changes in systemic blood flow.
This suggests that L-arginine acts on the renal
vasculature to produce vasodilatation. This
may be due to an increase in NO production.
In the group of patients with hypoxic COPD
L-arginine had no effect on renal blood flow.
Defective endothelial function has been dem¬
onstrated in forearm arteries in patients with
heart failure secondary to ischaemic heart dis¬
ease,27 and our results suggest that defective
endothelial function is present in the renal
vessels of patients with cor pulmonale. This is
in contrast to patients with congestive heart
failure secondary to ischaemic heart failure
whose renal blood flow is relatively preserved.28
In a previous study we have shown that
oxygen is a potent renal vasodilator in hypoxic
patients with COPD.67 A possible mechanism
of this effect is that oxygen, which is necessary
for the production of nitric oxide, is deficient in
the endothelium of these patients and therefore
NO dependent vasodilator tone is reduced
causing vasoconstriction. Alternatively, oxygen
concentrations might be necessary at a high
level to synthesise nitric oxide by a different
mechanism (an example might be by in¬
fluencing the availability of ATP). Finally, this
effect of oxygen might be via a different mech¬
anism. These hypotheses might be addressed
by assessing renal blood flow with and without
oxygen therapy in the presence and absence of
infused L-arginine. However, in this study we
have shown a disturbance in the L-arginine/
nitric oxide pathway in hypoxic patients with
COPD. This is evidence that the derangement
in renovascular control in patients with COPD
and cor pulmonale, and the renal vasodilatation
seen with oxygen therapy in these patients, may
be caused, at least in part, by an abnormality
of the nitric oxide pathway. Further work, as
outlined above, will be needed to clarify this.
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Background - Obstructive airways disease
adversely affects quality of life, although
relationships between quality of life and
lung function have been shown to be weak.
The relationships between the results of a
quality of life questionnaire, spirometric
tests, and methacholine bronchial chal¬
lenge were investigated in a population
sample ofmiddle aged and elderly people.
Methods - A random population sample
of the white population of Central Man¬
chester, UK were contacted by post. Re¬
spondents were invited to undergo
bronchial challenge with methacholine
(Newcastle dosimeter method) and to
complete the St George's Respiratory
Questionnaire. This self-completed ques¬
tionnaire quantifies quality of life as three
component scores, with higher scores in¬
dicating greater impairment of quality of
life.
Results - Two hundred and twenty seven
subjects aged 45-86 years completed the
St George's Questionnaire and performed
spirometric tests; 190 completed the
methacholine challenge. All quality of life
scores were higher in subjects with a forced
expiratory volume in one second (FEV,)/
forced vital capacity (FVC) of <65%, in¬
dicating impaired quality oflife in subjects
with airways obstruction. There was no
relationship between quality of life and
age. Multiple regression analysis showed
independent relationships between quality
of life scores and both baseline FEV! and
bronchial responsiveness. However, the
amount of variation in quality of life at¬
tributable to variation in FEV, or bron¬
chial responsiveness was less than 10%.
Subgroup analysis indicated that the qual¬
ity of life score was independently as¬
sociated with bronchial responsiveness
and not FEV, in subjects aged <65 years,
but with baseline FEV, and not bronchial
responsiveness in older subjects.
Conclusions - Obstructive airways disease
significantly impairs quality of life in ad¬
ults. The reduction in quality of life in
these patients is related to both baseline
pulmonary function and non-specific
bronchial responsiveness. The impact of
airways obstruction on quality of life does
not decrease with advancing age.
(Thorax 1996;51:520-525)
Keywords: quality of life, chronic airways obstruction,
bronchial hyperresponsiveness.
Obstructive airways disease is common in the
elderly, affecting approximately 16% of people
over the age of 65.1 It has a substantial impact
on quality of life, impairing not only physical,
but also psychological and social function.23
The relationship between the degree of quality
of life impairment and the severity of airways
obstruction as measured by pulmonary func¬
tion tests has, however, generally been found
to be weak.2"5
It has been suggested that the impact of
obstructive airways disease on quality of life
may be less in older subjects.356We have there¬
fore compared the quality of life in subjects
with and without chronic airways obstruction
and bronchial hyperresponsiveness to assess
the effects of chronic obstructive airways dis¬
ease and asthma on quality of life in a popu¬
lation sample of adults aged 45-86 years.
Methods
Names of adults aged >45 were taken using
random number tables from practice lists of 22
local general practitioners. Those who were
confused or housebound were excluded, to¬
gether with the few unsuitable for other reasons.
Non-white subjects were excluded because
of interracial differences in bronchial re¬
sponsiveness.7
Subjects were sent an explanatory letter and
questionnaire concerning previous asthma,
bronchitis, ischaemic heart disease, smoking
history, and current medication. Non-re-
sponders were sent a reminder, followed by a
second reminder with an abbreviated ques¬
tionnaire. A random sample of persistent non-
responders was contacted by telephone or
home visit.
Questionnaire responses were used to
identify those excluded from methacholine
challenge. Exclusion criteria were ischaemic
heart disease or medication with (3 blockers,
anticholinergics or oral steroids. Subjects not
excluded on this basis were invited to attend.
Attendance was delayed for six weeks after a
respiratory tract infection or exacerbation of
wheezing. Subjects were requested to refrain
from caffeine for 12 hours and to omit broncho-
dilators for 12 hours (inhalers), 24 hours (oral
preparations), or 48 hours (sustained release
preparations) before attendance.
Written informed consent was obtained from
all subjects attending and the study was ap¬
proved by the Central Manchester Health
Authority ethical committee. A resting 12 lead
electrocardiograph was performed, and sub¬
jects with evidence of myocardial ischaemia
were excluded from methacholine challenge.
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Baseline pulmonary function was measured
(Compact, Vitalograph, Buckingham, UK)
using the mean of six reproducible readings.
Methacholine challenge was performed only if
baseline forced expiratory volume in one sec¬
ond (FEV,) was >60% predicted.
Subjects completed the St George's Res¬
piratory Questionnaire,8 which is a self-com¬
pleted questionnaire validated as a measure of
quality of life in subjects with chronic airways
obstruction. Three component scores are cal¬
culated: Symptoms (frequency and severity),
Activities (causing or limited by breath-
lessness), and Impacts (on employment and
emotions, feelings of panic or control), as well
as a total score. Higher scores indicate greater
morbidity.
Methacholine challenge was performed by
the Newcastle dosimeter method.910 Briefly,
doubling doses ofnebulised methacholine were
inhaled at five minute intervals by the subject
while seated and wearing a noseclip. FEV,
was measured before each subsequent dose;
as recommended, three readings reproducible
within 10% were performed each time and
the mean was used. End points were a 20%
decrease in FEV, or administration of a max¬
imum cumulative dose of 6-4 mgmethacholine.
Results were expressed as (a) dose of metha¬
choline producing a 20% fall from baseline
FEV, (PD20), and (b) the slope of the dose-
response curve to methacholine (dose-response
slope) which gives a continuous non-censored
measure of bronchial responsiveness expressed
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figure 1 Age distribution of subjects performing
spirometric tests.
of <65% in those aged <65 years; since this
ratio decreases with normal ageing, a predicted
value and lower limit of normal for FEV,/FVC
was calculated for subjects aged > 65 using
equations from the Cardiovascular Health
Study.16
Bronchial hyperresponsiveness was defined
as a PD20 of <100 pg methacholine; this level
has been shown to have a predictive value for
current asthma of nearly 100%.17 In all cases
significance was defined at the 5% level.
DATA ANALYSIS
St George's Questionnaire scores and values
for the dose-response slope were log trans¬
formed to achieve normal distribution. To allow
log transformation of all St George's Ques¬
tionnaire scores, the value 0-5 was allocated to
those subjects with scores of 0. One subject had
a slight increase in FEV, during methacholine
challenge producing a negative dose-response
slope; to allow logarithmic conversion of this
result a constant of 0-43 was added to all dose-
response slope values.12 Relationships between
quality of life scores and pulmonary function
were analysed by linear correlation and multiple
regression. Subgroups were compared by
grouped t tests.
To avoid the age and height bias associated
with the expression of FEV, as a percentage of
predicted values, baseline FEV, was expressed
as standardised residuals (SR) for calculation
of correlation coefficients and multiple re¬
gression.13 These were calculated using the
equation SR= (recorded value—predicted
value)/RSD, where RSD is the residual stand¬
ard deviation about the regression equation
used to calculate the predicted values.14 The
prediction equations used for the calculation
of standardised residuals were derived from
urban white UK adults over a wide age range
comparable to that of the current study.15
Chronic airways obstruction was defined as
a ratio of FEV, to forced vital capacity (FVC)
Results
We contacted 783 eligible subjects; 508 re¬
turned the full questionnaire and could be
assessed for suitability for methacholine chal¬
lenge. A further 215 subjects completed ab¬
breviated questionnaires (overall response rate
92-3%). Responders were representative of the
population in age and sex distribution; those
completing full and abbreviated questionnaires
were similar in terms of smoking history and
prevalence of diagnosed asthma or bronchitis.
One hundred and thirteen subjects were ex¬
cluded from methacholine challenge because
of heart disease or medication; of the 395
invited to attend, 247 agreed. There was a
slight age difference between attenders and
non-attenders (mean age of attenders 64-5
years, non-attenders 66-1; p = 0-02), but at¬
tenders were representative in terms ofsmoking
habit, diagnosed asthma and bronchitis, and
prevalence of respiratory symptoms.
Two hundred and twenty seven attenders
performed reproducible spirometric tests and
completed the St George's Questionnaire, of
whom 26 had a baseline FEV, of <60% pre¬
dicted, two had electrocardiographic evidence
of ischaemic heart disease, and nine were un¬
able to complete the methacholine challenge.
Challenge results were thus available for 190
subjects.
One hundred and twenty eight of the 227
subjects who performed spirometric tests were
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Figure 3 Distribution of total quality of life scores.
Seventy one subjects were current smokers and
91 were ex-smokers. Thirty three reported a
previous diagnosis of asthma and 52 "bron¬
chitis"; 33 were using inhaled bronchodilators
and/or an inhaled steroid.
Figure 2 shows the distribution of baseline
FEV!. Fifty nine subjects had chronic airways
obstruction (FEV,/FVC of <65% or lower than
predicted level)16; the mean (SD) age of these
subjects was 66-2 (10-0) years (range 47-84).
There was no age difference between these
subjects and the 168 subjects without airways
obstruction (mean (SD) age 64-1 (11-2) years,
range 45-86; t= — 1-3, p =NS). Twenty five
subjects with chronic airways obstruction were
aged <65 years and 34 were aged > 65 years
(X2 = 0-6, p =NS).
A PD20 value was obtained in 135 subjects
ofwhom 48 had bronchial hyperresponsiveness
(PD20< 100 |ig). The mean ages of subjects
with and without bronchial hyperresponsive¬
ness were similar (PD20< 100 |ig: mean (SD)
age 64-4 (11-2), range 45-86; PD20>100 pg:
mean (SD) age 63-6 (10-8), range 45-86; t =
— 0-4, p =NS). Twenty three subjects with
bronchial hyperresponsiveness were aged <65
years and 25 were >65 years (x2 = 0-1, p =NS).
The distribution of total St George's Ques¬
tionnaire scores is shown in fig 3; 16 subjects
had a score of zero (indicating no quality of
life impairment). Geometric mean quality of
life scores were similar for men and women.
There was no correlation between quality of
life scores and age. However, the mean Ac¬
tivities score was significantly higher for sub¬
jects aged >65 years (geometric mean (SD)
1-04 (0-71)) than for those aged <65 years
(0-81 (0-76); t= -2-34, p = 0-02).
Total quality of life scores were significantly
higher in the 59 subjects with chronic airways
obstruction, indicating quality of life im¬
pairment in subjects with obstructive airways
disease. Similarly, all quality of life scores ex¬
cept the Impacts score were significantly higher
in those with bronchial hyperresponsiveness
(table 1).
For the whole group there was significant
negative correlation between log total quality
of life score and baseline FEV! (expressed as
standardised residuals) (r= — 0-47, p<0-001;
fig 4). There was also a significant positive
correlation between log total quality of life
score and log dose-response slope (r=0-20,
p<0-005; fig 5). Similar correlations were seen
between baseline FEV! (standardised residuals)
and log Activities score (r= —0-38, p<0-001),
log Impacts score (r= — 0-47, p<0-001) and
log Symptoms score (r= —0-37, p<0-001), and
between the log dose-response slope and log
Activities score (r=0-18, p<0-01), log Impacts
score (r=0-17, p<0-01), and log Symptoms
score (r=0-23, p = 0-001).
Table 1 Geometric mean (SD) quality of life scores in subjects with and without chronic airways obstruction and
bronchial hyperresponsiveness
Total score Activities score Impacts score Symptoms score
Subjects with chronic airways 1-18 (0-49) 1-18 (0-65) 0-76 (0-73) 1 -41 (0-56)
obstruction
Subjects without chronic airways 0-84 (0-53) 0-85 (0-75) 0-34 (0-69) 0-92 (0-77)
obstruction
t= —4-2 t= —3-0 t= -3-9 t= -4-5
p<0-0001 p<0-005 p = 0-0001 p<0-0001
Subjects with bronchial 0-98 (0-47) 1-03 (0-64) 0-39 (0-70) 1-21 (0-70)
hyperresponsiveness
Subjects without bronchial 0-81 (0-51) 0-80 (0-73) 0-29 (0-70) 0-89 (0-74)
hyperresponsiveness
t= —2-0 t= —1-9 t= -0-9 t= —2-6
p = 0-05 p = 0-05 p =NS p = 0*01
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Figure 4 Relationship between total quality of life score
and baseline FEVl (standardised residuals).
_L _L _L _L _L _L
0 0-5 1 1-5 2 2-5 3 3-5
log dose-response slope
Figure 5 Relationship between total quality of life score
and log dose-response slope.
Multiple regression analysis was performed
with quality of life score as the dependent
variable and baseline FEV,, log dose-response
slope, age, and sex as independent variables.
As there was a significant correlation between
the baseline FEV, and log dose-response slope,
an interaction term was included in the re¬
gression12; this was not significantly related to
quality of life in any of the analyses. For the
whole subject group, both total and separate
component quality of life scores showed in¬
dependent negative relationships with baseline
FEV, (standardised residuals); only the Symp¬
toms score showed a significant association
with the log dose-response slope (table 2).
The effect of smoking on quality of life was
assessed by comparing total St George's Ques¬
tionnaire scores of never smokers and smokers
(ex-smokers plus current smokers). Quality of
life was significantly impaired in smokers (total
score 10-3 (3-2) versus 5-6 (3-9); t=— 3-3,
p = 0-001). When smoking status (current, ex-
smoker, or never smoker) was added to the
multiple regression for the whole subject group,
the total quality of life score was found to be
significantly associated with smoking status as
well as baseline FEV,. However, because of the
interrelationship between FEV, and smoking
status, it was necessary to include an interaction
term in the regression. When this was added
it was significantly associated with quality of
life score, and the relationship between quality
of life score and smoking status itself was no
longer significant, indicating that the effect of









FEVi (standardised residuals) B = -015 B= —0-18 B= -0-16 B= -0-13
SE = 0-04 SE = 0-05 SE = 0-05 SE = 0-06
p<0-0001 p<0-001 p<0-002 p<0-05
Log dose-response slope B = 0-04 B = 0-06 B = 0-06 B = 0-11
SE = 0-04 SE = 0-06 SE = 0-05 SE = 0-06
p =NS p = NS p =NS p = 0-05
Age B = 0-0003 B = 0-0003 B = 0-002 B= -0-006
SE = 0-003 SE = 0-005 SE = 0-004 SE = 0-005
p =NS p =NS p =NS p =NS
Sex B= -0-05 B= —0-16 B = 0-02 B = 0-10
SE = 0-07 SE = 0-1 SE = 0-01 SE = 0-1
p =NS p =NS p =NS p =NS
R2 = 0-08 R2 = 0-05 .R2 = 0-05 R2 = 0-01
Table 3 Correlation between quality of life scores and bronchial responsiveness, and between quality of life scores and
baseline forced respiratory volume in one second (T'EVf in older and younger subjects
Log total Log activities Log impacts Log symptoms
score score score score
Log dose-response slope
Age <65 r= 0-31 r= 0-27 r= 0-33 r= 0-30
p = 0-001 p<0-005 p<0-001 p = 0-001
Age >65 r=0-08 r=0-07 r=0-01 r=0-16
p =NS p =NS p =NS p =NS
FEV, (standardised residuals)
Age <65 r= -0-42 r= -0-35 r= -0-41 r= -0-31
p<0-001 p<0-001 p<0-001 p<0-001
Age >65 r= -0-51 r= -0-40 r=0-51 r= -0-42
p<0-001 p<0-001 p<0-001 p<0-001
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smoking status on quality of life was the result
of the interaction between smoking and FEV,,
rather than an independent effect.
The effect of age on the relationship between
quality of life and lung function was assessed by
repeating the analysis with the subjects divided
into two age groups: <65 years (n=106) and
>65 years (n= 121). Calculation of linear cor¬
relation coefficients for the two groups gave
similar results to those for the whole group,
except that in the older age group there was
no correlation between the log dose-response
slope and quality of life scores (table 3). How¬
ever, multiple regression analysis revealed
differences between the age groups: in subjects
aged <65 years the total quality of life score
was significantly associated with the log dose-
response slope (B = 0-17, SE =O05, p<0-001)
but not baseline FEV! (B= —0-08, SE = 0-06,
p =NS), whereas in the older group the
opposite was true (log dose-response slope:
B= -0-02, SE = 0-05, p =NS; baseline FEV,:
B= -0-18, SE = O05, p = 0-0005).
Discussion
Our results confirm that obstructive airways
disease impairs quality of life. We have found
no relationship between quality of life and age
or sex, but have shown significant relationships
with baseline FEV, and with non-specific bron¬
chial responsiveness. Both chronic airways ob¬
struction and bronchial hyperresponsiveness
were relatively common in our population. This
may reflect the large numbers of current and
ex-smokers in this inner city area. However,
smoking status itself was not found to be in¬
dependently associated with quality of life.
Although the relationships between FEV,
and quality of life scores were statistically sig¬
nificant, the value of R2 for the multiple re¬
gression calculations was low, indicating that
variation in FEV, explains only a small amount
of the variation in quality of life. This weak
relationship between quality of life and lung
function indices in patients with airways ob¬
struction has been previously reported,2'5 and
has led to the suggestion that variability be¬
tween patients in perception of breathlessness
is a more important determinant of disability
than the degree of airways obstruction itself.18
Psychological assessment of patients with ob¬
structive airways disease has shown that illness
attitudes and beliefs are stronger predictors of
breathlessness and exercise tolerance than are
measures of airways obstruction.1920
Although perhaps under-rated by doctors as
a cause ofdistress, our results show that airways
obstruction is associated with significant emo¬
tional dysfunction and limitation of activities.
This impact of respiratory symptoms on activity
was highlighted by a large population survey
of elderly people in 197621 in which 17% of
housebound individuals or those confined to
bed identified "pulmonary conditions" as the
cause of their immobility and were second only
to "arthritis, rheumatism" as the most common
factor reducing independence.
The St George's Questionnaire is a disease-
specific quality of life score designed for use in
subjects with airways obstruction. As such, it
has not been validated in a general population
sample. In the current study subjects with no
airways disease tended to record very low qual¬
ity of life impairment, particularly for the
Symptoms score. This produced a skewed
distribution of quality of life scores. St George's
Questionnaire scores have been shown to be
independent of age in subjects aged up to
75 years,8 but the questionnaire has not been
validated in older subjects. The lack of cor¬
relation between quality of life scores and age
in the current study suggests that the ques¬
tionnaire is also valid in the elderly. However,
the mean Activities score was higher for older
subjects, indicating reduced activity levels with
age.
Interestingly, where other studies have shown
a change in quality of life with increasing age
in subjects with asthma or obstructive airways
disease, this has generally been an improvement
in quality of life in older subjects.3"6 This has
led to the suggestion that older subjects may
be more tolerant of the effects of airways ob¬
struction due to a reduction in their normal
activity levels or in their expectations of life. It
has been shown that older adults describe less
severe symptoms than younger adults when
exposed to the same degree of methacholine-
induced bronchoconstriction.22 However, there
is no evidence for a general decrease in the
reporting ofdistressing symptoms by the elderly
- indeed the opposite may be true.23 The results
of the current study do not confirm a reduction
in the impact of obstructive airways disease on
quality of life in older people.
Our results show that the interrelationships
between bronchial responsiveness, baseline
FEV,, and quality of life scores change with
age. The reasons for this are not clear. Mortagy
et al have described a cluster of respiratory
symptoms representing "bronchial irritability"
which are associated with increased bronchial
responsiveness in young adults.24 However, the
predictive value of these symptoms for in¬
creased bronchial responsiveness is much lower
in the elderly.' Since respiratory symptoms
affect quality of life, the lack of "bronchial
irritability" symptoms in older adults with in¬
creased bronchial responsiveness may reduce
the strength of the relationship between bron¬
chial responsiveness and quality of life in this
age group. Alternatively, our results may reflect
a change in the interaction between baseline
FEV, and bronchial responsiveness with age,
rather than a change in their interaction with
quality of life.
Schrier et al have also shown that obstructive
airways disease is associated with impairment
of quality of life in adults over a wide age
range.2 However, it is not clear whether quality
of life was related to age in this study. The
influence of increased bronchial responsiveness
on quality of life was studied in young asth¬
matics by Malo et a/25 who found the mean
quality of life score to be weakly but sig¬
nificantly correlated with baseline FEV, and
non-specific bronchial responsiveness, as in the
current study.
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In summary, we have measured quality of
life, airways calibre, and non-specific bronchial
responsiveness in a population sample over a
wide age range and have shown significant
correlations between quality of life and both
baseline FEV, and non-specific bronchial re¬
sponsiveness. Multiple regression showed a sig¬
nificant independent relationship between
quality of life and FEV, in older subjects, and
between quality of life and non-specific bron¬
chial responsiveness in younger subjects. How¬
ever, the amount of variability in quality of
life attributable to changes in FEV, and non¬
specific bronchial responsiveness is small. The
impact of obstructive airways disease on quality
of life does not decrease with advancing age.
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Detection of the multidrug resistance marker
P-glycoprotein by immunohistochemistry in
malignant lung tumours























Background - The multidrug resistance
marker P-glycoprotein (P-gp) was studied
immunohistochemically in 78 primary
malignant lung tumours. P-gp is a 170 kD
transmembrane ATP dependent drug
efflux pump which has been shown to be
important in the resistance of some
tumours to chemotherapy. Certain normal
tissues express P-gp and tumours derived
from these tissues are often insensitive
to cytotoxic agents, showing raised P-gp
levels innately or following chemotherapy
or radiotherapy.
Methods - Samples from 78 patients
undergoing surgery for primarymalignant
lung tumours were snap frozen and stained
immunohistochemically using the mono¬
clonal antibody C219 which reacts with a
P-gp epitope. None of the study group had
received chemotherapy or radiotherapy
before surgery was performed.
Results - Twenty seven of the 78 lung
tumours (34-6%) showed immuno¬
histochemically detectable levels of P-gp
which varied with tumour type; 17 of 54
squamous cell carcinomas (31-5%), seven
of 15 adenocarcinomas (46,7%), and nei¬
ther of two small cell carcinomas showing
positive staining. In six of seven cases
normal respiratory epithelium present
showed the presence of P-gp.
Conclusions - P-gp is immunohisto¬
chemically detectable in frozen tissue from
a proportion of malignant lung tumours
before exposure to radiotherapy or drugs
associated with multidrug resistance. It
may have a role in tumour resistance to
cytotoxic drugs, but further clinical stud¬
ies will be required to evaluate any cor¬
relation between P-gp levels and response
to treatment.
(Thorax 1996;51:526-529)
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as an ATP dependent drug efflux pump, re¬
ducing intracellular drug concentrations and
thereby producing resistance to a large number
of structurally unrelated cytotoxic agents.23
These include vinca alkaloids, anthracyclines,
and epipodophyllotoxins. P-gp has also been
observed in drug resistant strains of the malaria
parasite Plasmodium falciparum.4
Certain normal human tissues have plasma
membrane P-gp, with highest levels being ob¬
served typically in tissues with an excretory or
secretory function such as colonic epithelium,
adrenal, kidney, and liver tissue.' Interestingly,
tumours derived from these tissues are often
insensitive to cytotoxic agents.
In vitro and in vivo studies have identified
increased mdr 1 gene expression and its product
P-gp in several human tumours and cell lines.56
Some workers have reported a correlation be¬
tween innate and acquired multidrug resistance
and P-gp expression, suggesting that its pres¬
ence may be an indicator of resistance to
chemotherapy. Inhibition of the pump action
ofP-gp by verapamil and other agents has been
shown to increase cytosensitivity to chemo-
therapeutic drugs in certain cases.78
Lung cancer is one of the commonest human
malignancies and carries a poor prognosis.
Non-small cell lung carcinomas generally show
a poor response to chemotherapy, but the
reasons for this are largely unknown. Mech¬
anisms of multidrug resistance probably have
a pivotal role in this process. There has recently
been some renewal of interest in chemotherapy
for non-small cell lung carcinoma9 with sig¬
nificant response rates in a number of trials,10
especially when used as an adjunct to
surgery."12 Small cell lung carcinoma often
shows a temporary response to chemotherapy,
but treatment is largely palliative with little
chance of a long term cure.
This study evaluates the expression of P-gp
in 78 primary malignant lung tumours un¬
exposed to the potential modulating effects of
radiotherapy or chemotherapeutic agents using
the monoclonal antibody C219 which re¬
cognises the mdr 1 gene product P-gp.
Cytotoxic drug resistance is a major problem
in cancer chemotherapy. The resistance of neo¬
plastic cells to cytotoxic agents may be innate
or acquired and occurs by a number of mech¬
anisms, one of which is associated with the
presence of a 170 kD transmembrane protein,
P-glycoprotein (P-gp).1 This is a product of
the multidrug resistance gene mdr 1, which acts
Methods
Tumour tissue was obtained from 77 patients
undergoing lobectomy for primary malignant
lung tumours, immediately snap frozen in
liquid nitrogen, and stored at — 80°C. In one
patient material was obtained during media¬
stinoscopy and similarly treated. None of the
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